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Introduction 
1.1 Preface and study objective 
Androgens are C-19 steroid hormones that cause development of the male 
phenotype in utero. They stimulate and maintain male secondary sex characteristics 
during and after puberty, respectively. They act through specific and high affinity 
binding to the androgen receptors in androgen responsive tissues. Although it has 
long been thought that androgens play a minor role in females they are important as 
intermediates for oestrogen production and thus they are involved in the 
development of the reproductive female. In women, only part of the androgens 
originates from direct secretion by the ovaries and the adrenal cortex. The 
remainder is formed by peripheral conversion of weak androgen 'pre-hormones' 
[e.g. androstenedione (A<) and dehydroepiandrosterone (DHEA)] into steroid 
hormones with stronger androgenic activity [e.g. testosterone (T) and 
dihydrotestosterone (DHT)]. Peripheral conversion of these prehormones occurs in 
androgen target tissues such as the skin, the pilosebaceous unit and parts of the 
central nervous system such as the hypothalamus. About half of the production of 
testosterone for instance is derived from conversion of androstenedione while the 
other half is secreted directly by the ovaries and the adrenal glands in 
approximately equal amounts (Longcope 1986). 
Stimulation by androgens is a prerequisite for the development of sexual hair. 
Androgens are necessary for the transition of soft thin vellus hair into longer coarse 
terminal hair. Low androgen concentrations are sufficient to induce ambosexual hair 
which is present in both sexes in androgen sensitive areas such as the axillae, 
pubic area and on the arms and legs. It has been suggested that weak adrenal 
androgens such as DHEA and DHEAS may play an even more important role in the 
maintenance of axillary hair in women than does testosterone (Ishihara ef al. 1993). 
Hair growth on the chest, back, upper pubic triangle and in the beard area requires 
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relatively high concentrations of potent androgens. 
Overproduction of androgens in women (i.e. hyperandrogenism) from the ovaries 
and/or adrenals, may lead to hirsutism i.e. a pattern of hair growth in androgen 
sensitive areas of the skin which is usually seen in males, and may be accompanied 
by acne and menstrual disturbances (Ferriman and Gallwey 1961). For the 
assessment of hirsutism ethnical and familial variability of the hair pattern should be 
taken into account. Moreover hirsutism may be drug induced or develop from 
exogenous administration of anabolic steroids. In severe cases of androgen 
overproduction the androgen excess may manifest itself in true virilization with 
clitoromegaly, receding temporal hair, breast atrophy and an increased muscular 
mass (Kirschner 1984). Finally, hypertrichosis is a condition characterized by 
excessive growth of non-sexual hair which is not associated with hyperandrogenism, 
but due to diseases such as anorexia nervosa or porphyria and should not be 
confused with hirsutism. 
Hyperandrogenism of ovarian origin may result from polycystic ovarian disease 
(Barnes and Rosenfield 1989) or ovarian neoplasms. Adrenal causes include 
Cushing's syndrome, congenital adrenal hyperplasia and adrenal neoplasms. 
Moreover, glucocorticoid receptor resistance, i.e. end-organ resistance to Cortisol, 
accompanied with increased levels of ACTH may lead to a relative overproduction 
of androgens in association with slightly increased glucocorticoid levels (Lamberts et 
al. 1989, Werner ef al. 1992). In idiopathic hirsutism no apparent cause of androgen 
excess is discernible. However, in this condition increased peripheral conversion of 
androgen prehormones has been demonstrated. 
Thus, although hirsutism is often considered as a cosmetic problem, it can be an 
early sign of serious endocrine disorders, including adrenal or ovarian tumor. 
In hirsutism, and especially in the milder cases, it is often difficult to identify the 
source of the androgen excess, not in the least because androgens are secreted 
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episodically and may exhibit diurnal variations. Prior to the development of specific 
radioimmunoassays urinary 17-ketosteroid levels were used to evaluate 
hyperandrogenicity. Urinary 17-ketosteroids are derived from weak androgens 
mainly of adrenal origin. However, there is no correlation between plasma 
testosterone and urinary 17-ketosteroids (Maroulis et al. 1977). Less than 20% of 
the plasma testosterone is converted into urinary 17-ketosteroids (mainly 
etiocholanolone and androsterone). Thus androgen excess may be present without 
elevated urinary 17-ketosteroids. Selective catheterization of the adrenal and 
ovarian veins for diagnostic purposes is only considered in severe virilization when 
neoplasms are suspected that can not be localized by computerized tomography 
(Wajchenberg ef al. 1986). Dynamic testing may be performed to determine the 
source of the androgen excess. During these tests either adrenal steroidogenesis is 
inhibited by administration of glucocorticoids or stimulated by corticotropin (Lucky et 
al. 1986, Siegel et al. 1990, Eldar-Geva ef al. 1990, Ehrmann and Rosenfield 
1990a), or ovarian function is inhibited by administration of oestrogens or LHRH 
analogs, or stimulated by gonadotrophins (Goldzieher 1981) or GnRH agonists such 
as nafarelin (Rosenfield ef al. 1990). The administration of synthetic ACTH after 
overnight dexamethasone suppression has also been applied to test adrenal 
function (Azziz ef al. 1994). Although the specificity of inhibition tests (Moltz et al. 
1982), as well as the overall diagnostic value of ACTH stimulation tests have been 
disputed (Cobin ef al. 1985), dynamic function tests in many cases may provide 
valuable diagnostic information. 
The interpretation of measurements of the total concentration of androgens in 
plasma in the light of their biological activity is complicated by the fact that most 
androgens are bound to plasma binding proteins, predominantly sex hormone 
binding globulin (SHBG) and albumin. Only a relatively small fraction of each of the 
hormones circulates in the non-protein bound, free form. In the case of 17-ß-
hydroxy steroids (e.g. DHT and T) the free fraction is only about 1% or less in 
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women and slightly higher in men. The free fraction of 17-keto-steroids in plasma 
(e.g. DHEA and A<) is larger (5-10%) (Dunn ef al. 1981). Many investigators found 
that the physiological activity of steroid hormones is better correlated with their 
unbound concentration, than with the total concentration in plasma (Ekins 1990a, 
Mendel 1989). This is in line with a theory, known as the 'free hormone hypothesis', 
that originally was proposed by Robbins and Rail (1957). In this model, free and 
bound hormone fractions are in dynamic equilibrium (Ekins 1990b). It is assumed 
that only the free hormone can penetrate the cell membrane. Yet, the notion that 
the unbound concentration of steroid and for that matter, thyroid hormone in plasma 
reflects their biological activity, has repeatedly been challenged. However, authors 
representing this line of thinking (Pardridge 1990, Cumming and Wall 1985, Manni 
ef al. 1985) basically misinterpret the free hormone hypothesis as a static model in 
which only the free hormone fraction is available for target cells and no significant 
dissociation of hormone bound to specific binding proteins occurs. The latter group 
of authors adheres to the concept that the fraction of Τ in plasma, which is albumin-
bound reflects the biologically available T. 
The concentration of SHBG in plasma appears to be regulated by androgens and 
oestrogens (Anderson 1974, Rosner 1990). Its production by liver cells is induced 
by oestrogens and counteracted by androgens. Hyperandrogenism, amongst others, 
may lead to reduced levels of SHBG with higher levels of unbound androgens and 
an increased metabolic clearance. Obesity and hyperinsulinemia may be 
accompanied with decreased levels of SHBG and increased levels of unbound 
androgens (Nicolas ef al. 1993, Nestler 1993). In the case of low levels of SHBG, 
the total concentration of testosterone may be within the normal range, whereas the 
concentration of the unbound testosterone may be elevated. Thus especially in the 
case of hyperandrogenism the measurement of unbound androgens is indicated. 
Vlahos ef al. (1982), amongst others, confirmed that the concentration of the free 
testosterone in plasma is a better indicator of hyperandrogenism than the 
concentration of plasma total testosterone. However, measurements of unbound 
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androgens in plasma are technically complicated (Biffignandi and Massucchetti 
1983) since the in vitro level depends, amongst others, on dilution, pH, and 
temperature. The equilibrium between bound and free fractions of steroid hormones 
in plasma is difficult, if not impossible, to reproduce in vitro. 
Alternatively, the T/SHBG ratio has been recommended as an index of 
androgenicity in hyperandrogenic conditions (Badawy ef a/. 1982). 
More than twenty years ago Katz and Shannon (1969) showed that the 
concentration of glucocorticoids in saliva correlates well with the non-protein bound 
glucocorticoids in plasma. Hence, the measurement of salivary steroids has been 
advocated as an alternative to the assessment of plasma free hormones. This 
approach has been further investigated (Riad-Fahmy et al. 1982, James 1982, 
Wellen et al. 1983, Benraad and Otten 1984) and was applied successfully, 
particularly in children (Otten ef al. 1983, Otten 1987), because of the ease of 
multiple sample collection. Some reports have been published concerning the 
measurement of salivary testosterone in hirsute women, demonstrating the 
significance of the assessment of this parameter in these patients (Vining and 
McGinley 1987, Baxendale ef al. 1982, Ruutiainen ef al. 1987, Luisi et al. 1983, 
Smith ef al. 1979, James and Baxendale 1983, Baxendale et al. 1983). 
The aim of the present study was to examine the relationships between plasma 
total, plasma free and salivary levels of T, A4, and DHEA in normal women and in 
women with androgenizing disorders and to investigate which of these parameters is 
the most appropriate index of androgenicity. We are not aware of studies in which 
plasma total, plasma free and salivary levels of T, A4, and DHEA have been 
measured simultaneously. 
The techniques used for the measurement of plasma and salivary steroid hormones 
often lack sensitivity and specificity. Reported values, particularly of plasma free and 
salivary levels of androgens vary between laboratories. These discrepancies may 
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largely be attributed to procedural differences In this thesis we describe the 
development of sensitive and specific radioimmunoassays for the determination of 
total and salivary DHEA, A4, and Τ The specificity was achieved by incorporating 
extraction and chromatographic purification of the samples For the determination of 
the free fraction of A4 and DHEA we developed equilibrium dialysis methods An 
assay for free Τ was developed according to the principle of symmetric dialysis 
(Ross 1978) 
In the light of recent discussions with respect to the possible value of 
measurements of the fraction of testosterone which is not bound to SHBG (n-
SHBGT) as a marker of androgenicity, this parameter was also included 
The relationship between plasma total, free and salivary levels of these androgens 
in normal and hirsute women during the combined dexamethasone/synthetic 
corticotropin test was studied to investigate whether the diagnosis of androgenizing 
disorders may be refined by measuring any of these parameters under these 
experimental conditions The measurement of plasma free and/or salivary androgen 
concentrations may provide important diagnostic information particularly in those 
cases where hyperandrogenemia is masked by apparently normal plasma total 
levels of androgens together with low concentrations of binding proteins 
Two aspects of hormone delivery may be reflected in the concentration of steroid 
hormones in saliva First, the concentration of steroids in saliva appears to be 
correlated with the concentration of free rather than the total concentration in 
plasma Second, the salivary gland may be considered as a model system of 
hormone metabolism in androgen target tissues such as the skin Comparison of the 
relation between plasma free and salivary androgens between women with 
androgenizing disorders and control groups might support this assumption 
8 
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1.2 Androgen production in normal women 
Androgens 
In part 1.1 androgens were defined as C19-steroid hormones which bind specifically 
and with high affinity to androgen receptors and consequently induce male 
secondary sex characteristics. The low plasma concentrations of androgens in 
women cause normal development of ambosexual hair. According to this definition 
testosterone (T) and in particular dihydrotestosterone (DHT) are potent androgens. 
The steroids androstenedione (A4) and dehydroepiandrosterone (DHEA) by 
themselves do not fulfil the above mentioned criteria. However, in androgen target 
tissues these steroids may be converted to biologically active androgens. Thus, A4 
and DHEA have also been termed pre-androgens (Bruchovsky 1971) or androgen 
pre-hormones (Baird ef al. 1968). Historically the potency of androgens has been 
assessed in the capon's comb test which relates to the early observations by 
Aristotle 300 years ВС described in the Historia Animalium concerning the effects of 
castration on the development of sexual characteristics in birds (Aristoteles 1907). 
Much later the rat seminal vesicle test was also used for this purpose (Dorfman and 
Shipley 1956) as well as tests for nitrogen retaining activity in vivo. 
Circulating androgens in women originate primarily from the adrenals and the 
ovaries. For the greater part they are secreted as androgen pre-hormones which 
require metabolic activation by peripheral conversion. 
Adrenal androgenesis 
The adrenal cortex is divided into three zones: a thin outer layer, the zona 
glomerulosa, the intermediate zona fasciculata and the inner layer, the zona 
reticularis. Androgens and glucocorticoids are secreted from the zona reticularis and 
9 
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the zona fasciculata (Maroulis and Abraham 1980). Functionally the zona reticularis 
and the zona fasciculata are not separate entities. Their respective cells are 
potentially capable of synthesizing both glucocorticoids and androgens. However, 
there is a preference for androgen synthesis in the zona reticularis and for 
glucocorticoid synthesis in the zona fasciculata. The zona glomerulosa is associated 
with mineralocorticoid production (Tait eí al. 1970). Production of aldosterone 
requires 18-hydroxysteroid dehydrogenase which is exclusively found within this cell 
layer. This mineralocorticoid is synthesized from progesterone (P4) via an 18-
dihydroxy intermediate. 
The generally accepted pathway for the production of steroids in the adrenals and 
the enzymes involved are depicted in fig 1.2.1. Most of the enzymes involved in 
steroidogenesis are members of the cytochrome P450 group of oxydases. 
Cholesterol is the precursor of all steroid hormones. Sources of cholesterol include 
plasma low density lipoprotein cholesterol (LDL), esterified cholesterol stored in 
lipid-rich cells of the adrenal zona fasciculata and de novo synthesis of cholesterol 
by adrenal cells (Gwynne and Strauss 1982). Under normal physiological conditions 
cholesterol is derived from the plasma pool by active, adrenocorticotropic hormone 
(ACTH) dependent, LDL receptor-mediated uptake. If rapid synthesis of steroids is 
required, cholesterol is derived from hydrolysis of cholesterol-esters stored in the 
cells of the zona fasciculata. Subsequently, free cholesterol is transformed to Δ5-
pregnenolone (P5) via 20ff-hydroxy-cholesterol and 20o-22e-dihydroxycholesterol by 
cytochrome P450scc (C20.22 side chain cleavage) located in the mitochondrial 
cristae. The cytochrome P450 enzymes are hydrophobic hemoproteins that catalyze 
oxidation in adrenal and ovarian steroidogenesis. Cytochrome P450scc catalyzes 
20-hydroxylation, 22-hydroxylation and C20.22 side chain cleavage on one active site 
(Di Biasio er al. 1987). This process is the rate limiting step in adrenal 
steroidogenesis (Ehrmann and Rosenfield 1990b). Side-chain cleavage activity, and 
consequently the conversion of cholesterol to P5, is under control of ACTH 
(Rosenfeld ef al. 1975, Rosenfield ef al. 1990). 
10 
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From P5 the A5-steroids 17-hydroxypregnenolone (170HP5), DHEA and Δ5-
androstenediol (A5) are formed involving 17-hydroxylase, C17-20-lyase and 17-
ketosteroid reductase activity. The first two activities are present on a single 
enzyme, cytochrome Р450с17ог, which is also stimulated by ACTH (Rosenfield et al. 
1990, Nakajin et al. 1984). Similarly, cytochrome P450c17a binds progesterone (P4) 
and converts it via 17-hydroxyprogesterone (170HP, by 17a-hydroxylase activity) to 
A4 (by C17-20-lyase activity). The A5-steroids are converted to the A4-steroids P4, 
170HP and A4 by the non-cytochrome P450-dependent 3£-hydroxysteroid 
dehydrogenase- A5-3-ketosteroid isomerase (30-HSD) enzyme complex. In the 
adrenals the so-called Δδ-pathway is preferred, and more DHEA than A4 is formed. 
Τ is formed mainly via the DHEA/A4 route. Formation of Τ from A4 requires 17-
ketosteroid reductase activity. A5 does not appear to be an important precursor 
hormone for Τ (Kirschner et al. 1973). 
The adrenals produce both unconjugated and conjugated androgens. The function 
of conjugated androgens is not clear and needs further study. 
Dehydroepiandrosterone-sulfate (DHEAS) may either be formed from sulfurylation of 
DHEA to DHEAS by steroid sulfotransferase (Wallace ef al. 1963) or from 
sulfurylated precursors (cholesterol sulfate). However, the latter is not a major 
pathway (Lebeau era/. 1964). 
Adrenal vein catheterization indicates adrenal production of DHEA, DHEAS, A4 and 
small amounts of Τ (Longcope 1986). 
The synthesis and secretion of steroid hormones by the adrenals appears to be 
under control of adrenocorticotropic hormone (ACTH) released from the pituitary. 
The feedback of adrenal steroid production is governed by Cortisol. Thus androgen 
levels in plasma show a distinct circadian rhythm (Rosenfeld et al. 1975, Lachelin er 
al. 1979) with the exception of the level of DHEAS. The metabolic clearance rate of 
DHEAS is slow and small variations in the secretion rate do not cause detectable 
fluctuations in the level of plasma DHEAS. Administration of synthetic ACTH results 
in a rise in the plasma concentration of DHEA (Vermeulen and Ando 1978, Givens 
12 
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et al. 1975) demonstrating that adrenal androgen production is under control of this 
hormone. However, physiological changes in the relative production of Cortisol and 
adrenal androgens during life has led some investigators to believe that other 
factors than ACTH may regulate adrenal androgen secretion. 
During the first years of life androgen secretion by the adrenals is minimal in both 
sexes. At the end of the first and throughout the second decade, adrenal androgen 
production, especially DHEA, DHEAS (de Peretti and Forest 1978, Hopper and Yen 
1975) and A4 increases whereas Cortisol production remains at the same level. 
During this period, the adrenarche (Rich et al. 1981, Kelnar and Brook 1983), pubic 
and axillary hair develop under the Influence of adrenal androgens. The adrenarche 
is characterized by an altered response to adrenocorticotropin as a result of a shift 
in adrenal steroidogenesis. During adrenarche 3/Î-HSD activity as well as 11/7-
hydroxylase activity decrease while 17a-hydroxylase activity of P450c17o increases 
slightly and 17,20-lyase activity increases considerably (Rosenfield et al. 1990, 
Lucky et al. 1986). Moreover adrenal cortical cells acquire sulfokinase activity 
during adrenarche. These changes are coincident with and may result from the 
development of the zona reticularis. After adrenarche, adrenal androgens are 
secreted synchronously with Cortisol (Rosenfeld et al. 1975). With advancing age, 
and especially about the time of menopause, adrenal androgen production gradually 
decreases whereas Cortisol production remains unchanged (Purifoy er al. 1980). 
This dissociation between adrenal androgen and glucocorticoid production is also 
observed in treated patients with 21-hydroxylase deficiency. In these patients ACTH 
may be normalized whereas adrenal androgen production is already suppressed. It 
has been suggested that this dichotomy may be due to suppression of a specific 
factor necessary for adrenal androgen production (McKenna and Cunningham 
1991). This putative adrenal androgen stimulating hormone, which might be derived 
from the ACTH precursor molecule pro-opiomelanocortin (POMC) is thought not to 
affect glucocorticoid synthesis (Parker and Odell 1980). As indicated above, 
alternatively it has been proposed that adrenal androgen secretion depends on the 
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maturation of specific cell types (Hopper and Yen 1975, Rich ef al. 1981, Anderson 
1980, Dickerman er al. 1984). In this context it is interesting to note that Semple ef 
al. (1987) and Parker et al. (1985) observed a shift from the androgen to 
glucocorticoid pathway during chronic illness which may serve to maintain Cortisol 
secretion. 
Ovarían androgenesis 
The ovary is a complex cyclically changing endocrine tissue consisting of 
morphologically and functionally different substructures. The ovaries secrete 
oestrogens, progestogens and androgens, particularly A4. Androgens are formed in 
the stromal cells, in the theca and granulosa cells of the follicle and in the corpus 
luteum. 
Although the general pathway for the production of androgens in the ovaries is 
similar to the process of androgen synthesis in the adrenal (Fig 1.2.2), ovarian 
steroidogenesis appears to be more compartmentalized. 
The stroma, or interstitial tissue, produces androgens (particularly A4) via the Δ4 
and Δ5 pathway (Leymarie and Savard 1986) and is not capable of further 
aromatizing them into oestrogens (McNatty ef al. 1979). Somma et al. (1969) 
concluded that the quantitative contribution of the stroma to ovarian steroidogenesis 
is not significant. In contrast Rice and Savard (1966) suggested that the stroma is 
the major source of ovarian androgens. The disparity in these findings may be due 
to the homogeneity of the isolated ovarian substructures used in experiments to 
assess their steroidogenic potential. 
The majority of the ovarian steroids is formed in the theca and granulosa cells. In 
the theca interstitial cells of the Graafian follicle cholesterol is converted to 
pregnenolone and subsequently to A4, Τ and oestrogens (McNatty ef al. 1979). 
From the steroids synthesized in the theca cells mainly A4 and oestradiol (E2) are 
secreted into venous blood. Moreover, A4 is transported across the basement 
membrane of the follicle into the granulosa cells where it is converted via Τ mainly 
14 
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pregnenolone progesterone 
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Fig 1.2.2 Pathway for the production of steroid hormones in the ovary. 
The enzymes involved in ovarían steroidogenesis are A: P450scc 20a-
hydroxylase (Mi), B: P450scc 22-hydroxylase (Mi), C: P450scc C!0_22 
desmotase (Mi), D: P450C17 17-hydroxylase (ER), E: 3ß-hydroxysteroid 
dehydrogenase - Δ5-3 ketosteroid isomerase complex (ER), F: P450C17 
C17,20-lyase (ER), G: 17-ketosteroid reductase (ER), H: P450 aromatase (ER) 
(ER, Mi: subcellular location: smooth endoplasmic reticulum and mitochondria, 
respectively). 
15 
Part 1 
to E2 which accumulates in the follicular fluid. The granulosa cells possess only 
weak 17-hydroxylase and little or no C17-20-lyase activity (Short 1964, Ryan and 
Petro 1966). The aromatization of Τ in the granulosa cells is regulated by follicle 
stimulating hormone (FSH). Side chain cleavage of cholesterol as well as 
cytochrome P450C17 activity in the theca cells is under control of luteinizing 
hormone (LH) (Rosenfield et al. 1990, Longcope 1986). This model is known as the 
two-cell/two gonadotropin theory (Fig 1.2.3). The amount of oestrogen formed by 
the granulosa cells seems to depend on the availability of A4 precursor produced by 
the theca cells. 
Barnes ef al. (1989) suggested that insulin resistance may play a role in the 
pathogenesis of polycystic ovary disease (PCO). Interestingly insulin as well as 
insulin-like growth factor-l appear to amplify the LH signal and may increase 
androgen biosynthesis (Erickson et al. 1985, Cara and Rosenfield 1988, Prelevic ef 
al. 1992, Nobels and Dewailly ef al. 1992). Insler ef al. (1993) further suggest that in 
obese women hyperinsulinaemia causes excessive androgen production through 
enhancement of IGF-I receptors which in synergism with LH cause increased 
activity of cytochrome Ρ450ο-17σ. 
Androstenedione appears to be the major androgen secreted by the ovaries. 
Arteriovenous gradients were found for A4 and T. DHEA was also present in ovarian 
venous blood (Lloyd et al. 1971). 
The production of androgens by the ovaries varies through the menstrual cycle. 
Recently Hillier (1991) and Hillier and Miro (1993) demonstrated that inhibin and 
activin modulate steroidogenesis in the ovaria. Human thecal cell androgen 
biosynthesis was inhibited in vitro by activin-A whereas inhibin caused a moderate 
increase in the production of androstenedione and dehydroepiandrosterone. 
In the early follicular phase, when no active follicle is present the ovaries produce 
mainly A4 and small amounts of E2. In the late follicular phase the ovary containing 
the larger follicle produces considerable amounts of E2 and A„ whereas no change 
in activity is seen in the contralateral ovary. The higher production of A„ and E2 is 
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maintained through the luteal phase (McNatty et al. 1976). On the other hand, Lloyd 
et al. (1971) found equally high levels of Τ and A4 during both phases of the cycle. 
Aedo et al. (1980a) measured the ovarian vein levels of androgens and oestrogens 
and compared those with their peripheral concentrations before and after 
enucleation of the largest follicle. In contrast to the findings reported by McNatty ef 
al. (1976) these authors conclude that the levels of A4, Τ and 170HP are the same 
before and after enucleation of the largest follicle, indicating that this structure does 
not contribute significantly to ovarian androgen production. Secretory products from 
the follicle include E2 and oestrone (E,) (Aedo er al. 1980a). 
Enucleation of the corpus luteum resulted in slightly diminished levels of A4 in the 
vein of the ovary which contained the major follicle as well as in the peripheral 
blood. Ovarian vein levels of A4 and Τ remained higher than their peripheral levels. 
It was concluded that the most important steroids secreted by the corpus luteum are 
P4, 170HP, E2 and oestrone (Aedo ef al. 1980b). Aedo er al. (1980a, 1980b) noted 
that their observations should be interpreted with caution, pointing out that the 
stress associated with surgical enucleation of the corpus luteum and the follicle 
causes ACTH release which stimulates adrenal androgen production. 
Peripheral metabolism 
The peripheral metabolism of the androgen prehormones is important for the 
production of physiologically active androgens. This mechanism has been 
suggested to provide potent hormones to local structures without producing a 
general hormonal effect (Horton and Lobo 1986). DHEA appears to be a relatively 
important precursor in this respect. About 0.7% of the circulating DHEA is converted 
to Τ in the normal adult female, accounting for 15% of the total Τ production (Horton 
and Tait 1967). DHEA is largely unavailable for conversion into Τ because of the 
very fast conjugation of the circulating DHEA to DHEAS (Rosenfeld et al. 1972). A5 
appears to be a less important precursor. It accounts for only 1-4% of the total 
production of Τ (Kirschner et al. 1973). A4 on the other hand is an important 
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precursor for Τ at the target level since about half of the total production of Τ in 
women is derived from peripheral conversion of A4 (Horton and Tait 1966). 
The formation of dihydrotestosterone (DHT) is a crucial step in the peripheral 
metabolism of androgens (Bruchovsky and Wilson 1968). It is generally accepted 
that DHT is the principal intracellular androgen which is responsible for the 
androgenic effects due to its high affinity for the androgen receptor (Martini 1982). 
This androgen is one and a half to three times more potent than Τ in bioassays for 
androgenic activity (Kirschner 1972). DHT is not derived from direct secretion from 
the adrenals or the ovaries, but almost exclusively and irreversibly from 5o-reduction 
of circulating, or locally formed, Τ (Fig 1.2.4). In women the 5a-reductase activity is 
located in the liver and in peripheral androgen responsive structures such as skin, 
hair follicles and sebaceous gland (pilosebaceous unit) as well as in non-classic 
androgen-responsive tissues such as the salivary glands (ElAttar 1974). Moreover, 
5o-reduction occurs in neuroendocrine structures, particularly the hypothalamus 
where it is responsible for the feed-back effect of Τ (Martini 1982). 5a-Reductase 
activity is competitively inhibited by steroids with a A4-3-keto configuration (e.g. 
progesterone)(Mauvais-Jarvis era/. 1974). 
Recently it was recognized that two 5o-reductase isoenzymes are present which are 
encoded by genes on different chromosomes (Itami et al. 1991, Jenkins et al. 1992, 
Wilson er al. 1993). Type 1 5a-reductase has a broad neutral to alkaline pH 
optimum whereas type 2 is characterized by an acidic pH optimum. Both 
isoenzymes have different affinities for inhibitors and testosterone. Type 1 reductase 
has a 25-fold lower affinity for testosterone than the type 2 isoenzyme. Type 2 
reductase is found mainly in androgen target tissues such as the epididymis and 
beard area (Itami et al. 1991, Thigpen er al. 1993). It is thought to be responsible 
for external virilization in the male. Type 1 is present in scalp hair (Harris et al. 
1992). 
DHT is metabolized by За- and 3/?-hydroxysteroid dehydrogenase to 3o-Diol and a 
small amount of 3/?-Diol. Interestingly, while 3a-Diol is also an even more potent 
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androgen than Τ and causes nitrogen retention in man, 3/?-Diol does not possess 
such activity. DHT formed in the skin does not enter the circulation and 
consequently plasma DHT poorly reflects peripheral events (Deslypere et al. 1982). 
Unconjugated plasma 3σ-ϋίοΙ is thought to reflect these events more accurately. 
Androgen end metabolites, DHT, 3a-Diol, and androsterone are glucuronized by 
glucuronyl transferase and excreted in urine. Urinary and plasma 3o-Diol 
glucuronide (За-Diol-G) have been proposed as markers of peripheral androgen 
action as the formation of these glucuronides was assumed to occur in 
extrasplanchnic tissue (Lobo er al. 1987). Pang er al. (1992) found a significant 
correlation between the 3a-Diol G and hirsutism score in women with hirsutism 
related to adrenal causes and in women with idiopathic hirsutism. A correlation 
between 5a-reductase activity and the level of A-diol-G has been demonstrated 
(Lobo er al. 1987). However, recent evidence suggests that androgen metabolites 
are conjugated to glucuronic acid mainly in the liver (Rittmaster er al. 1993b). This 
implies that the level of plasma Заг-Diol-G is not a good marker of skin androgen 
metabolism. 
Figure 1.2.5 shows the relative contributions of each of the sources of androgens in 
women (Longcope 1986). Obviously most of the circulating DHEAS is derived from 
the adrenals. 
DHEA either directly or indirectly via conversion of DHEAS, is also mainly produced 
by the adrenals. DHEA and DHEAS are the major secretory products of the 
adrenals. One third of the production of A5 is derived from peripheral conversion of 
DHEA. The remainder, as shown by ovarian and adrenal vein catheterization 
studies, is secreted mainly by the ovaries. A4 is produced almost in equal amounts 
by the adrenals and the ovaries. As mentioned earlier about half of the circulating Τ 
is derived from both the adrenals and the ovaries in equal amounts. The remaining 
half is derived from peripheral conversion of Τ precursors. Since the contribution of 
A5-steroids to the formation of Τ is minimal, A„ appears to be the most important 
androgen prehormone, at least in normal women. 
21 
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1.3 Androgenizing disorders 
Hirsutism and virilization 
Hyperandrogenism may result from ovarian or adrenal overproduction of androgens, 
from increased conversion of androgen prehormones or from a combination of these 
sources (Table 1.3.1). Optimal pharmacologic treatment of androgenizing disorders 
largely depends on the accurate assessment of the cause of hyperandrogenism. 
Hirsutism, characterized by the presence of excessive terminal, coarse, dark-
pigmented hair in areas where hair growth is exclusively seen in males, represents 
the early manifestation of hyperandrogenism in women. The severity may be 
assessed using the Ferriman-Gallwey score (Ferriman and Gallwey 1961) in which 
eleven androgen sensitive areas, such as facial areas as well as the chest, 
circumareolair area, midline abdomen and thighs, are graded 0 (no hair) to 4 (male 
hair growth pattern) and summed. Generally, if a woman has a Ferriman-Gallwey 
score of 8 or more, she is considered hirsute. 
Unwanted hair growth does not necessarily signify a clinical abnormality. In fact it 
has been debated whether hirsutism by itself is abnormal (Rittmaster 1992). 
Obviously the ethnical and familial background of women must be taken in account. 
Dark facial hair is commonly present in women of Mediterranean origin whereas in 
Japanese women it is rare. 
A distinction should be made between hirsutism and androgen independent 
excessive vellus hair growth which is thin, soft and unpigmented. This condition, 
hypertrichosis, may be congenital but is usually caused by medication (phenytoin, 
minoxidil, cyclosporine) or metabolic disorders (hypothyroidism, anorexia nervosa, 
porphyria) (Ehrmann and Rosenfield 1990a). 
Hirsutism as a result of androgen excess of unknown origin is often referred to as 
idiopathic hirsutism (Ehrmann and Rosenfield 1990b). Upon closer examination, in 
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many of these subjects increased peripheral conversion of androgen prohormones, 
or increased adrenal or ovarian androgen production can be demonstrated 
(Mauvais-Jarvis et al. 1983, Ehrmann and Rosenfield 1990). 
In severe cases hyperandrogenism may lead to true virilization characterized by 
clitoromegaly, temporal balding, increased muscle mass and deepening of the voice 
(Kirschner 1984). 
Ovarian and adrenal tumors 
Extremely elevated levels of at least one of the androgens are found in the rare 
cases of adrenal or ovarian tumors. The most severe cases of hirsutism and virilism 
in adults (Table 1.3.1) are often due to neoplasms (Osborn and Yannone 1971). In 
many instances a sudden onset and rapid progression of virilization occurs. Plasma 
Τ concentrations -either due to direct secretion or via conversion of A4- may exceed 
7 nmol/l (Leinonen ef al. 1991) (male levels range from 10 to 35 nmol/l). In case of 
adrenal tumor DHEA, DHEAS and A„ are often extremely elevated. DHEAS levels 
exceeding 18.5//mol/L suggest an adrenal tumor (Ehrmann and Rosenfield 1990b). 
Kruimel et al. (1991) described a patient with an extensive adrenocortical carcinoma 
who showed clinical signs of Cushing's syndrome as well as amenorrhea, severe 
hirsutism, acne and virilization. Plasma levels of T, A4, 170HP and DHEAS were all 
excessively (about 30-fold) increased. Cortisol levels were only mildly elevated (1.5-
fold). 
Virilizing ovarian tumors generally produce much less DHEA and DHEAS. Ovarian 
androgen producing tumors include sex cord stromal tumors, Sertoli-Leydig cell 
tumors, lipid cell tumors as well as granulosa-theca cell tumors (Farquharson 1988) 
(Table 1.3.1). Computerized tomography of the adrenal or sonographic scanning of 
the ovaries may visualize tumors. Alternatively androgen-secreting tumors may be 
localized preoperatively by direct venous blood sampling using selective 
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Table 1.3.1 Causes of hirsutism. 
A. Stronalv increased serum androaen levels 
Adrenal 
Ovarian 
androgen secreting adenoma, carci 
congenital adrenal hyperplasia 
polycystic ovarian syndrome 
hyperthecosis 
neoplasms 
noma 
21-OH lase deficiency 
30-HSD deficiency 
11-OH lase deficiency 
(insulin resistance) 
sex cord-stromal cell tumor 
Sertoli-Leydig cell tumor 
granulosa-theca cell tumor 
lipid cell tumor 
B. moderately increased serum androaen levels 
Adrenal Cushing's disease 
Congenital adrenal hyperplasia 
deficiency 
deficiency 
Ovarian 
Cortisol resistance 
Polycystic ovary syndrome 
С Normal serum androaen levels 
D. 
late onset 21-OH lase 
late onset 3/7-HSD deficiency 
late onset 11-OH lase 
decreased sex hormone binding globulin 
increased skin 5a-reductase activity 
'idiopathic hirsutism' 
Medication, anabolic steroids 
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catheterization of the ovarian and adrenal veins. Moltz et al. (1984) used this 
technique in non-neoplastic hyperandrogenism and found elevated glandular output 
of at least one androgen in 80% of the cases. However, these authors recommend 
catheterization only in patients with suspicion of neoplastic hyperandrogenism on 
the basis of elevated plasma levels of Τ and DHEAS. Wentz ef al. (1975) concluded 
that bilateral catheterization is not clinically useful because of interindividual 
anatomic variation, the episodic and parallel character of adrenal steroid hormone 
secretion, and the effects of stress associated with the sampling procedure. Ovarian 
androgen secretion is not parallel and the developing follicle or corpus luteum cause 
secretion gradients which interfere with distinguishing ovarian dysfunction. 
Congenital Adrenal Hyperplasia (САН) and exaggerated 
adrenarche 
Congenital adrenal hyperplasia may be the result of 21-hydroxylase, 11-
hydroxylase, or 3/?-hydroxysteroid dehydrogenase deficiency. These deficiencies are 
inherited as autosomal recessive disorders. 
Generally Cortisol synthesis is impaired in the face of increased levels of ACTH. 
Two classic types of 21-hydroxylase deficiency are discerned. Type I is 
characterized by virilization unaccompanied with salt loss. In two thirds of the 21-
hydroxylase deficiency patients virilization is accompanied by salt loss due to 
impaired aldosterone synthesis (Type II) (Kater and Biglieri 1983). In both forms of 
САН ambiguous genitalia may be present at birth. 
In the classic cases of 21-hydroxylase deficiency decreased Cortisol production is 
accompanied by extremely elevated levels of A4 and particularly 170HP (Otten et al. 
1983, Otten 1987, Pang ef al. 1979). Due to peripheral conversion of these 
prehormones the plasma concentration of Τ may be increased (Horton and Frasier 
1967, Rivarola et al. 1967). In contrast to the classic, severe forms, 'late-onset' 21-
hydroxylase deficiency presents around the time of, or a few years after puberty 
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with hirsutism or virilization as well as menstrual disturbances depending on the 
degree of penetration of the deficiency 
The major b-locus of the histocompatibility complex is genetically linked to the gene 
encoding the 21-hydroxylase enzyme which is located on the short arm of 
chromosome 6 (Eldar-Geva et al 1990) Consequently, HLA-typing may be used to 
detect heterozygotes for the 21-hydroxylase gene or to detect carriers for the 21-
hydroxylase deficiency gene (Kuttenn ef a/ 1985, New et al 1983) 
Basal levels of Cortisol are not significantly different from normal in the late-onset 
type and levels of 170HP, A„ and Τ are not necessarily increased ACTH 
stimulation of adrenal function may be used to reveal the defect 
Whereas classic 21-hydroxylase deficiency is rare, the late-onset form is a common 
cause of hirsutism (Chrousos et al 1982) In a group of 400 pre- or postpubertal 
hirsute women 24 (6%) were found to have the late onset form of this enzyme 
defect (Kuttenn ef al 1985) Chetkowski et al (1984) found only one woman (1 2%) 
with 21-hydroxylase deficiency in a group of 83 unselected hirsute women while 
Pang et al (1985) reported an incidence of 13 8% Eldar-Geva ef al (1990) found 
18 (10%) women with 21-hydroxylase deficiency in a group of 170 hirsute Israeli 
women Siegel ef al (1990) also reported a substantial proportion (61%) of 
(selected) women with hirsutism to have mild defects in adrenal steroidogenesis, 
which were revealed following ACTH stimulation, suggesting late onset congenital 
adrenal hyperplasia Evidence of 21-OH-lase deficiency was present in 5 out of 32 
patients 
Dewailley ef al (1988) confirmed the relatively high incidence of an exaggerated 
170HP response to ACTH in hirsute women, but these authors found that this high 
response was not exclusively linked to 21-hydroxylase deficiency In 8 7% of a 
group of 265 hyperandrogenic patients Azziz et al (1991) found abnormally 
elevated levels of 170HP following ACTH stimulation These were consistent with 
late onset congenital adrenal hyperplasia in approximately one-third of the cases 
(1 8%) In 3 4% of the women the exaggerated 170HP increment after ACTH was 
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not consistent with late onset congenital adrenal hyperplasia. A high 170HP 
response after ACTH may represent a normal 170HP adrenocortical response 
superimposed on an elevated circulating level of 170HP which is not of adrenal 
origin. Secondly, hyperfunction of P450c17a as seen in exaggerated adrenarche 
has been hypothesized to be the cause of this high response (Rosenfield et al. 
1990). 
In 11-hydroxylase deficiency, also inherited as an autosomal recessive trait, Cortisol 
synthesis is blocked leading to accumulation of 11 -deoxycortisol and 11-
deoxycorticosterone. Since the latter has mineralocorticoid activity this deficiency in 
its classic form is characterized by hypertension. Prenatal virilization may occur due 
to increased concentrations of A4. In the late-onset type of 11-hydroxylase 
deficiency symptoms may vary from hirsutism with or without acne, mild virilization 
and in some cases arterial hypertension (Cathelineau et al. 1980, Zadik ef al. 1984). 
This deficiency was found to have an incidence of 8% in a group of 170 hirsute 
women (Eldar-Geva et al. 1990). 
When completely expressed, 3/?-HSD deficiency may be fatal in the prenatal or 
neonatal period as a result of Cortisol and aldosterone deficiency. The late-onset 
form of 3/MHSD deficiency is characterized by high ratios of Δ5/Δ4 steroids e.g. 17-
OH-pregnenolone/17-OH-progesterone and DHEA/A4. Morning levels of DHEA and 
P5 were found to be elevated (Pang ef al. 1985). Similar to late-onset 21-
hydroxylase deficiency genetic heterogeneity of 3/?-HSD deficiency results in various 
degrees of penetration of the enzyme defect. The deficiency has been shown to 
occur both in adrenal and gonadal tissue although this does not necessarily 
coincide (Bongiovanni ei al. 1981). The estimated incidence of 30-HSD deficiency 
in a somewhat preselected group of 116 hirsute women was 12.9% (Pang ef a/. 
1985) . Siegel et al. (1990) found evidence of 30-HSD deficiency in 5 out of 32 
patients (16%), while Barnes ef al. (1993) reported an incidence of steroid 
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responses to ACTH suggestive of 3-0HSD deficiency as high as 20%. The 
peripheral 3/ff-HSD activity in these patients appears to be intact (Rosenfield ef al. 
1980). 
Elevated levels of A4-steroids in patients with A5-steroid profiles characteristic of 
3/7-HSD deficiency may be the result of exaggerated adrenarche (dysregulation of 
cytochrome P450c17a activity) (Rosenfield ef a/. 1990, Lucky et al. 1986). In the 
latter defect a relatively deficient 3/MHSD activity is associated with increased C17-
20-lyase activity. Barnes et al. (1993) concluded that in most cases increased 
activity of C17-20-lyase is responsible for what is termed 3/?-HSD deficiency. These 
changed enzyme activities resemble the events normally occurring at adrenarche. 
As a result OHP5, DHEA and A4 accumulate (fig 1.3.1). In contrast, Cutler et al. 
(1990) reported little change in 3/?HSD activity during adrenarche. It is hypothesized 
that patients have an hyperplastic zona reticularis rather than being hyperresponsive 
to ACTH (Laue er al. 1991). 
17-OH PREGNENOLONE > 17-OH PROGESTERONE 
DEHYDROEPIANDROSTERONE * ANDROSTENEDIONE 
Fig 1.3.1. The relative increase in 17,20-lyase and decrease in 30-HSD enzyme activity 
characteristic of exaggerated adrenarche (Lucky et al. 1986). 
The diagnosis of adrenal enzyme defects depends on the detection of an 
accumulation of steroid hormones preceding the enzyme defect. In the mild cases, 
specific defects are not always apparent from baseline levels. Stimulation of the 
adrenals with synthetic corticotropin with or without overnight dexamethasone 
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preparation may reveal the enzyme deficiency (Eldar-Geva er al. 1990, Chrousos ei 
al. 1982, Pang er al. 1985, Siegel et al. 1990, Lucky et al. 1986). According to 
Rosenfield ef al. (1985) overnight dexamethasone administration appears to offer no 
practical advantage in ACTH testing for mild defects in 21 hydroxylation. Ehrmann 
ef al. (1990) suggested to perform a five-day low-dose dexamethasone test (2 mg 
daily) to separate adrenal from ovarian hyperandrogenism and to identify women in 
whom an ACTH stimulation test may be considered. Although the ACTH stimulation 
test has proven its value in the diagnosis of late-onset congenital adrenal 
hyperplasia, the overall diagnostic value of this test has been disputed (Cobin et al. 
1985). 
Cushing's disease and Cortisol resistance 
In Cushing's disease (Cushing 1932) bilateral hyperplasia of the adrenals occurs 
due to overproduction of ACTH, usually due to basophilic cell microadenoma of the 
pituitary. The pathogenesis is not clear, but it has been suggested that CRH may 
play a role in the progression of pituitary adenoma (Kovacs 1993). Primarily, 
Cushing's disease is characterized by hypercortisolism but in women hirsutism or 
even virilization as a result of increased adrenal androgen production may also 
manifest itself (Smais et al. 1977). 
In the rare case of primary end-organ Cortisol resistance (an autosomal dominantly 
inherited trait) some patients present with hypertension which in women may be 
accompanied by hirsutism, mild virilization and/or menstrual irregularities. To date 
end organ resistance to glucocorticoids has been reported in 8 unrelated kindreds 
(Karl ef al. 1993). Cortisol production is increased and does not suppress normally 
after dexamethasone administration. Glucocorticoid resistance has been linked to 
quantitative and/or qualitative alterations of the glucocorticoid receptor inducing 
decreases in the receptor concentration and ligand binding affinity, thermolability, or 
abnormal interaction with DNA. 
Lamberts ef al. (1986) described a 26-years old woman with elevated plasma 
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concentrations of Cortisol, AA and T. Unlike the absence of diurnal variation in 
Cushing's syndrome, Cortisol levels in this patient showed a normal diurnal rhythm 
albeit at a high level. Clinically this patient showed hirsutism but no hypertension or 
symptoms of Cushing's syndrome. The authors suggest that partial Cortisol 
resistance may be more common among hirsute women with increased adrenal 
androgen production. Moreover, they suggest that some patients diagnosed as 
having Cushing's disease, actually may have partial end-organ Cortisol resistance. 
Polycystic Ovary Syndrome 
Although the clinical and biochemical manifestation of the polycystic ovary 
syndrome (PCO) is very heterogenous and in fact some researchers in the field 
doubt if the designation 'syndrome' is justified (Goldzieher 1981), PCO may be 
characterized by functional gonadotropin-dependent ovarian hyperandrogenism. 
Originally described by Stein and Leventhal (1935) PCO is often presenting with 
hirsutism and obesity as well as oligo- or amenorrhea at the onset of puberty. The 
ovaries may be enlarged two- to five-fold and multiple subcapsular atretic follicles 
are present. Ultrasound imaging may be used to confirm the diagnosis, although the 
ovaries are not necessarily enlarged in all cases. 
Franks (1989) identified polycystic ovaries in 87% of 46 women diagnosed initially 
as idiopathic hirsute' on the basis of regular ovulatory cycles. Conversely, of 32 
women with PCO 60% were hirsute. 
The plasma levels as well as the production rates of A4, (plasma free) Τ and За-diol 
were increased in women with PCO regardless of the presence or absence of 
hirsutism (Lobo er al. 1983). In most patients the elevated plasma Τ appears to be 
derived from direct ovarian secretion (Horton and Neisler 1968, Bardin and Lipsett 
1967). 
The pathogenesis of PCO has been the subject of extensive discussion. 
In many cases plasma particularly bioactive LH is increased whereas 
immunoreactive and bioactive FSH levels are normal (Fauser et al. 1991) resulting 
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in an elevated LH/FSH ratio Moreover, an exaggerated response of LH may be 
observed after exogenous GnRH stimulation Finally, the pulsatile and diurnal 
secretion of LH may be abnormal (Barnes and Rosenfield 1989) Due to the 
increase of LH over FSH theca cell androgen production is stimulated while 
granulosa cell aromatization of androgens is relatively inhibited Consequently more 
androgens than oestrogens are formed 
Those cases in which LH abnormalities are prominent have been referred to as 
'type I', the classic polycystic ovary disease, as opposed to cases in which 
gonadotropins are near normal (type II) (Barnes and Rosenfield 1989) 
On the basis of the frequent finding of polycystic ovaries in Cushmg's syndrome and 
congenital adrenal hyperplasia it has been suggested that androgens of adrenal 
origin are the stimulus for the development of PCO (Benjamin et a/ 1986, Enckson 
1989) Late onset САН may even present initially as polycystic ovarian disease 
(Chrousos ef al 1982) In early reports the adrenal involvement in the androgen 
excess in PCO was estimated by assessing dexamethasone suppressibility of 
hyperandrogenemia (Rosenfield et al 1972) 
According to the classic 'oestrone hypothesis' increased production of A4 and 
peripheral aromatization of A< to oestrone are central to the sensitization of the 
pituitary to secrete LH Aromatization activity is particularly increased in obese 
women LH release subsequently stimulates the ovary to produce androgens, 
particularly A4 (McKenna 1988) On the other hand Barnes and Rosenfield (1989) 
concluded that there is no direct relationship between high oestrone and LH levels 
Moreover not all patients have elevated levels of LH 
Early observations indicate an aromatase defect (Ginsberg and Havard 1976) or 
partial deficiency of 3/7-HSD activity (Lobo and Goebelsmann 1981) resulting in an 
accumulation of androgens Rosenfield ef al (1990) suggested that 
hyperandrogenism in PCO arises from 'masculinized' dysregulation of cytochrome 
P450c17o (with C17-20-lyase and 17o-hydroxylase activity) particularly in the Δ4-
pathway These authors observed greater 170HP and A„ responses during GnRH 
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agonist (nafarelin) testing in women with PCO than in controls (Dewailly ef al. 1988, 
Barnes et al. 1993, Lobo and Goebelsmann 1981). P450c17cr is stimulated by small 
amounts of LH. Hyperfunction of P450c17a may be the result of increased LH 
stimulation due to insulin and insulin-like growth factor mediated inhibition of thecal 
cell LH receptor down-regulation. This group considers hyperinsulinemic insulin 
resistance primary to the pathogenesis of PCO (Rosenfield ef al. 1990, Barnes and 
Rosenfield 1989, Barnes ef al. 1989). In fact, insulin and insulin-like growth factors 
(IGF) have been recognized as important regulators of steroid hormone metabolism 
(Nestler and Strauss 1991). Direct effects of insulin and IGF on ovarian theca and 
stromal cells, synergistically with LH, have been reported (Barbieri et al. 1983, 
Barbieri et al. 1984, Barbieri et al. 1986, Rittmaster 1993a). Hyperinsulinemia is 
present in many patients with PCO. Yet, there is no correlation between 
testosterone and insulin levels: in obese women with PCO, who have high levels of 
insulin, testosterone may be similar to the level in lean women with PCO (Franks 
1989). A positive correlation between insulin and androgens was established in 
patients with hyperthecosis of the ovaries (see below). 
Recently it has been hypothesized that increased 5ar-reductase activity in the liver 
and the skin observed in hirsute women not only leads to hirsutism by the enhanced 
conversion of testosterone to DHT, but also to increased hepatic metabolism of 
Cortisol. As a result, corticotropin secretion will increase to maintain normal Cortisol 
levels at the expense of androgen excess providing the basis for PCO (Stewart ef 
al. 1990). 
Moreover, ovarian 17-ketosteroid reductase deficiency (the enzyme which converts 
androstenedione to testosterone and oestrone to oestradiol) may cause a syndrome 
closely resembling PCO, primarily due to the low secretion of oestradiol and the 
lack of feedback on LH. The high intra-ovarian levels of A4 may also contribute to 
the morphologic changes of the ovary (Toscano et al. 1990). 
In about one fourth of the patients, PCO is accompanied by hyperprolactinemia. Half 
of the patients with PCO who have normal basal levels of prolactin show an 
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exaggerated prolactin response to exogenous thyrotropin-releasing hormone 
(Franks 1989). However, hyperprolactinemia does not necessarily induce hirsutism. 
In fact, it has been suggested that 5o-reductase activity is decreased in 
hyperprolactinemic patients explaining the low incidence of hyperprolactinemia with 
hirsutism despite elevated levels of androgens (Lobo and Kletzky 1982). Vermeulen 
ef al. (1982) concluded that in prolactinomas SHBG appears to be decreased 
resulting in increased clearance rate of testosterone. Hyperprolactinemia has been 
attributed to increased gonadotropin-releasing hormone secretion, which may act as 
prolactin-releasing hormone (Barnes and Rosenfield 1989). It has also been 
suggested that disorders of hypothalamic dopamine regulation are involved (Franks 
1989). 
Hyperthecosis 
Ovarian hyperthecosis is characterized by the presence of islands of luteinized lipid-
rich thecal cells in the ovarian stroma. Patients with stromal hyperthecosis can 'be 
differentiated from those with PCO by their refractoriness to clomiphene therapy 
(Karam and Hajj 1979) and normal levels of gonadotrophins (Steingold et al. 1986). 
Testosterone levels often exceed 7 nmol/l and may lead to severe hirsutism and 
even mild virilization (Abraham and Buster 1976). The onset of symptoms of 
androgen excess is slow in hyperthecosis in contrast with the course of 
androgenization caused by neoplasms. 
Interestingly insulin levels in these,- often obese,- patients are elevated. A positive 
correlation between insulin and the ovarian vein concentration of androgens was 
found. As on PCO, insulin resistance has been suggested to play a role in the 
pathogenesis of ovarian hyperthecosis by inducing stromal luteinization (Nagamani 
ef al. 1986). It has been suggested that stimulation of ovarian androgen 
biosynthesis is mediated through the insulin-like growth factor I receptors 
(Nagamani ef al. 1990). Furthermore, circulating levels of SHBG are decreased in 
insulin resistance amplifying the androgenic effect (Nestler 1993, Birkeland et al. 
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1993, Peiris eí al. 1993, Preziosi et al. 1993). 
Peripheral Conversion 
Increased peripheral metabolism of androgens has been suggested to be central to 
the development of hirsutism (Carmina and Lobo 1991). 17-Ketosteroid reductase 
activity, that converts androstenedione to testosterone was elevated in tissues of 
hirsute women (Horton and Lobo 1986). In 'idiopathic' hirsutism the peripheral 
conversion of testosterone to δσ-reduced metabolites appears to be increased as a 
consequence of increased 5a-reductase activity (Kuttenn ef al. 1977, Gompel et al. 
1986, Serafini et al. 1985) confirming the key role of 5o-reductase in the 
development of hirsutism. Consequently, Serafini and Lobo (1985) consider the term 
'idiopathic' a misnomer. The increased peripheral 5a-reductase activity leads to 
higher excretion of urinary 3a-androstanediol glucuronide (3a-diol-G). 3a-Diol-G is 
the major metabolite of the potent androgens DHT and androstanediol formed in 
hair follicles and the skin. On the basis of the relatively long half-life the plasma 
concentration of 3o-diol-G (Greep ef al. 1986) is expected to reflect increased 
androgen production better than steroids which are quickly cleared from the 
circulation. Horton concluded that 3a-diol-G is a suitable marker of peripheral 
androgen action in idiopathic hirsutism (Horton ef al. 1982). In patients with PCO, 
3o-diol-G was markedly elevated in hirsute subjects, whereas in non-hirsute patients 
with PCO the levels were normal (Lobo et al. 1983). Ovarian A4 and Τ contribute to 
C19 conjugates. Kirschner (Kirschner et al. 1987) found an increased level of 
plasma 3o-diol-G in 27 out of 28 consecutive hirsute women whereas the levels of 
T, free Τ and A4 were not as often elevated. During treatment the lowered levels of 
3a-diol-G reflected the clinical improvement of hirsutism. On the other hand Lobo ef 
al. (1985) did not observe changes in the levels of Зст-diol-G after treatment of 
hirsutism despite diminished hair growth whereas Ponjee ef al. (1991) reported a 
significant decrease of serum 3a-Diol-G after cyproterone acetate as well as the 
hirsutism score in hirsute women. 
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Pang ef al. (1992) found a significant positive correlation between the hirsutism 
score and the level of 3a-diol-G in idiopathic hirsutism and in hirsutism related to 
adrenal androgen overproduction. 3a-Diol-G levels responded to the administration 
of dexamethasone, indicating the significance of the contribution of adrenal 
androgen precursors to the production of 3<7-diol-G. Similar observations (Carmina 
and Lobo 1991) indicate that the adrenal is the principal source of precursors for 
markers of peripheral androgen metabolism. Moreover on the basis of a high 
correlation between 24 h urinary 17-ketosteroids and 3a-diol-G in patients with a 
virilizing form of congenital adrenal hyperplasia these authors (Pang ef al. 1991) 
concluded that measurement of plasma За-diol-G provides a useful metabolic index 
of integrated adrenal androgen secretion. Conversely, it has been suggested that 
Заг-Diol-G as well as other C19 conjugates may be influenced by precursors from 
the ovary, principally A4 and Τ (Matten 1992). 
The significance of 3a-diol-G as a specific metabolite of androgen target tissue was 
disputed by Giagulli et al. (1993). These authors concluded that the 17/?-
hydroxyandrogen glucuronides are mainly formed in the splanchnic circulation. 
Moreover, it has been shown that during hyperthyroidism 3<7-diol-G levels are 
elevated without evidence of hyperandrogenicity due to increased hepatic 5σ-
reductase activity (Scanlon ef al. 1988, Giagulli and Vermeulen 1992). 
Alternatively the 5o-reduced metabolite androsterone-glucuronide has been used as 
a marker of peripheral metabolism (Reed and Franks 1988). However it was 
hypothesized that DHEAS is the main precursor of androsterone-glucuronide via 
hepatic enzyme activity rather than peripheral action (Giagulli et al. 1993). 
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1.4 Free androgens in plasma 
Androgens in plasma for the larger part are bound to plasma proteins, mainly sex 
hormone-binding globulin (SHBG) and albumin, leaving only a small fraction in the 
non-protein bound, free form To a small extent, androgens are also bound to 
corticosteroid-binding globulin (CBG), a protein which predominantly binds 
corticosteroids On the basis of estimations of association constants and 
Table 14 1 Transport of endogenous steroids in normal women in the follicular phase of 
the menstrual cycle The calculated plasma distnbution of steroids is shown 
as the percent of the total steroid circulating in each fraction The association 
constant of the binding of each steroid to the proteins is shown between 
brackets (10e M1) (After Dunn et al 1981) 
Steroid 
DHEA 
Androstenedione 
Testosterone 
Total 
(nM) 
17 
54 
1 3 
Unbound 
(%) 
3 93 
7 54 
1 36 
SHBG 
(%) 
7 88 
[66] 
6 63 
[29] 
66 0 
[1600] 
(CBG) 
(%) 
<0 1 
[<0 1] 
1 37 
[0 58] 
2 26 
[5 3] 
Albumin 
(%) 
88 1 
[0 04] 
84 5 
[0 02] 
30 4 
[0 04] 
The concentrations of SHBG, CBG and albumin were 37 nM, 0 7 μΜ and 0 56 mM, 
respectively 
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measurements of the concentrations of plasma binding proteins and steroid 
hormones, Dunn et al. (1981) calculated the plasma distribution of steroids into 
SHBG-bound, CBG-bound, albumin-bound and non-bound fractions (Table 1.4.1). 
Albumin is the most abundant plasma protein (0.6-0.8 mmol/l), representing about 
fifty percent of the total protein in plasma. It has a very high binding capacity, but 
low binding affinity ( K¿ 10"4 to 10s M) for a variety of steroids. Each albumin 
molecule has multiple steroid binding sites. 
DHEA and androstenedione are bound predominantly to albumin, whereas 
testosterone is largely bound to SHBG. The percent binding to CBG of these 
steroids is small. 
Mercier et al. (1965) first described a testosterone/oestradiol binding globulin in 
plasma. SHBG is referred to as a specific binding protein because of its high affinity 
binding of C-19 steroids with a 17/?-hydroxyl function (K,, 10"9 M). These steroids 
include dihydrotestosterone and testosterone but also -albeit with lower affinity-
oestradiol. In contrast, albumin binds these steroids with low affinity but with a high 
binding capacity, as pointed out above (Rosner 1990, Westphal 1971, Westphal 
1986). SHBG is a homodimeric glycoprotein with one steroid binding site comprising 
two subunits, each with a molecular weight of about 52 kDa. Amino acid analysis 
disclosed 373 residues apart from oligosaccharide chains. The steroid binding site is 
assumed to be located near the carboxy terminus of the molecule (Hammond 1990), 
although there is some controversy with respect to this location (Rosner 1991). 
The level of SHBG in plasma is influenced primarily by sex hormones and thyroxin 
(Table 1.4.2). SHBG is synthesized constitutively in the liver (Anderson 1974). This 
was demonstrated in vitro in experiments utilizing human hepatoblastoma cells 
(Khan er al. 1981). SHBG deficiency associated with low total and normal free levels 
of Τ is inherited as an autosomal trait with incomplete penetrance (Gross and 
Horton 1971). 
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SHBG levels in pregnant subjects (250-500 nmol/l) are much higher than in controls 
(20-120 nmol/l) After delivery the SHBG level falls with a half-life of seven days 
SHBG has been reported to be slightly higher in the oestrogenic phase of the 
menstrual cycle (Plymate ef al 1985) It has been suggested (Rosner 1990) that the 
dose-related increase in SHBG in conditions associated with relatively high levels of 
oestrogens must be attributed to a decrease in the clearance rate, rather than an 
increase in production by hepatocytes Oestrogens might cause a greater degree of 
sialylation of SHBG, which would then be cleared slower from the circulation than 
less sialylated forms 
Table 14 2 Conditions affecting the level of sex hormone-binding globulin in human 
plasma 
increased SHBG 
high thyroxin 
hyperthyroidism 
exogenous T4 
high oestrogen 
pregnancy 
oestrogenic phase of the 
menstrual cycle 
oral contraceptives 
cirrhosis of the liver 
anorexia nervosa 
decreased SHBG 
high androgens in women 
polycystic ovary disease 
hirsutism 
hyperprolactmemia 
increased insulin-like growth factor 
increased growth hormone 
menopause 
obesity 
hypennsulinaemia 
Thyroxin (T4) apparently induces SHBG formation by direct stimulation of the 
hepatocytes Utilizing a hepatoma cell line, Rosner et al (1984) demonstrated that 
there is a direct relationship between the production of SHBG and the concentration 
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of T4. During hyperthyroidism the level of SHBG is increased two to three times. 
These elevated levels normalise following administration of antithyroid drugs (Aoki 
et al. 1986). An alternative explanation was provided by Aoki ef al. (1986) who 
observed that free oestradiol was increased in hyperthyroidism probably as a result 
of increased peripheral conversion of androgens into oestrogens. Thus, the increase 
in SHBG in vivo with increasing levels of T4 might be secondary to the elevated 
concentration of non-protein bound E2. 
Androgens counteract the effect of oestrogens on the level of SHBG in vivo. 
Interestingly this effect is not observed in vitro (Plymate et al. 1990). Thus, SHBG 
levels in men (10-50 nmol/l) are lower than those in women, and in hirsute women 
levels are lower than those in controls (Rosenfield 1971). In adult men after the age 
of 50 SHBG levels increase concomitant with a decrease in levels of androgens 
(Anderson 1974). 
Hyperprolactinemia is characterized by decreased SHBG which returns to normal 
after treatment with bromocriptine (Glickman ef al. 1982). Insulin also lowers SHBG 
secretion by hepatocytes in vitro. Obesity is often accompanied with very low 
SHBG, which may be associated with the increased plasma insulin in these subjects 
(Mathur ef al. 1982, Nicholas ef a/. 1993, Nestler 1993). Preziosi ef al. (1993) 
reported an inverse relation between the level of plasma SHBG and insulin in pre-
and postmenopausal women. In patients with anorexia nervosa, a condition which is 
also characterized by low levels of T3 and T4, high levels of SHBG have been 
reported (Moore and Bullbrook 1988). Insulin-like growth factor (IGF-I) likewise 
decreases the production of SHBG by hepatoma cells in vitro. It has been 
suggested that the decrease in SHBG seen in boys and girls before and during 
puberty is the result of increasing IGF-I (Plymate ef al. 1990). 
Recently SHBG has been shown to interact with sites on cell membranes which 
have properties of receptors. Rosner et al. (1991) investigated the binding of SHBG 
to the solubilized receptor obtained from prostatic tissue. This group found a high 
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affinity binding site with а Κ„ of 1.5 nM and a molecular weight of 167 KD (Rosner 
1991, Hrybera/. 1989). 
There is some controversy in the literature with regard to the binding of SHBG to its 
receptor. Hryb et al. (1990) , utilizing solubilized receptor from human prostatic 
tissue, reported that only non-liganded SHBG is able to bind to the receptor. This 
group suggests that SHBG complexed with DHT or Τ assumes a conformation that 
prohibits binding. Once bound to its receptor, SHBG is able to bind DHT. On the 
other hand the group of Strel'chyonok (Strel'chyonok ef al. 1984, Awakumov et al. 
1986) reported that only SHBG complexed with oestrogens is able to bind to the 
SHBG-receptor on decidual endometrium membranes. 
Interestingly, the concentration of c-AMP in human prostatic carcinoma cells was 
shown to increase in a dose-dependent way after binding of either DHT or E2 to 
unliganded SHBG-receptor complex (Nakhla et al. 1990). This observation suggests 
absence of biological steroid specificity of the system. 
The physiological activity of androgens has been demonstrated to be correlated with 
their free concentration measured in vitro, better than with the plasma total level 
(Ekins 1990b). This is especially apparent in cases of elevated or decreased 
concentrations of binding proteins e.g. in pregnancy, after oestrogen administration, 
in obesity, or in the rare case of deficiency of binding proteins. The free fraction of 
sex hormones in plasma is largely controlled by the concentration of SHBG. The 
metabolic clearance rate of androgens is directly related to the free androgen 
fraction in blood (Vermeulen and Ando 1979), which has led to the supposition that 
SHBG plays a subsidiary role in the regulation of androgen metabolism. 
The free hormone hypothesis, as it is nowadays understood, assumes that free and 
bound hormone are in rapid dynamic equilibrium, so that any free hormone that is 
taken up by target cells from the blood immediately is replaced by dissociation of 
hormone from its binding proteins (Robbins and Rail 1979). 
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In a number of studies Pardridge (1982) presented evidence that for all organ 
systems studied, the fractional uptake of radiolabelled steroid or thyroid hormones 
during a single pass exceeded the dialysable fraction in serum. This finding led to 
his rejection of the free hormone hypothesis, notwithstanding the fact that this 
hypothesis implicitly allows for this inequality and does not require that single pass 
fractional extraction should be equal to the in vitro dialysable fraction. In contrast 
with the free hormone hypothesis, such a requirement does exist for the Tait and 
Burstein model (Tait and Burstein 1964) in which exclusively the free hormone is 
available for target organs. The protein-bound hormone fraction during passage 
through a target tissue is considered as immobile and therefore unavailable for 
transport. 
Pardridge explained his findings by stating that it is the albumin-bound fraction that 
is available for transport into tissues in some cases (thyroid hormones and steroids 
into brain, T4 and testosterone in liver), and in other cases also the globulin-bound 
fraction (T3, oestradiol and corticosteroids into liver). According to this theory it is 
the ty, of the dissociation of the hormone from a binding protein versus the capillary 
transit time that determines whether hormone bound to this particular protein is 
available for transport. 
From 1984 onwards, Pardridge introduces the "modified Kety-Renkin-Crone" 
equation as the model of choice for describing hormone uptake by tissues 
(Pardridge 1987). This equation defines the fractional uptake of hormone in terms of 
its free fraction in plasma and capillary permeability, assuming that equilibration 
between free and serum protein-bound hormone is instantaneous. This equation in 
fact explains how, in terms of the free hormone hypothesis, the fractional extraction 
of hormone during the single pass experiment, may very well exceed the in vitro 
free hormone fraction. However, this requires substantially higher values for the 
permeability constant than Pardridges' own estimates, obtained during liver 
perfusion experiments in the absence of serum in the injected bolus. Therefore he 
postulates an entirely new mechanism in which the in vivo equilibrium (dissociation) 
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constant of some proteins, particularly albumin, exceeds the in vitro equilibrium 
constant through the interaction of the protein-hormone complex with capillary 
endothelia. On this "enhanced dissociation mechanism" Pardridge's "bound 
hormone hypothesis" is founded. 
Two alternative explanations for the above mentioned apparent contradiction have 
been given: Mendel ef al. (1988) provides evidence suggesting that Pardridges 
estimates of capillary uptake rate constants may be some orders of magnitude too 
low, so that there is no reason to abandon the free hormone hypothesis. According 
to these authors the low extraction estimates reported by Pardridge reflect 
contamination of the injected bolus with rat plasma protein in liver perfusion 
experiments. Such underestimation is also assumed by Ekins, who, in contrast, 
offers an explanation in which the rate of extraction of hormone from the capillary is 
limited by its dissociation rate from binding proteins, which evidently means that it is 
the bound hormone concentration that dictates hormone efflux. Ekins in this case 
employed an equation that is a simplification of his own model for hormone efflux 
that encompasses also the influence of transport phenomena like diffusion and flow. 
It can be shown that in fact the "Kety-Renkin-Crone" equation is a further 
simplification of the simplified Ekins model. The latter "bound hormone hypothesis" 
has the advantage of explaining the observations in terms of well-known 
physicochemical laws, rather than relying on postulations of hitherto unknown 
mechanisms. 
Alternative to the free hormone hypothesis, Keller ef a/. (1969), as well as Siiteri et 
al. (1982, 1985) hypothesized that the bound hormone is transported into the cell 
along with the binding protein. 
Determination of free androgens in plasma 
Free hormones in blood can be determined by physically separating the protein-
bound from the free hormone fraction, using equilibrium dialysis or ultrafiltration 
(Table 1.4.3). Steady state gel filtration has also been applied for this purpose 
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(Fisher and Andersen 1974). The free hormone can also be measured using 
immunological techniques. Particularly in the field of thyroidology, immunoassays for 
routine free hormone estimation are widely available. These were discussed in 
detail by Ekins (1990b). 
Dunn et al. (1981) calculated the free concentration of steroid hormones from 
estimated dissociation constants and measurements of the concentrations of binding 
proteins and steroids. 
There are two approaches to determine free steroids in plasma by equilibrium 
dialysis or (centrifugal) ultrafiltration. 
In the direct method (henceforth referred to as direct equilibrium dialysis) the 
concentration of the free steroid in the dialysate or ultrafiltrate is determined by 
radioimmunoassay. This technique, which is generally considered as the standard 
method, was first developed for the estimation of free thyroid hormones (Ellis and 
Ekins 1973). Since the free hormone concentration in many instances is very small, 
its direct measurement requires highly sensitive and specific radioimmunoassays. 
Moreover, the determination of free hormone may be negatively biased as a result 
of adsorption of the hormone in the essentially protein-free dialysate or ultrafiltrate. 
Alternatively indirect methods may be used which are based on the measurement of 
the free fraction and the total concentration of the steroid in plasma. 
In the indirect equilibrium dialysis method tritium-labelled steroid is first added to the 
plasma. This mixture is subsequently dialyzed to equilibrium against buffer 
(Daughaday 1958, Slaunwhite and Sandberg 1959, Forest et al. 1968). The tracer is 
assumed to distribute identical to the endogenous steroid in the sample. The 
concentration of radiolabelled steroid in the dialysate, relative to the total 
concentration of labelled hormone is an estimation of the free fraction. The dilution 
inherent in dialysis against buffer results in a decrease of the free hormone 
concentration as compared to the original, undiluted sample, the magnitude of which 
depends on the free fraction itself. Particularly in the case of steroid hormones 
which have a relatively high free fraction (1-10%) sample dilution with a factor of 5-
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10 may lead to significant errors in the estimation of the concentration of free 
hormone in the original sample (Ross 1980, Geiseler and Ritter 1983). Although the 
method for calculation of the free hormone fraction according to Slaunwhite and 
Sandberg (1959) has widely been used, it is of limited validity. Their procedure 
involves the measurement of c, (total tracer concentration in the dialysand) and c2 
(concentration of the free tracer both in the dialysate and in the dialysand) and the 
subsequent calculation of the free fraction of hormone in the dialysand f=c2/cr 
Dilution of the dialysand as a result of fluid shift during equilibrium dialysis, causing 
a decrease in c,, is neglected. 
Using computations as proposed by Ekins (1990b) and Ross (1980) the free fraction 
of the hormone in the undiluted sample can be approximated while at the same time 
the effect of dialysand dilution is circumvented. This is accomplished by using the 
total tracer concentration in the dialysis system as the reference, rather than 
concentration of the tracer in the dialysand. 
In the indirect methods the radiochemical purity of the tracer is of paramount 
importance. Even relatively minor impurities may lead to gross overestimation of the 
free hormone fraction. For instance, the presence of 2% of radiolabelled material in 
tritiated testosterone which does not bind to any of the plasma proteins will lead to 
the assessment of an almost twice higher free testosterone in female sera at a 1:1 
dilution. 
In addition to the temperature during dialysis, the composition of the buffer used in 
dialysis or in ultrafiltration is of importance for the assay results (Umstot and 
Andersen 1986). 
In ultrafiltration (Hammond et al. 1980), either in the direct or the indirect approach, 
some protein leakage through the filtration membrane may occur, yielding 
erroneously elevated levels of free steroid hormone (Willcox ef al. 1983). 
Most of the problems associated with indirect equilibrium dialysis for the 
assessment of the free fraction of steroids in plasma can be circumvented by using 
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the symmetric or rate dialysis technique. The principle of this method was first 
applied by Christensen (1959). It was further developed and provided with a 
theoretical base by Ross (1978, 1980). Later the method was adopted by Willcox et 
al. (1983), Swinkels et al. (1987) and Cooke et al. (1990). 
In symmetric dialysis the same plasma sample is present on both sides of the 
dialysis membrane. Tritium labelled steroid is added to one of the dialysis cell 
compartments. The rate at which this tracer migrates from one compartment to the 
other is, in addition to membrane permeability and sample volume, a function of the 
free fraction of the hormone. Symmetric dialysis allows the determination of free 
steroid in undiluted serum. Moreover, since for optimal precision the dialysis 
process is terminated when about one third of the tracer has migrated to the other 
compartment, minor tracer impurities do not influence assay results. The method is 
based on the comparison of the dialysis rate of the tracer in a reference sample 
with a known free fraction (determined by direct equilibrium dialysis) with the 
dialysis rate of unknowns. 
45 
co 
9- S1 Й [Τ]Ώ 
9¡.S=-o Д О 
-
и
са S 2 
э sr s § 
о 
I-
^g 
— w СО с о 
" S r n l S 
3 н э «л 
5 о _ сч 
a *
 Л 
m ä a a 
? s а з 
SL3S3 
э 
с 
э 
о 
оз -. 
со Тз 
α °> 0J 
8 Ч 5 0 
ё- ч s φ
оз -5 
э -
З І 9 - о 
5 оЗ 
η з 3 δ 
S S С 
_ ? о> ^ 
CD 03 ТЗ 2 
* о з- ? 
3 О ~ Со 
η 3 Со 
" 3 1 о> 
Q . _ Э 
о-
Dj ( Q 
ο -S i» χ 
Ili ¡г о э 
стад 9> 
§ 1 * à 
3 аз § 2 
3 S-3 о 
"Л g 
8 * ч§. 
Γη о о· ω 
»II« 
f з ν -, ja с 
5· о i« 
46 З 5 з-
О 0 
3 3 CD CD 
3 3 
= • - h 
С О 
CD = -
Q) О 
— c_ 
fil 
- 1 
О О 
lp» ω 
СЛ v i 
- , 0 ρ 
N5 '-» 
1°. Η! 
3 3 
> > 
m m 
тз ТЗ 
О О 
О 0 
СЛ .f» 
ω -Ρ». 
—. —^  0 ρ 
N3 ^ 
v i СЛ 
—~ "^ 
m m 
О D 
H 
3 -
Сй 
3 -
CD 
СП 
V) 
ТЗ 
О 
о 
О 
Ъ> 
СЛ 
^. 
О 
кэ 
СЛ 
37 
> 
m 
H 
Ι ­
Ο 
, 
' 
тэ 
CD 
3 
CD 
3 
0 
ш 
с 
СП 
03 
s 
О 
3 
CD 
3 
ρ 
ίο 
v i 
^^ 
ρ 
_ Λ 
^ 
3 
> 
m 
ч 
ι
-
η 
, 
' 
га 
Ol 
χ 
CD 
3 
а. 
ш. 
CD 
С О 
0 0 
ω 
> 
CD 
3 
CD 
3 
О 
тз 
01 
с 
СЛ 
DI 
S 
О 
3 
η 
3 
о 
со 
СЛ 
^^  
о 
о 
со 
3 
> 
m 
> 
сг 
, 
' 
тз 
с 
г* 
N 
со 
00 
to 
3-
ел 
с 
CD 
о 
3 
CD 3 
О 
О 
О 
N3 
1 
О 
О 
v i 
со 
33 
> 
m 
О 
χ 
( 
' 
тэ 
а 
3 
CD 
3 
О 
тз 
0) 
с 
со 01 
І 
О 
3 
CD 
3 
0 
о 
о N3 
1 
о 
о 
ω 
0 5 
з 
> 
m 
Ò 
X 
, 
Ξ 
Ûl 
3 
со 
со 
œ 
05 
тз 
η 
О 
о 
о 
_ - і 
05 
О 
О 
-с* 0 0 
3 
> 
m 
H 
Γ­
η 
( 
' 
3 · 
ω 
с 
CD 
О 
3 
O l 3 
0 
0 
—» N3 
t 
О 
О 
CO 
αϊ 
3 
> 
m 
H 
Γ­
η 
О 
b 0 
СЛ 
m 
D 
σ 
χ 
Η 
тз 
CD 
3 CD 
3 
0 
тз 
01 
с 
СП 
01 
s 
О 
3 CD 
3 
0 
о 
—* 
о 
о 
о 
N3 
ОЗ 
3 
> 
m 
H 
ι
-
η 
о 
ò 0 
N3 
m 
D 
Ш 
01 
χ 
CD 
3 
Q . ÇD_ 
CD 
С О 
00 
ω 
0 
3 
CD 
3 
с 
CD 
О 
05 
œ 
, , 0 
-P» 
о 
3 
> 
m 
тз 
η 
о 
СЛ 
05 
_ 
о 
ω 
00 
~~" 
m 
σ 
О 
3 
CD 
3 
-ь 
О 
ñ 
0) 
-ч 
О 
03 
— к 
„ . 
о 
ώ 
N3 
3 
> 
m 
тэ 
η 
O 
СЛ 
0 3 
_ O 
ω 
£ 
m 
σ 
Η 
3 -
со 
з -
CD 
СП 
со 
О 
3 
CD 
3 
0 
СЛ 
КЗ 
_^ 
о 
!_. 
2 
3 
> 
m 
η 
η 
! 
г— 
01 
л 
со 
со 
со 
О 
3 
о 
3 
ρ 
ίο 
I 
ρ 
œ 
η 
2 
СЛ 
, 
' 
о 
01 
СЛ 
7Г 
ср_ 
СО 
00 
о 
D 
I 
m 
> 
тз 
о 
СЛ f-* 
3 CD 
3 
0 
тз 
0 1 
с 
СП 
9L 
S 
0 
3 CD 
3 
0 
кэ N3 
. 
о 
о 
M 
О . 
—ч 
CD 
0 
3 
> 
( 
< 
CD 
7Г 
CD 
00 
ω 
з -
о 
3 
о 
3 
CD 
CO 
с 
σ 
'm 
О 
co 
3 и 
3 2. 
о < 
i 01 
CD 
О 
з -
3 
η 
с 
CD 
ТЗ 
01 
3 CO 
3 3 
0 οι 
CD 
CD 
r+ 
CD 
η 
3 -
3 
η 
с CD 
-, 
CD 
CD 
CD 
3 
О 
CD 
er 
- b . 
co 
О 
о 
3 
s 
3 
о 
3 
со 
Со 
01 
2 
03 
3 
α 
тз 
01 
со 
3 
01 
§· 
3 
о 
3 
•6 3 
ев 
3 
е-
о 
с: 
з 
03 
з 
I 
CQ 
CD 3 
со ? 
CD 
01 
3 
H-
СО 
D 
03 
3 
CQ 
CD 
о 
α) 
и 
с 
Q) 
ι -
0J 
3 
с 
и 
0) 
4-» 
0) 
О) 
і _ _ 
га "δ 
E E 
и с (D 
"5. 
0) 
з 
CT 
E 
u 
со 
4 J 
га ~ 
> О 
râ E 
co с 
u 
cu 
3 
IO 
с 
о 
E 
ί -
Ο 
JZ 
T -
1^· 
T
~ 
с 
cu 
E 
ω 
> 
Ί -
Is« 
к. 
cu 
JZ 
со 
£ 
U . u. 
O 
I 4 * -
* ^ СО 
i¿ ь 
Q Q CD O Q . 
LU 
CM 
τ -
Ο 
о 
' 
с 
cu 
E 
о 
δ 
"δ 
+з 
с 
о 
υ 
Ι ­
Ο Ι 
см 
со 
о 
о" 
1 
с 
со 
E 
о 
5 
CU 
4 ^ 
з 
СО 
к . 
.с 
to 
ω 
£ 
^^ 
r~ 
^" 
о 
CM 
q 
τ ­
ι 
С 
CU 
E 
о 
δ 
"δ 
+ j 
с 
о 
υ 
to 
to 
<£ 
^^ 
см 
ю 
о 
0 0 
Я 
τ ­
ι 
с 
cu 
E 
о 
δ 
cu 
3 
to 
к. 
Ξ. 
ш 
CÑ 
о 
о 
о , 
см 
см 
о 
о 
I 
< < 
1
 ш 
LL. 
LO 
СМ 
о 
о 
i n 
о 
о 
ь_ 
с ™ 
cu 3 
E i ? 
δ ч-
— с 
о cu 
Ρ E 
и S 
ш 
u. 
œ 
CM 
d 
1 
LO 
00 
о 
о 
— co 
CU 
4 J 
_2 
с 
co 
E 
о 
δ 
о 
œ 
τ -
тэ 
с 
о 
E 
E 
га 
I 
Q 
u. 
D 
О 
£ 
^^ , 
σ> 
о 
о 
о 
σ> 
о 
1 
к. 
J0 
3 
О 
О 
с 
со 
E 
о 
δ 
ω 
CD 
f — 
с 
с 
3 
Q 
тэ 
О О *! 
LL. 
3 
U. J2 
э э Ü Ü Ü 
# 
. , 
го 
q 
га 
υ 
£ 
.—. Sí 
о о о 
LO 
œ 
о 
• 
—-
га 
си 
_з 
с 
0) E 
о 
δ 
«° LO 
О 
' ' 
С 
cu 
Ε
Ί 5 8 s 
^ — 
if 
ел E 
cu о 
5. δ 
Ό 
υ 
га 
3 
^о 
га 
υ 
ю 
Τ ­
Ο 
d 
• 
к. 
JO 
3 
о 
"δ 
с 
cu 
E 
о 
δ 
см 
ω 
CT) 
г— 
Sì 
га 
тэ 
с 
си 
X 
га 
Ш 
I I 1 
о о о 
• I • 
1- 1 - H 
Ш Ш Ш 
< < < 
ОС СП ОС 
δ> δ) 5 
о ι - « 
о о о 
о о о 
г^ о см 
СМ LO г ^ 
о о о 
o d d 
с 
cu 
E 
о 
δ 
"¡ô с: 
со c u 
i E 
О S 
Ss 
ε
 3 о 
» ¡ ¡ и 
о. л α. 
LO 
ω 
ω 
cu 
υ 
. с 
5 
κ h -
ο ο to 
to 
CD 
О 
о 
о 
см 
см 
о 
ω to 
о 
τ -
Ο 
о 
см 
о 
о о 
1 
— 
га 
cu 
с 
со 
E 
о 
δ 
ι 
к. 
ja 
3 
υ 
"δ 
с 
со 
ε 
о 
δ 
LO 
ω 
co 
> 
' ' ' 
< < < 
ОС ( Г 
co ü 
CU co 
Q Q 
¡ ю CM 
О CM 
о о 
о о 
СМ τ -
6 ) 0 ) 
о о 
о о 
с 
с со 
І § Î1 
_ га 
га со 
со 3 
з га 
ОС 
о 
со 
Q 
со 00 
О 
О 
0 0 
со 
τ -
Ο 
та и . i j 
α о η 
о с
 u 
с со 
M £ о 
Q. О. 
с 
си 
E 
о 
δ 
LO 
CD 
СП 
« J 
о 
со 
E 
э 
CD 
0 0 
ел 
с 
t5 
га 
Σ 
Q О . 
ш 
^^ 
со 
о 
о 
о 
4 
о 
о 
о 
( О 
о 
о 
о 
1 
с 
со E 
о 
δ 
о 
«-» 
с 
о 
υ 
ш 
^^ 
*t 
CM 
q 
q 
σ> 
о 
о ' 
о 
г^ 
τ -
Ο 
о 
LU 
• < 
oc 
CO 
о 
о 
, о 
^· 
«а-
о 
d 
с 
со 
E 
о 
δ 
с "¡5 
cu ίο 
E 3 i S s о 
í> ¡Б 
3 E 
JZ Q 
Ë 8 i s 
«о co 
s К «¡ 
Ь ^ CD 
•С <r Ä 
S·? ^ 
DiU. Ц_ 
fi -CD 
со С to E l « 
ρ о 
« S sf 
L* CO ^ * 
« я 
S· °>-В 
ε χ ® 
а ¡ο4 s 
ES я a 
•S о ~ i$ с со 
« 3 & 
s» ε - g i if 
І-§І 
c ^ U j t 
И З О 
= S? ^ 
E * -è» 
о с» 
•s fi ϋ 
ffl co i : ES n° S І 
Ρ- * 5 LU ο ^ 
S « ^ 
l ^ 
uil 
со -с з тэ 
J O С ς 
га -э is 
t си er О 
¿ а 0 5 
S I UJ ^ 
а 
О ) ^ со 
СО 
ε 
о 
«о 
о 
со g 
со О 
c o i l S 
CD S § δ 47 
Sî j 9.D 
о 3 
Э CD 1 
3 и 
<Q 
С 
3 
о 
0) 
Со 
Со 
0 1 
0) -», „ 
j i g o 
mil 
CQ s c 
CS 
CO 
& 
S 
3 
01 
(D 
« CD 
С >< 
3 О Ό 
3 Э CD 
S.o. S 
Й a i t 
¿ 3 £ 
Со 5Г 
O'S 
1 3 
си 3" 
о 
o Гп 
3 о 
з -, 
о 
а.« 
's .3-
" a l 
D
 -, - s 
nj СУ 
n a g ; 
Ili 
3" 3 э 
c?3<o 
Q ε с» 
S. о 5. 
^ ? =• s g§ 
§ 1 
a i o 
у 3 » 
а з 
< " £ 3 
со З ш 
О" о 
гл
 С! 2 
48 
а-f 
¡ Ч . CD 
Q) CO 
2. S 
а-
3D 
S 
m 
о 
5 S S 
о о о 3 3 3 
CD CD Π) 
3 D D 
5 ° S stm
e
 
licula
 
eal 
- i 3 
О 
Ό 
Ol 
С 
СЛ 
O l 
О О 
О О 
Μ M 
СО -Р» 
δ 5" ' 
о о 
о о 
£9 ^ 
33 з 
> > 
m m ' 
Ό Ί3 
О О 
О О 
О О о 
о о ° 
со œ о
^ ч . ^ ч * 
О О СО 
о о τ 
о о ~ 
-ρ» ω 
~ 
СЯ со 
о σ 
н 
3 " 
ІЛ 
з
-
CD 
а 
Я 
S s 
о о 3 3 
CD CD 
3 D 
5 о 
Φ — 
ш о 
— c_ 
Q) 
^ 
r ι 
о о 
ò b 
Μ ω 
co -> 
S œ 
A ώ 
—* ~~ 
m 
σ 
го 
Ol 
s 
со 
со 
ω 
з· 
СЯ 
с 
CD 
о 
3 
CD 
э 
ρ 
L k 
О 
ел 
О 
о 
ел 
if. 
D 
CD 
О 
l-f 
33 
> 
, 
тэ 
CD 
3 
CD 
з 
О 
тэ 
O l 
с 
СЛ 
s 
о 
3 
CD 
э 
о 
'о 
ел 
го 
о 
о 
00 
σ 
¡S 
33 
> 
, 
о 
ел 
CD 
α. T T 
Ol 
-, 
к 
со 
00 
со 
g-
ел 
с 
CD 
О 
3 
CD 
3 
О 
о 
ω 
ω 
о 
* 
ел 
33 
> 
m 
, 
Η 
•a 
CD 
3 
CD 
з 
о 
•о 
Ol 
с 
ел 
S 
о 
3 
CD 
3 
о 
b 
—1 
ел 
О 
* . 
О 
со 
33 
> 
m 
, 
%. 
ш 
3 
со 
со 
00 
01 
з-
о 
3 
о 
3 
CD 
ел 
с 
CD 
η 
ел 
3 ел 
3 SL 
° < 
^ . Ol 
CD 
Π 
3 " 
3 
η 
с 
CD 
тт. 
Ol 
3 ел 
3 3 
o _ Ol 
' — - h 
—ι 
CD 
φ 
Ι - , 
CD 
О 
3 · 
3 
- О 
С 
CD 
CD 
-*. CD 
CD 
3 
О 
CD 
Ш 
ö-
S" 
CO 
О 
| 
3 
с 
CD 
О 
о 
3 
о 
CD 
3 
о 
3 
Со 
Со 
0 1 
0) 
3 
CL 
01 
Со 
3 
01 
да 
да 
з 
о 
3 
•о 
3 
да 
3 
es­
ci 
с 3 CL 
да 
Со 
сТ to 
да 3 
э 
CD 
да 
01 
э 
со 
D 
о 
-, 
S 
3 
CQ 
CD 
Introduction 
1.5 Androgens in saliva 
With the aim of monitoring endocrine activity using non-invasive sampling 
techniques in an easily accessible medium, Shannon et al. (1959) in the late fifties 
measured 17-hydroxycorticosteroids in parotid saliva after stimulation of the adrenal 
cortex with corticotropin as well as after administration of single doses of Cortisol 
(F). The concentration of glucocorticoids in saliva is relatively high (the morning 
level of F is about 10 nmol/l) and can be assessed using the Porter-Silber (Silber 
and Porter 1954) method. Moreover, Shannon ef al. (1959) demonstrated that the 
concentration of glucocorticoids in saliva was positively correlated with the 
corresponding plasma concentration of glucocorticoids. 
With the advent of sensitive radioimmunoassays, allowing the accurate 
measurement of the low concentrations of steroids in saliva, this observation was 
further studied (Read et al. 1982, Walker ef al. 1978a, Walker et al. 1978b, Guechot 
ef al. 1982, Fiet ef al. 1981) and extended to various unconjugated hormones such 
as mineralocorticoids (McVie ef al. 1979, Few ef al. 1986a, Few et al. 1986b), 
oestrogens (Marder et al. 1979, Joshi étal. 1976, Evans étal. 1980), progestogens 
(Walker ef al. 1979a, Gombe 1977, ElAttar 1975) and androgens (Walker ef al. 
1980, Baxendale ef al. 1980, Schurmeyer ef al. 1982, Often et al. 1983, James 
1982, Wellen et al. 1983) as well as other steroid hormones such as 170H-
progesterone (Often ef al. 1983, Walker ef al. 1979b, Walker ef al. 1979c, Price ef 
al. 1979, Walker and Fahmy 1979d, Riad-Fahmy ef al. 1982) and progesterone 
(Vittek 1984). 
Steroids, depending on their polarity, may enter the saliva by two possible 
mechanisms (Vining ef al. 1984, Vining ef al. 1983). It has been assumed that lipid 
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soluble small molecules, including steroid hormones, enter the saliva by passive 
diffusion through the salivary gland cells (intracellular route). The transport of 
steroids across the gland is not limited by the diffusion rate, even at high 
(stimulated) salivary flow rates. 
Small water soluble molecules with a molecular weight less than 300 Daltons are 
thought to enter the saliva by ultrafiltration through micropores between the salivary 
gland cells (extracellular route) excluding any proteins. Unlike the concentration of 
steroid hormones entering the saliva by diffusion through salivary gland cells, the 
concentration of water soluble hormones entering the saliva via the tight junctions is 
affected by salivary flow. 
This differential effect of salivary flow rate on the concentration of unconjugated and 
conjugated steroids was clearly demonstrated by Vining et al. (1982). The 
concentration of F apparently was not affected by saliva flow rates varying from less 
than 60 to more than 350 μΙ/min. The concentration of DHEAS on the other hand 
decreased significantly at higher flow rates. 
The assessment of the endocrine status by measuring steroids in saliva offers 
several practical advantages. The diagnostic value of measurements in a single 
blood sample at a single point in time is often of limited diagnostic value. 
Measurement of steroids in saliva allows for multiple sampling for sequential 
temporal studies under conditions without the possible stress associated with blood 
sample collection (Riad-Fahmy et al. 1983). Saliva can be obtained under conditions 
where blood collection is inconvenient or even impossible. It can be collected 
outside the hospital setting by ambulatory subjects without the assistance of medical 
personnel. The salivary flow can easily be stimulated by adding a drop of a solution 
of citric acid to the tongue without affecting the correlation between the plasma and 
salivary concentrations of most steroid hormones. 
Pure parotid saliva can be obtained using a so-called Lashley cup which is placed 
over the opening of the parotid duct. However, the advantages of parotid saliva, 
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which is essentially cell- and debris-free, are not sufficiently great to make selective 
collection worth-while. The mechanisms of transfer of steroids across the salivary 
glands probably do not differ from one gland to another and so parotid saliva should 
contain the same steroid concentrations as does oral fluid (Ferguson 1984). Indeed, 
Sannika et al. (1983) as well as Vittek ef a/. (1985) found no difference between the 
concentration of testosterone in submandibular parotid saliva and mixed whole 
saliva. Mixed saliva is easily to collect in all age groups. After freezing, thawing and 
subsequent centrifugation of mixed whole saliva a clear supernatant results. 
There are also some limitations to the use of saliva for the determination of steroid 
hormones. Spuriously elevated levels of salivary steroids may occur when saliva is 
contaminated with blood or e.g. in patients with periodontitis (Vittek 1984). It has 
been calculated that the presence of SHBG in saliva at a level of only 0.1% of that 
in plasma could increase the salivary testosterone concentration by 10% (Hammond 
and Langley 1986). To circumvent this, Schramm et al. (1990, 1991) developed an 
osmotic pump consisting of a dialysis membrane enclosing an osmotically active 
substance (e.g. sucrose). The collector is placed in the mouth where it accumulates 
a volume of 5 millilitre of salivary ultrafiltrate over a period of about 15 minutes. The 
authors report a high correlation (r=0.89) between the concentration of testosterone 
in the ultrafiltrates and the testosterone concentration in matched whole saliva 
samples collected in the usual way by simply expelling saliva. Moreover the 
concentration of progesterone in such ultrafiltrates of saliva was a reliable indicator 
of luteal function during the menstrual cycle. This sampling technique combines 
several advantages such as the ease of sample collection and exclusion of potential 
blood contamination and interference by binding proteins. Moreover, possible 
metabolism of hormones in the saliva may largely be prevented. Specimens 
collected in this way have a reduced viscosity and are more easily pipetted. 
A similar oral diffusion sink (ODS) device was developed by Wade ef al. (1991, 
1992a, 1992b). This device consists of a small cylindrical polycarbonate shell with 
perforations giving access to a dialysis membrane. It contains either an antiserum or 
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non-specific binding polymer (cyclodextrin), the latter allowing the sampling of a 
variety of steroid hormones. The ODS is worn in the lateral gutter of the mouth and 
actively accumulates compounds from the saliva. The uptake rate of steroids by the 
ODS depends on their specific diffusion constants. According to the authors, the 
amount of a particular steroid accumulated during a specific time interval is a linear 
function of the concentration of steroids in the surrounding medium. With this 
approach samples are obtained in which the concentration of salivary steroids 
represents the average tissue availability over a given period of time. Thus, the 
diagnostic information may be said to be similar to measurements of urinary free 
steroids (Shipley ef a/. 1992). Wade (1992b) maintains that the effect of steroid 
hormones is best understood as an average of their concentration fluctuations since 
steroid effects are rather slow and are only exerted some time after the level of 
steroid hormone has changed. According to this author this does not mean that 
episodic changes are physiologically unimportant. 
In addition to the above mentioned practical advantages, the assessment of steroid 
hormones in saliva, perhaps more importantly, is of fundamental interest. It has 
been established that generally the concentration of unconjugated steroid hormones 
in saliva quantitatively parallels the free hormone concentration in plasma 
(Baxendale et al. 1980, James 1982, Smith et al. 1979, Peters et al. 1982, Umeda 
ef al. 1981, Baxendale ef al. 1982, Umeda et al. 1981). It is assumed that only the 
free, non-protein bound hormone can diffuse into the salivary gland. 
The similarity of plasma free and salivary steroid hormone offers the unique 
possibility of the estimation of biologically active hormone without the need of time-
consuming and sometimes cumbersome techniques for the assessment of free 
hormone in plasma; saliva can be regarded upon as a medium in which the free 
hormone is naturally separated from the bound fraction. 
Nevertheless since the free hormone concentration in plasma and consequently the 
salivary hormone concentration is much lower than the plasma total concentration of 
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steroid hormones, the assessment of salivary steroid hormones requires very 
sensitive and specific assays. However, many studies on salivary steroid hormones 
have been performed with inappropriate assay techniques, lacking the required 
sensitivity or specificity, which may explain the wide variation in the values reported. 
The relationship between plasma and salivary levels of Cortisol has been extensively 
studied. This may partly be attributed to the relatively high concentration of salivary 
Cortisol (3-5 % of the plasma total Cortisol, about 15 nmol/l) which makes very 
sensitive assays unnecessary. The observation that variations in salivary Cortisol 
during the day are at least as great as (Walker ef al. 1978a, Walker et al. 1978b, Al-
Ansari et al. 1982, Vining et al. 1983 , Fiet et al. 1981, Walker 1984, Landon et al. 
1982) or even more pronounced (Guechot ef al. 1982, Fiet ef al. 1982) than those in 
the corresponding plasma levels of total Cortisol suggests that salivary F reliably 
reflects physiological fluctuations in the levels of plasma free Cortisol. 
Under conditions of relatively rapidly changing levels of Cortisol e.g. following 
administration of ACTH, the rise in the level of salivary as well as plasma free 
Cortisol (Katz and Shannon 1969, Brooks and Brooks 1982) is about twice greater 
than the rise in plasma total F concentration (Walker ef al. 1978a, Walker et al. 
1978b, Peters ef a/. 1982, Al-Ansari ef a/. 1982, Katz and Shannon 1969, Brooks 
and Brooks 1982). 
Of the androgens, particularly salivary levels of androstenedione (A4) and 
testosterone (T) have been determined, not only in men, but also in women to 
assess their androgen status. Literature data on measurements of the salivary 
concentration of the weak androgen pro-hormone DHEA are very scarce (Vittek ef 
al. 1984, Gaskell et al. 1980, Vittek et al. 1983). 
As far as the potent androgen dihydrotestosterone (DHT) is concerned, a good 
correlation between unbound plasma and salivary values has been reported in 
women (Baxendale ef al. 1983). The concentration of salivary DHT however 
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appeared to exceed the concentration of plasma unbound DHT almost ten times. 
This has been attributed to the action of δσ-reductase in the salivary gland. 
Salivary DHT poorly discriminates between hirsute women and controls (mean 
concentration 20.8 and 15.6 pmol/l respectively). Baxendale concludes that whereas 
salivary DHT reflects plasma free DHT, measurement of the former offers no 
particular advantage as compared to plasma DHT determinations. 
A4 concentrations in saliva appear to be similar in both sexes, amounting to about 
0.35 nmol/l (Wellen et al. 1983, Baxendale et al. 1983, Putz ei al. 1982, James et 
al. 1982). In women mean salivary A4 concentrations in the early follicular phase 
(0.46 nmol/l) were found significantly lower than in the late luteal phase (0.56 
nmol/l) (Benraad and Otten 1984). 
The salivary A4 concentrations, approximately 8 percent of the plasma total 
concentrations (Wellen et al. 1983, Baxendale et al. 1982), are of the same order of 
magnitude as the concentration of circulating free hormone (Benraad and Otten 
1984). The correlation between the salivary and plasma free hormone 
concentrations is very close (r=0.91-0.96) (James and Baxendale 1982, Baxendale 
and James 1982). A similar correlation was found to exist between the total A4 
concentration in plasma and the A4 concentration in saliva, both in normal adults 
and in women with hirsutism (James 1982, Baxendale et al. 1983, Putz et al. 1982, 
Baxendale et al. 1982, Turkes ei al. 1982). In hirsute women the levels of salivary 
A4 were two times higher than those in controls (524 pmol/l and 270 pmol/l 
respectively, Baxendale et al. 1983). In normal adults of both sexes salivary A4 
showed a circadian variation comparable to that of F, with evening values 40 to 50 
percent lower than morning values (James 1982, Baxendale eí al. 1983, Turkes et 
al. 1982). 
It has been reported (Putz et al. 1982) that during dexamethasone suppression of 
adrenocortical function the ratio of salivary over plasma A4 is similar to that under 
basal conditions. Salivary A4 was about one order of magnitude less than plasma 
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A4. During prolonged ACTH stimulation, after 2 days the increase in the 
concentration in salivary A4 was relatively higher than the increase in plasma A4. 
Apparently this reflects the higher concentration of free hormone in plasma relative 
to the total hormone. 
Literature data on salivary Τ determinations in adult men are in reasonable 
agreement and have been reported to vary between 0.24 and 0.35 nmol/l (Walker ef 
al. 1979a, Walker ef al. 1980, Baxendale ef al. 1980, James 1982, James and 
Baxendale 1982, Schurmeyer et al. 1983, Wang étal. 1981, Swift 1984, Read and 
Walker 1982, Magrini et al. 1986). The mean value of 0.3 nmol/l is about equal to 
the plasma free Τ level supporting the hypothesis that saliva Τ is derived from the 
plasma non-protein bound Τ (Baxendale et al. 1980, James 1982, Sannikka et al. 
1983, Dunn et al. 1981). High correlations of the salivary concentration of Τ with 
plasma total, or free hormone concentration have been reported (Baxendale et al. 
1980, James 1982, Sannikka et al. 1983, Smith et al. 1979, Baxendale étal. 1982, 
James and Baxendale 1982, Schurmeyer ef a/. 1983, Swift 1984, Read and Walker 
1982, Magrini eí al. 1986, Luisi ef al. 1982). The diurnal variation of salivary Τ in 
men represented the variation in plasma Τ (James and Baxendale 1982). Moreover, 
the rise in plasma Τ after exogenous Τ administration, as well as after stimulation 
with HCG, was accurately reflected in the levels of salivary Τ (Magrini ef al. 1986). 
Interestingly the relative rise in salivary Τ appears to exceed the rise in plasma total 
T, probably suggesting saturation of SHBG binding sites. 
Obviously the level of salivary Τ in women is much lower than in men. The levels 
reported in control subjects range from approximately 0.010 to 0.050 nmol/l (see 
table 1.4.3) The values among laboratories appear to be more variable than those 
of salivary Τ in men. This may partly be due to the fact that the low concentrations 
of salivary Τ in women are more difficult to assess accurately. The use of 
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commercial kits designed for the assay of plasma total Τ for this purpose may lead 
to the assessment of a false, usually higher, level of salivary T. Osredkar er al. 
(1989) and Vittek ef al. (1985) used a commercial direct assay to determine salivary 
testosterone in women and found higher levels than other groups. Turkes ef al. 
(1980) used an enzyme immunoassay for the determination of plasma and salivary 
testosterone. These authors also found relatively high levels of salivary testosterone 
(see Table 1.4.3). 
Despite the analytical problems associated with its determination, the concentration 
of salivary Τ in women has been shown to reflect menstrual cycle effects as well as 
diurnal variation of plasma Τ (Vittek ef al. 1984, Swift 1984, Turkes ef al. 1980, 
Dabbs and de la Rue 1991). A high correlation between plasma and salivary levels 
of testosterone was found (Navarro ef al. 1987). Vittek ef al. (1985) reported an 
even higher correlation between salivary Τ and plasma free Τ than between salivary 
Τ and plasma total T, suggesting that salivary Τ reflects plasma free Τ reliably. 
Concentrations of salivary Τ in hirsute women were twice higher than those in 
controls. There is a considerable overlap of salivary Τ levels in 'idiopathic' hirsute 
women with controls which is even larger than the overlap of plasma total Τ levels. 
These literature review data (James and Baxendale 1982) do not support the 
diagnostic usefulness of the measurement of salivary T. Similarly Wang ef al. (1986) 
concluded that there seems to be little indication for routine measurement of 
salivary androgens in hirsute women. In 29% of a group of 21 mild to moderately 
hirsute women a raised concentration of salivary Τ was found while plasma total Τ 
was elevated in 43% of the cases and the free Τ index (T/SHBG) even in 60%. On 
he other hand, in a study by Turkes ef al. (1980), one moderately hirsute 
Oligomenorrhoen patient had plasma total levels in the normal range, whereas 
salivary testosterone concentrations were elevated. Moreover, in a recent study 
salivary Τ was demonstrated to discriminate better between hirsute women and 
controls than plasma total Τ (Navarro ef al. 1987). The level of salivary Τ in women 
with PCO is even higher than in 'idiopathic' hirsute women. Treatment of the hirsute 
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women with cyproterone acetate and ethinyl oestradiol resulted in a decrease in 
salivary T, whereas a similar decrease in plasma total Τ was not observed in all 
cases (Baxendale et al. 1982). Salivary Τ in women with systemic lupus 
erythematosus treated with glucocorticoids was reduced (Navarro ef al. 1992). 
Reduction of serum Τ levels during glucocorticoid treatment is a well known 
phenomenon. 
In contrast to men, who have an almost similar salivary and plasma free T, salivary 
Τ in women is almost twice as high as the concentration of plasma free T. This 
observation has led to suppose that androgens may be subject to metabolism 
during passage through the salivary gland (Swinkels ef al. 1988, Swinkels ef al. 
1992, Rey ef al. 1988, Navarro et al. 1986) . Specifically, the relatively higher level 
of salivary Τ compared to plasma free Τ could be due to conversion of precursors to 
testosterone. Such metabolic conversion during passage through the salivary gland 
would complicate the relationship between plasma free and salivary steroid 
concentrations but not necessarily diminishes the value of salivary steroid hormone 
determinations. 
Metabolic conversion of steroids was clearly demonstrated in case of Cortisol which 
is partly converted to cortisone in the salivary glands. As a result the salivary 
cortisone level is considerably higher than might be expected on the basis of the 
plasma free concentration (Katz and Shannon 1969, Brooks and Brooks 1982). 
Hurlock ef al. (1959) actually demonstrated 11/?-hydroxysteroid dehydrogenase 
activity in the parotids of dogs. 
There is controversy in the literature with regard to the nature of the metabolism of 
androgens in the salivary gland. If metabolic conversion is assumed to be the cause 
of the difference between salivary and plasma free Τ in women the metabolism 
would be expected to be reductive, e.g. formation of Τ from A4. 
In fact this has been demonstrated in vitro in slices of human submandibular glands 
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and submandibular gland tumor (ElAttar 1974), indicating the presence of 170-
ketoreductase activity. 
Coffey and Crutchfield (1977) and Cardinali ef al. (1971) confirmed that the major 
metabolite of A4 in human submaxillary gland homogenates is T. In rats (Coffey et 
al. 1979) and mice (Coffey 1973) the metabolism also was reductive. A4 was chiefly 
converted to androsterone and Τ to androstanediol. Homogenates of the 
submaxillary glands of the boar converted androstanedione to the 5a-reduced 
metabolite 5a-androstanedione and further to androsterone. Τ was converted mainly 
to DHT and За- and 3β- androstanediol (Booth 1977). 
Unlike authors who reported reductive metabolism of A4 to Τ in the salivary gland, 
Baldi and Charreau (1972) found the reverse i.e. formation of A4 from Τ in 
submaxillary gland homogenates, particularly in those of female rats. In vivo 
oxidative transformation of Τ to A4 was also shown in the dog submaxillary gland 
(Weiner era/. 1970). 
Djoseland et al. (1982) concluded that the metabolism in normal and neoplastic 
parotid tissue is mainly oxidative. After in vitro incubation of Τ with homogenates of 
the glands A4 was recovered as the major product. There was no significant 
metabolism of A4 by these homogenates. After carotid injection of tritiated Τ in rats 
Cefalu et al. (1986) found a recovery of 30% of the injected radioactivity in the form 
of A4. These authors assume that albumin-bound Τ represents the bioavailable 
fraction. They explain the quantitative difference between this relatively large 
fraction in plasma relative to saliva by assuming intense oxidative metabolism of this 
steroid during passage through the gland. 
In conclusion, the concentrations of steroid hormones in saliva are much lower than 
their total concentration in plasma. The concentration in saliva in many cases is 
similar to the concentration of non-protein-bound, free hormone in plasma which is 
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thought to represent the biologically available hormone. Consequently, the level of 
salivary hormone is thought to reflect biologically available hormone. Literature data 
indicate however, that most steroids are more or less subject to metabolism during 
passage through the salivary gland. This may obscure the relationship between 
plasma free and salivary hormone. On the other hand, salivary steroid 
concentrations may reflect peripheral events which are of importance for the 
biological availability of the hormone. 
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2.1 Subjects and Sampling 
Matched specimens of plasma and mixed whole saliva were obtained from 22 
healthy women, aged 18-45 years (mean 32.8, SD 8.6 years), with a history of 
regular menses. Specimens were taken at day 5 and 19 of the menstrual cycle at 
0800 h. Moreover, plasma and saliva samples were collected from a healthy normal 
woman at hourly intervals during the day. To assess reference values for children, 
we collected saliva samples from children who visited the paediatric clinic for non-
endocrine related disease. 
Plasma and saliva specimens during combined dexamethasone/synthetic 
corticotropin administration were obtained from 25 consecutive unselected patients 
with moderate or severe hirsutism together with oligo- or amenorrhea and another 
group of 10 normal women (each of the latter in the follicular (day 5) as well as in 
the luteal phase (day 19) of the menstrual cycle). None of the patients had 
Cushing's syndrome nor adrenal or ovarian neoplasms ( this was demonstrated by 
dexamethasone suppression of Cortisol levels and ultrasound investigation 
respectively). 
During the dexamethasone/synthetic corticotropin test, subjects received 1 mg of 
dexamethasone (Oradexon; Organon, Oss, The Netherlands) orally at 2300 h on the 
day preceding the test. On the day of the test, starting at about 900 am, 0.25 mg of 
exogenous corticotropin 1-24 (Synacthen; Organon) in 100 mL of isotonic saline 
was administered intravenously via an indwelling cannula. Blood samples for the 
measurement of Cortisol and total and free DHEA, A4 and Τ levels were obtained in 
heparinized tubes 30 min before and 0, 30, 60, and 90 min after starting the 
infusion of synthetic corticotropin. Mixed whole saliva was collected in plastic cups 
during the time intervals between blood sample withdrawals. To be able to compare 
plasma with salivary steroid concentrations, the mean plasma value for each time 
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interval was calculated; e.g., the mean of the 0-min and 30-min values was 
designated as the 15-min value, whereas the basal value, designated 0 min, was 
calculated as the mean of the minus 30 to 0-min values. 
Before collecting the saliva, subjects were asked to rinse their mouth with tap-water. 
Saliva flow rate was stimulated by applying citric acid to the tongue. Saliva samples 
were collected in plastic cups, then stored at -20 °C until analysis. 
All patients showed a normal Cortisol response to the combined administration of 
dexamethasone/synthetic corticotropin (there was no difference in the 
concentrations of Cortisol between hirsute women and controls at the different time 
intervals during the combined dexamethasone Synacthen test). Approval was 
obtained from the hospital ethical committee. 
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2.2 Radioimmunoassay of steroid hormones in plasma 
and saliva 
2.2.1 Antisera 
The anti-DHEA antiserum was raised in Texel white sheep against DHEA-17-
carboxymethyloxime conjugated to BSA. Of the conjugate, 0.5 ml (1 mg/ml) was 
mixed with an equal volume of Freund's complete adjuvant (Behringwerke AG, Mar­
burg, Germany), emulsified, and injected subcutaneously each two weeks for four 
months. The antiserum titre was 1 : 60,000. The DHEA antiserum showed complete 
cross-reactivity with androstenediol (Table 2.2.1). 
Table 2.2.1 Percent cross reactivity of the DHEA, A^ and Τ antiserum. 
5a-androstane-3a-17/?-diol 
5a-androstane-3£-17/?-diol 
androstenediol 
androstenedione 
dehydroepiandrosterone 
dihydrotestosterone 
testosterone 
anti-DHEA 
<0.01 
12.9 
100 
0.04 
100 
4.3 
0.05 
anti-A4 
<0.01 
<0.01 
<0.01 
100 
5.4 
0.05 
0.68 
anti-T 
0.1 
0.1 
0.1 
2.2 
<0.01 
29 
100 
Although the normal concentration of DHEA in plasma is higher than that of 
androstenediol, interference from the latter in a direct RIA might be expected. 
However, androstenediol (Rf 0.19) was effectively separated from DHEA (Rf 0.50) 
by paper chromatography in the modified Bush A system. 
The anti-A4 antiserum was raised in rabbits against androstenedione-19-
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carboxymethylether conjugated to BSA (ICN Biomedicals 07-109016). The 
antiserum titre was 1:5,000 (Table 2.2.1). 
The anti-testosterone antiserum was a gift from Dr. J.J. Pratt (University of 
Groningen, the Netherlands) and was raised in rabbits against testosterone-7ff-
carboxythioethylether. The antiserum titre was 1:9,000. 
2.2.2 Extraction 
RIA of plasma or salivary steroid hormones was performed after extraction and 
paper chromatographic separation. Before extraction, saliva samples were sonicated 
with a MSE Soniprep 150 for 30 s (amplitude 14//m). To the appropriate volume of 
sample (Table 2.2.2) 10 000 dpm of recovery tracer in 100 μ\ of ethylene glycol in 
water (0.2% v/v) was added. The samples were incubated for 30 min at room 
temperature, then extracted with 15 ml of diethyl ether (no. 921, Merck, Darmstadt, 
FRG) by shaking the tubes vigorously during two minutes. The solvent was removed 
and evaporated under a stream of clean air. The residue was dissolved in a few 
drops of diethyl ether and applied to chromatography paper as described below 
(2.2.3.). 
An aliquot of 100 μ\ of recovery tracer was pipetted into counting vials in 
quadruplicate for the determination of total radioactivity added to the samples. In 
order to obtain a similar counting efficiency in the vials for total counting as in the 
remaining vials, 200 μ\ of ethylene glycol in water (0.2% v/v) and 300 μ\ of 0.1 mol/l 
borate buffer of pH=8.0 containing 2.5 g/l of bovine serum albumin (no A-9647, 
Sigma, St Louis, MO, USA) were added. 
2.2.3 Paper Chromatography 
The residues after extraction and evaporation of the solvent were applied onto 
Whatman no 1 chromatography paper. Each sheet of paper has eight 2-cm wide 
lanes of 40 cm length. The samples were chromatographed for 5 h in a descending 
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modified Bush A paper chromatography system [petroleum ether b.p. 80/110 °C (no. 
8242, JT Baker, Phillipsburg, NJ, USA)/methanol (no. 8208, Baker)/water, 9/7/4 by 
vol] (Bush 1961). After chromatography the sheets were dried. The tracer-label was 
located by radioscanning (Packard 7201 radiochromatogram scanner). The 
appropriate area of paper was cut out (Table 2.2.2) and the hormone was eluted 
from it with a volume of ethylene glycol in water (0.2% v/v). Of the paper eluates 
150 μ\ was pipetted into counting vials to determine the tracer recovery. To assure 
similar counting conditions as in the remaining counting vials 150 μ\ of ethylene 
glycol in water (0.2% v/v) and 300 μ\ of 0.1 mol/l borate buffer of pH=8.0 containing 
2.5 g/l of bovine serum albumin (no A-9647, Sigma, St Louis, MO, USA) was added. 
2.2.4 Radioimmunoassay 
Standard curves were set up in duplicate. From the paper eluates 100-, 200-, and 
300- μ\ aliquots were assayed. To each standard, control, and unknown 100 μ\ of 
tritiated steroid in 0.1 mol/l borate buffer of pH=8.0 containing 2.5 g/l of bovine 
serum albumin (no A-9647, Sigma, St Louis, MO, USA) was added as well as 200 
μ\ of antiserum diluted in the same buffer (Table 2.2.2). After overnight incubation at 
4 °C, antiserum-bound and free steroid were separated by adsorption of the free 
fraction to dextran coated charcoal, as follows: 150 μ\ of a charcoal suspension 
(Norit A, Fisher Scientific, Fair Lawn, NJ, USA) in 0.1 mol/l borate buffer, pH 8.0, 
containing 2 g of dextran T70 (Pharmacia, Uppsala, Sweden) per litre were pipetted 
into disposable caps (which were subsequently placed on the RIA test tubes). The 
suspension in the caps was mixed with the contents of the tubes by shaking all the 
tubes simultaneously. After 6 min at 4 °C the samples were centrifuged at 2000 χ g 
for 10 min at 4 °C. The supernates were decanted simultaneously (Vecsei and 
Gless 1975) into counting vials. After adding 4 mL of scintillation cocktail (Aqua 
Luma, Lumac, LSC BV, Olen, Belgium) the radioactivity in each sample was 
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determined using 4 minutes counting time. The lower limit of detection and 
reproducibility of each RIA are listed in Table 2.2.3. The intra-assay CV's were 
calculated as the relative variation of duplicates. The inter-assay CV's were 
determined from repeated analyses of quality control samples in each assay. 
2.2.5 Calculation 
In the calculation of measurement results corrections involving those for procedural 
losses (recovery) during paper chromatography and the effects caused by the use 
of the recovery tracer itself (both by mass and radioactivity) are incorporated. The 
standard curve is fitted using a four-parameter fit procedure according to Rodbard 
(Mcintosh and Mcintosh 1980). 
The concentration of steroid hormone present in sample eluates is read from the 
standard curve after correction of the total counts for the contribution by the 
recovery tracer to the measurement signal: 
τι _ τ volume eluate assayed -,, „ 
com V - com Τ + , — " " * 7/ 8 * cpm. 
volume recovery counts r 
Where cpm T: total counts, corrected for the contribution by recovery counts, 
cpm Τ : total counts added in the radioimmunoassay. 
cpmr : counts obtained from 15% of the total eluate volume. 
The factor 7/8 is derived from the amount of supernatant decanted from the total 
volume present in the tube. 
Moreover the recovery tracer contributes to the concentration of steroid hormone in 
the eluate depending on its specific activity. This is determined in each 
measurement series by assessing the decrease in binding when twice the amount 
of tracer is present. The percentage binding is calculated by dividing the specifically 
bound counts by twice the amount of total counts. The mass corresponding to this 
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percentage binding is read from the standard curve. This mass is equivalent with 
8/7 times the total counts (8/7 to correct for the décantation factor). Thus each tube 
is corrected for the contribution of the mass of recovery tracer : 
eluate volume assayed
 + 
,. + volume 15% eluate •»-
Mass recovery tracer = *<*"""> ^ '° тиаю
 + mass γ 
* 8/ 7 * cpm Τ 
The concentration of steroid hormone present in each eluate volume is corrected for 
the contribution of the blanc which is assessed by extracting and subsequently 
assaying 2 ml of water. 
Thus the concentration of steroid in each tube is calculated as: 
m c o r = m - m«b - m r 
Where m ^ = the amount of steroid present in each tube corrected for water 
blanc and mass contribution by the recovery tracer 
m = the amount of steroid present in each tube as read from 
the standard curve 
mwb = water blanc 
mr = mass contribution of the recovery tracer in each tube 
Finally, the results of the measurements from 100, 200 and 300 μ\ eluate volume 
were combined into a weighted mean of the sample, corrected for percentage 
recovery. 
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2.3 Free hormones in plasma 
2.3.1 Free dehydroepiandrosterone 
The free fraction of DHEA in plasma was measured by equilibrium dialysis using 
Diachema dialysis equipment (Diachema AG, Rüschlikon-Zürich, Switzerland) (Ross 
1980). This apparatus holds twenty dialysis cells, either of microtype (working 
volume 2 χ 0.2 ml, membrane area 2 cm2) or of macrotype (working volume 2x1.0 
ml, membrane area 4.5 cm2) The dialysis cells are rotated at a constant speed (20 
rpm) in a water bath at 37°C. Visking dialysis membranes (exclusion limit 8000-
15000 Da) were washed with distilled water and soaked in 0.05 mol/l of phosphate 
buffer 0.1 M NaCI, pH 7.4. For the assessment of free DHEA, microtype dialysis 
cells were used. 
[1,2,6,7-3H]DHEA (of specific activity 87 Ci/mmol) was purified by paper chromato­
graphy in a modified Bush A system (as described above). The paper was scanned 
for radioactivity and the peak eluted from it with 100% ethanol. Aliquote containing 
30 000 dpm of [3H]-labelled DHEA were pipetted into borosilicate glass tubes. The 
ethanol was evaporated under a stream of nitrogen. 300 μ\ of undiluted plasma 
sample was added to the residue and incubated for 30 min at 37 °C. An aliquot of 
180 μ\ of this incubate was pipetted into one half of a dialysis cell and dialyzed for 4 
h at 37 °C against 180 μ\ of 50 mmol/l phosphate buffer in 0.1 mol/l NaCI solution, 
pH 7.4. 
An aliquot of 50 μ\ of the plasma incubate was counted in duplicate to assess the 
total radioactivity. After determination of the radioactivity in the dialysate at V,/V0-fold 
dilution the free fraction of DHEA in the undiluted sample was estimated according 
to the formula: 
f 0 = 1 / [(Co/c2) - (V/V0) + 1] 
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where f
 0 = the estimate of the free fraction of the undiluted sample 
c0 = the concentration of radioactivity in the original sample 
c2 = the concentration of radioactivity in the dialysate 
V, = the total volume of the dialysis system 
V0 = the original sample volume. 
Multiplication of f0 with the total concentration of DHEA in the sample yields the 
estimate of the concentration of free DHEA in the undiluted sample. 
The indirect equilibrium dialysis for the assessment of free DHEA as described 
above was validated by comparison with the assessment of free DHEA in plasma 
dialysates by RIA. For this purpose 1.0 ml of plasma was dialyzed for 4 h at 37 °C 
against 1.0 ml of the phosphate buffer in NaCI solution. The concentration of DHEA 
in the dialysate was measured by RIA after extraction and chromatography as 
described above. The concentration of free DHEA in the undiluted sample (F'0) was 
calculated according to the formula: 
F'0 = H0/[(H,/F)-(V/Vo) + 1] 
where F'0 = the estimate of the concentration of free DHEA in the 
undiluted sample 
H0 = the total concentration of DHEA in the original sample 
F = the concentration of DHEA in the dialysate 
V, = the total volume of the dialysis system 
V0 = the original sample volume. 
The intra-assay coefficient of variation of the determination of the percentage free 
DHEA, expressed as the relative variation of duplicates, was 3.9% (n=50, the mean 
free fraction (±SD) was 3.02 ± 0.27 %). The intra-assay variation of the 
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concentration of plasma total DHEA was 4.8%. Consequently the total variation of 
the determination of the concentration of plasma free DHEA was 6.2%. 
The concentration of free DHEA in plasma assessed by the indirect method (/) 
agreed well with the concentration of free DHEA determined by direct equilibrium 
dialysis (x), i.e. by RIA of DHEA in plasma dialysates [least squares linear 
regression analysis: y = 1.01 * χ + 0.04 nmol/l, r= 0.988, Ρ <0.001, η = 40]. 
2.3.2 Free androstenedione 
Plasma free A4 was measured by equilibrium dialysis as described above for DHEA 
using the same equipment. Purified [1,2,6,7-3H]A4 (of specific activity 80-110 
Ci/mmol). Aliquote containing 30,000 dpm of [3H]-labelled A4 were evaporated under 
a stream of nitrogen and 300 μ\ of undiluted plasma sample was added to the 
residue and incubated for 30 min at 37 °C. An aliquot of 180 μ\ of this incubate was 
pipetted into one half of a dialysis cell and dialyzed for 4 h at 37 °C against 180 μ\ 
of 50 mmol/l phosphate buffer in 0.1 mol/l NaCI solution, pH 7.4. 
To measure the total radioactivity an aliquot of 50 μ\ of the plasma incubate was 
counted in duplicate. After determination of the radioactivity in the dialysate the 
percentage free A4 in the undiluted sample was calculated as described above. 
The intra-assay coefficient of variation of the determination of the percentage free 
A4, expressed as the relative variation of duplicates, was 3.0% (n=50, mean 7.60 ± 
1.29 %). The intra-assay variation of the concentration of plasma total A4 was 3.3%. 
Consequently the total variation of the determination of the concentration of plasma 
free DHEA was 4.5%. 
2.3.3 Free testosterone1 
When the free fraction of steroid hormone in plasma is very small, as is the case 
with the free Τ (about 1 - 2 %), radiochemical contamination of the tracer used in 
'Published in Clinica Chimica Acta 1987; 185 :341-349. 
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equilibrium dialysis has a profound effect on the outcome of the determination of 
non-protein bound hormone in plasma (see paragraph 2.3.4). The symmetric 
dialysis technique (Ross 1978) is much less influenced by radiochemical impurities 
of the tracer than equilibrium dialysis. Moreover, using this technique, the fraction of 
non-protein bound Τ in plasma can be assessed directly in undiluted serum. 
In symmetric dialysis the plasma sample is present on both sides of the dialysis 
membrane. The rate of transfer of radiolabelled hormone from one dialysis 
compartment to the opposite one is related to the free fraction of the hormone 
according to the relation: 
V t ο
λ
 + c2 
where AD/V = cell permeability constant, in which A represents the effective 
membrane area, D the membrane diffusion constant and V the 
sample volume in the dialysis system 
t = dialysis time (h) 
c, = the concentration of radioactivity in compartment 1 
c2 = the concentration of radioactivity in compartment 2 
Two additional variables are defined: the tracer distribution I = (c, - c2)/(c, + c2), and 
the dialysis rate U = -(1/t) χ ln(l) so that U = 2(AD/V) χ f. 
The equation 2(AD/V) χ f=-1/t χ ln(l) implies: a. direct proportionality between the 
dialysis time (t) and the log tracer distribution -ln(l) and, b. direct proportionality 
between the dialysis rate U = -1/t ln(l) and the free fraction f. These relationships 
should experimentally be demonstrated to validate the symmetric dialysis method. In 
order to establish the relation between dialysis time and the tracer distribution, the 
tracer distribution of two samples (free fraction of Τ 0.036 and 0.014) was recorded 
at 30 min time intervals during symmetric dialysis in microtype dialysis cells 
(Swinkels ef a/. 1987). The transfer of radiolabelled Τ, as expressed by the 
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О f-0 036 
• (-0 014 
Fig 23 1 The relation between 3H Testosterone distribution and the dialysis time 
following rate dialysis m microtype cells at 37°C The regression slope, i_e_ the 
dialysis rate, evidently depends on the free fraction of testosterone (TT = 0 014 
y = 0008 + 0 170x, r = 0 999, TT = 0 036 y = 0016 + 0 443x, r = 0 999) 
о microtype 
• macrotype 
0 00 0 02 0 04 0 06 0 08 0 10 
free fraction Τ 
Fig 23 2 The relation between the dialysis rate U and the free fraction of testosterone 
(TT) following rate dialysis in micro- and macrotype cells at 37°C The free 
fraction of Τ in the samples was detemiined by direct RIA of free Τ in the 
dialysate after equilibnum dialysis) 
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function of -ln(l) is linear with time (r=0.999) in both plasma samples, with a 
negligible intercept (Fig 2.3.1). This allows the estimation of the dialysis rate U from 
a single measurement at a given point of time. 
The slope of the lines in Fig 2.3.1 [i.e. the dialysis rate (U)] obviously relates to fT. 
To further elaborate the relation between the free fraction of testosterone (fT) and 
the dialysis rate, the dialysis rate of eight samples (diluted 1:1) with a known fT was 
recorded. The fT of these samples was obtained by direct equilibrium dialysis of 
undiluted samples against an equal volume of buffer and therefore pertains to a 
dilution of 1:1. To correspond with this the samples were also diluted 1:1 during 
symmetric dialysis. Both the microtype as well as the macrotype dialysis cells were 
used to establish the relation between f and U (Fig 2.3.2). 
In both experiments a linear relation was found (r=0.950 in microtype, and r=0.990 
in macrotype cells. The ratio 2AD/V in microtype cells was 13.2 ±1.0 (SEM) and 3.6 
± 0.2 (SEM) in macrotype cells. These ratios relate to the A/V characteristics of both 
cell types (11.1 and 4.5 cm'1 respectively). 
The free hormone fraction (fx) is calculated from the dialysis rate Ux of the sample 
under study and the dialysis rate Ur of a reference sample with a known free 
fraction fr according to: fx = (IVU,) χ fr. In each assay the dialysis rate of a reference 
sample was measured in quadruplicate. 
Of each sample 500 μ\ was incubated with 20 000 dpm of [1,2,6,7-3H]-T (previously 
purified by paper chromatography in a Bush A system) for 30 min at 37 °C. Of the 
incubate 180 μ\ was pipetted in one compartment of a temperature equilibrated 
dialysis cell (Diachema AG, Rüschlikon-Zürich, Switzerland), while two 50 μ\ aliquots 
were counted for total radioactivity in duplicate. The other compartment was filled 
with 180 μ\ of the same plasma sample without [3H]-T. Undiluted samples were 
dialyzed for 5 h at 37 °C. Following dialysis 50 μ\ of the samples in each 
compartment were counted in duplicate. The free fraction of Τ was calculated as 
described above. 
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The ¡ntra-assay coefficient of variation of the determination of the percentage free 
testosterone was 2.8%. The intra-assay coefficient of variation of the determination 
of the concentration of free testosterone was 6.3%. The inter-assay coefficient of 
variation of the determination of the free fraction of testosterone was 5.0%. 
2.3.4 Effects of sample dilution and tracer contamination 
In five plasma pools the free fraction of testosterone was assessed by symmetric 
dialysis and indirect equilibrium dialysis in two times and ten times diluted plasma 
samples. We also used symmetric dialysis to assess fT in the undiluted samples. 
Moreover the free fraction of Τ in these samples was calculated using the computer 
program described in paragraph 2.5. For these simulations we used the measured 
total concentration of Τ (varying from 0.85 to 16.25 nmol/l) and SHBG (varying from 
52.0 to 33.4 nmol/l) and estimations of association constants as reported by Dunn 
et al. (1981). The effect of tracer contamination was assessed by using purified 
and non-purified 3HT (the latter with an approximate radiochemical purity of 97%) 
(fig 2.3.3). 
Computer simulation predicts a mean decrease of the concentration of free Τ (FT) 
with a factor of 0.893 ± 0.007 when undiluted plasma is diluted once and with a 
factor of 0.867 ± 0.022 upon dilution from a dilution factor of 2 to 10. The decrease 
of free testosterone when comparing FT of undiluted and two times diluted plasma 
as assessed by symmetric dialysis (0.871 ± 0.043) exceeded the predicted values. 
The fall in FT from a dilution factor 2 to 10 as determined by symmetric dialysis was 
similar to predicted values and largely independent of the radiochemical purity of the 
tracer (the factor using purified tracer was 0.857 ± 0.044 and non-purified tracer 
0.818 ±0.019). 
The decrease of FT under the same conditions as assessed by indirect equilibrium 
dialysis exceeded the decrease predicted by computer simulation and observed 
during symmetric dialysis especially when radiochemically contaminated tracer was 
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used. The levels of fT determined by indirect equilibrium dialysis using purified 
tracer were higher than the calculated level (157%). The level determined by 
symmetric dialysis was 27% less than the calculated percent free T. 
dilution factor dilution factor dilution factor 
Fig 2.3.3. The effect of dilution was simulated based upon measurement of total Τ and 
SHBG in the samples and using steroid binding data and concentrations of 
steroids and their binding proteins as reported by Dunn et al. (1981) (leñ 
panel). The effect of radiochemically contaminated (middle panel) and 
radiochemically pure (right panel) tritium-labelled testosterone at different 
dilutions on the concentration of free Τ as determined by symmetric dialysis 
(+• — · ) and indirect equilibrium dialysis (·—) . 
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2.4 Other assays 
2.4.1 Determination of plasma non-SHBG bound testosterone 2 
Non-SHBG bound testosterone, i.e. the fraction of circulating testosterone in plasma 
which is not bound to sex hormone binding globulin (including albumin-bound, 
corticosteroid binding globulin-bound and free testosterone), was assessed using 
the method for the determination of SHBG by ammonium sulphate precipitation as 
described by Rosner (1972). [1σ-2σ-3Η]-Τ (10 000 dpm) in ethanol (previously 
purified by paper chromatography, see above) was pipetted in polystyrene tubes. 
The ethanol was evaporated under a stream of nitrogen. 100 μΙ plasma samples 
were added to these tubes. The tubes were vortex mixed, incubated for 30 min at 
room temperature and another 90 min at 4 °C. SHBG-bound Τ was then 
precipitated, during continuous mixing, with 900 μ\ of cold ammonium sulphate 
solution at a final concentration of 50% saturation. The tubes were centrifuged for 
15 min at 2000 χ g and 4 °C. Two 200 μΙ-aliquots of the supernatant were counted 
for radioactivity (Swinkels et al. 1991). 
Corticosteroid-binding globulin was not precipitated with 50% ammonium sulfate, as 
demonstrated by selective ammonium sulfate precipitation of plasma samples 
incubated with tritiated Cortisol and by measurement of CBG in the supernate (Fig 
2.4.1a). Addition of Cortisol to steroid-free plasma samples that had been incubated 
with tritiated testosterone showed that the percentage n-SHBGT decreased with 
increasing concentration of Cortisol (P<0.01, Friedman test) (fig 2.4.2). 
The inter-assay coefficient of variation was 7.4% at a level of 28.9 % non-SHBG 
Published in Clinical Chemistry 1991; 37(2):180-185 and in Clinical Chemistry 
1991; 37(8):1461. 
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bound Τ (η = 11). The intra-assay coefficient of variation calculated as the relative 
duplicate variation was 7.3% in a range of samples with a level of 32.3 ± 13.1% 
(mean ± SD) non-SHBG bound Τ (n = 50). 
120 
20 40 60 80 
percent ammonium sulfate 
—+ — serum-DHT 
- Δ- HSA-DHT 
— O— Serum-F 
Fig 2.4.1a Selectivity of ammonium sulfate precipitation. Incubation of plasma with 3H-
dihydrotestosterone showed that sex hormone binding globulin (SHBG) was 
precipitated at 50% ammonium sulfate solution, while incubation of plasma with 
3H-cortisol demonstrated that com'costeroid-binding globulin (CBG) was not 
precipitated at this ammonium sulfate concentration. Human serum albumin (5 
g/L) incubated with 3H-dihydrotestosterone demonstrated that albumin was 
precipitated at 70-80% ammonium sulfate solution. 
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Fig 2 4 1b Measurement of SHBG (original concentration 26 5 nmol/l) and CBG (onginal 
concentration 0 90 цтоШ) m the supemate after ammonium sulfate 
precipitation showed the same precipitation pattern as in fig 2 4 1a 
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Fig 2 4 2 The relation between non-sex-hormone-binding globulin bound testosterone (n-
SHBGT, mean ± SEM) and Cortisol The fraction of n-SHBGT in steroid-free 
plasma, after ammonium sulfate precipitation with 50% saturated ammonium 
sulfate solution decreased with increasing concentration of Cortisol 
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2.4.2 Plasma Cortisol 
Cortisol was measured by direct RIA after heat denaturation of CBG as described 
previously (Smais et al. 1978). In short, plasma samples and standards were diluted 
1:100 in 5% ethanol in water. Standards (0-1.77 /лтюІ/І) were prepared in steroid-
free plasma. 
100 μ\ of diluted standards and samples were heated for 60 min at 70°C to 
eliminate interference from plasma-binding proteins (in casu CBG). After cooling the 
tubes 250 μ\ (10,000 dpm) of [1,2,6,7-3H]-Cortisol (hydrocortisone, NET-396, Du 
Pont de Nemours (The Netherlands) BV, 's Hertogenbosch, NL) and 250 μ\ of 
antiserum (final dilution 1:48,000), both in 0.1 mol/l borate buffer containing 1 g/l 
lysozyme (no 28260 Serva, Heidelberg, Germany) was added. After overnight 
incubation antiserum bound and free Cortisol were separated using 150 μ\ of 
charcoal suspension as described under 2.2.4. 
The intra-assay coefficient of variation from duplicates was 5.0% in 20 samples with 
a mean concentration of 0.37 //mol/l (range 0.20 - 0.55 /лпоІ/І). The sensitivity of the 
assay is 5 nmol/l. 
2.4.3 Plasma sex-hormone binding globulin (SHBG) and 
corticosteroid binding globulin (CBG) 
For the estimation of SHBG an IRMA-kit was used (Farmos Diagnostica, Farmos 
Group Ltd, Oulunsalo, Finland). The mean intra-assay duplicate coefficient of 
variation between 7 and 110 nmol/l SHBG is 3.2%. The inter-assay coefficient of 
variation, according to information supplied by the manufacturer, ranged from 1.11 
to 9.98% with mean levels ranging from 9.88 to 678 nmol/l. The lower limit of 
detection was 0.5 nmol/l (defined as two SD of the binding of the zero standard). 
CBG was determined using a double antibody RIA kit (Techland, Liège, Belgium) 
with a reported within assay variation of 3.6% and a between assay variation of 
7.5% at a level of 825 nmol/l. 
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2.5 Computer simulation 
A computer program written in BASIC, based on an algorithm by Colas (1967) was 
used to simulate the interaction between 21 steroid hormones and their binding 
proteins. Association constants were taken from Dunn er al. (1981). Concentrations 
of binding proteins and steroids were taken from the same publication, except for 
those of SHBG, testosterone, DHEA, A< and Cortisol, which were all measured. The 
results from computer simulations were compared with experimental data. 
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2.6 Statistical Analysis 
For comparison of means the unpaired Student's f-test adjusted for unequal 
variances was used where necessary, unless stated otherwise. Friedman's non-
parametric analysis of variance was used to identify trends in the levels of each 
parameter during combined administration of dexamethasone/synthetic corticotropin. 
Intra-assay variations (Sr) were calculated as the relative variation of duplicates (x,„ 
x2l) according to the formula: 
N 
£ ( dj /77,) 2 / 2/7 
where d, = x,, - x2l, m, = (x„ + x2,)/2 
Correlations were evaluated with the Spearman rank order test or after applying a 
general linear model procedure (statistical analysis system, Sas Institute Inc., Cary, 
N.C.), corrected for inter-individual variation in the case of dynamic tests. 
Coefficients of variation were compared using a Z-transformation. All values are 
expressed as mean (SD). 
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3.1 Plasma and salivary androgens in control women 
under basal conditions 
The concentrations of plasma total, free and salivary dehydroepiandrosterone, 
androstenedione and testosterone as well as those of sex-hormone binding globulin 
(SHBG), non-SHBG-bound testosterone and Cortisol were measured in samples 
obtained at 8.00 h from 22 control women under basal conditions in the luteal and in 
the follicular phase of the menstrual cycle. The mean concentrations of these 
androgens are shown in table 3.1.1. 
There was no statistically significant difference between luteal and follicular phase 
concentrations of plasma total, free, and salivary DHEA during the menstrual cycle. 
In each individual the concentrations of DHEA in plasma and saliva in the follicular 
phase were similar to those in the luteal phase of the cycle. The correlations of the 
follicular phase levels of plasma total (r = 0.740, p<0.001), plasma free (r = 0.700, 
p<0.001), and salivary DHEA concentrations (r = 0.787 p<0.001) with their 
corresponding concentrations in the luteal phase were highly significant, indicating a 
relatively small intra-individual variation in these concentrations during the menstrual 
cycle. 
About 2.0 % of the plasma DHEA circulates in the non-protein bound, free form. In 
the follicular phase, the concentration of salivary DHEA was not significantly 
different from that of plasma free DHEA. However, in the luteal phase of the cycle, 
the concentration of salivary DHEA slightly exceeded the concentration of plasma 
free DHEA (P <0.01, paired Student's t-test, Table 3.1.1). In both phases salivary 
DHEA concentrations correlated very strongly with the concentrations of plasma 
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Table 3 11 The mean concentrations (± SD) of plasma total, plasma free, and salivary 
dehydroepiandrosterone (DHEA), androstenedione (AJ and testosterone (T) 
in nonnally ovulating women (n=22) in the follicular (day 5) and luteal phase 
(day 19) of the menstmal cycle Samples were taken at 8 00 am The 
subjects were aged 18-45 years (32 8 ± 8 6 years) The concentrations of 
sex hormone binding globulin (SHBG) is also shown as well as those of 
non-SHBG-bound testosterone (n-SHBG-T) and Cortisol 
Plasma total DHEA (nmol/l) 
Plasma free DHEA (%) 
Plasma free DHEA (nmol/l) 
Salivary DHEA (nmol/l) 
Plasma total A„ (nmol/l) 
Plasma free A4 (%) 
Plasma free A4 (nmol/l) 
Salivary A4 (nmol/l) 
Plasma total Τ (nmol/l) 
Plasma free Τ (%) 
Plasma free Τ (pmol/l) 
Salivary Τ (pmol/l) 
Non-SHBG-T (%) 
Non-SHBG-T (nmol/l) 
SHBG (nmol/l) 
Cortisol (μιηοΙ/Ι) 
Follicular phase 
28 3(17 8) 
2 00(0 21) 
0 56 (0 34) 
0 61 (0 32)a 
4 99 (1 85) 
8 85 (0 70) 
0 44(0 15) 
0 37(0 15)c 
0 81 (0 29) 
1 02 (0 27) 
8 3 (3 4) 
23 6 (6 8)d 
30 6 (8 5) 
0 24(0 11) 
43 9(17 6) 
0 40(0 13) 
Luteal phase 
27 2 (18 6) 
2 05 (0 20) 
0 56 (0 38) 
0 68 (0 40)b 
6 21 (3 08) 
8 56 (0 54) 
0 53 (0 27) 
0 45 (0 22)° 
0 94 (0 35) 
0 99 (0 28) 
9 1 (3 5) 
25 7 (7 8)d 
29 0 (7 5) 
0 26(0 10) 
46 6 (19 4) 
0 40 (0 11) 
Ρ 
ns 
ns 
ns 
ns 
<0 01 
ns 
<0 05 
<0 05 
<0 01 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
' Not significantly different from plasm free DHEA 
" Significantly different from plasma free DHEA (p<0 01) 
c
 Significantly different from plasma free A4 (p<0 01) 
" Significantly different from plasma free Τ (p<0 01) 
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total [Fig 3.1.1, r=0.924, p<0.001 (follicular phase); r=0.879, p<0.001 (luteal phase)] 
and plasma free DHEA [Fig 3.1.2, r=0.902, p<0.001 (follicular phase); r=0.878, 
p<0.001 (follicular phase)]. 
During the luteal phase total A„ and, though less pronounced, free and salivary A4 
were significantly higher than in the follicular phase. In both phases of the menstrual 
cycle the concentration of plasma free A4 was slightly higher than the concentration 
of salivary A4 (p <0.01). Salivary A4 concentrations correlated very strongly with 
those of plasma total [Fig 3.1.3, r=0.874, p<0.001 (follicular phase); r=0.949, 
p<0.001 (luteal phase)] as well as plasma free A4 [Fig 3.1.4, r=0.861, p<0.001 
(follicular phase); r=0.927, p<0.001 (luteal phase)] throughout the menstrual cycle. 
The correlations of follicular phase concentrations of plasma total (r=0.684), plasma 
free (r=0.548), and salivary A4 (r=0.610) with their levels in the luteal phase reached 
statistical significance (P<0.01) but were less high than those of DHEA. 
Plasma total Τ was slightly but significantly higher in the luteal than in the follicular 
phase of the menstrual cycle, while the difference between follicular and luteal 
phase concentrations of plasma free and of salivary Τ concentrations did not reach 
statistical significance. 
In both phases of the menstrual cycle the concentration of salivary Τ was two to 
three times higher than the concentration of plasma free Τ (ρ <0.001). The mean 
ratio of salivary Τ over plasma free Τ in the follicular and the luteal phase was 3.30 
± 1.49 and 3.12 ± 1.15, respectively. In contrast, salivary over free concentrations of 
androstenedione (follicular phase: 0.86 ± 0.15; luteal phase: 0.87 ± 0.14) and DHEA 
(follicular phase: 1.21 ± 0.37; luteal phase: 1.33 ± 0.37) approximated unity (but 
were significantly different from 1, p<0.01). 
The fractions of free DHEA and androstenedione are relatively constant between 
individuals (relative variation 10.5 and 7.9%, respectively) whereas the inter-
individual variation of the percentage free testosterone is much larger (26.5%) 
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reflecting the high affinity of testosterone for SHBG and the interindividual variation 
of SHBG. 
Although salivary Τ concentrations correlated with concentrations of plasma total 
[Fig 3.1.5, r=0.763, p<0.001 (follicular phase); r=0.643, p<0.001 (luteal phase)] and 
plasma free Τ [Fig 3.1.6, r=0.589, p<0.001 (follicular phase); r=0.634, p<0.001 
(luteal phase)] throughout the cycle, these correlations were less strong than in the 
case of DHEA and androstenedione. 
The concentrations of plasma total and free Τ in the follicular phase of the 
menstrual cycle were correlated with their levels in the luteal phase (r = 0.857, 
p<0.001 and г = 0.783 p<0.001, respectively). Interestingly however, no such 
Table 3.1.2 Spearman correlations between plasma total (T) plasma free (F) and 
salivary (S) concentrations of dehydroepiandrosterone (DHEA), 
androstenedione (AJ and testosterone (T) in the follicular phase of the 
menstrual cycle (upper right) and in the luteal phase (lower left) in 22 
normally ovulating women. All correlations were highly significant (P<0 001). 
DHEA 
\ 
Τ 
Τ 
F 
S 
Τ 
F 
S 
T 
F 
S 
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correlation was observed for salivary testosterone (r=0.396 n.s.)· SHBG was slightly 
higher in the luteal phase of the menstrual cycle, but this difference did not reach 
statistical significance. The mean levels of Cortisol were similar in both phases of 
the menstrual cycle. 
The levels of androgens were interrelated as indicated by the high correlations 
between plasma total, plasma free and salivary levels of DHEA, A4 and T, reflecting 
their metabolic relationship (Table 3.1.2). The concentrations of salivary A4 and 
DHEA each show the highest correlation with their plasma total and free 
concentrations. Interestingly, particularly in the luteal phase of the menstrual cycle, 
salivary testosterone tends to be correlated better (0.1<p<0.05) with the 
concentration of plasma total (r=0.871) and free (r=0.859) A4 and even more so with 
salivary A4 (0.884) than with plasma total (r=0.643) or plasma free Τ (r=0.634). 
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Fig 3 1 1 Upper left The relation between the 
concentration of DHEA in saliva and plasma 
total DHEA in control women (n=22) in the 
follicular phase of the menstrual cycle Salivary 
DHEA = 0 016 χ plasma total DHEA + 0 15 
nmol/l, r=0 924, p<0 001 
Upper right The relation between the 
concentration of DHEA in saliva and plasma 
total DHEA in control women (n=22) in the 
luteal phase of the menstrual cycle Salivary 
DHEA = 0 020 χ plasma total DHEA +0 13 
nmol/l, r=0 879, p<0 001 
Lower left The relation between the 
concentration of DHEA in saliva and plasma 
total DHEA in control women (n=22) in the 
follicular phase and the luteal phase of the 
menstrual cycle Salivary DHEA = 0 018 χ 
plasma total DHEA + 0 14 nmol/l, r=0 897, 
p<0 001 
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Fig 31 2 Upper left The relation between the 
concentration of DHEA in saliva and plasma 
free DHEA in control women (n=22) in the 
follicular phase of the menstrual cycle Salivary 
DHEA = 0 830 χ plasma free DHEA + 0 14 
nmol/l, r=0 902, p<0 001 
Upper right The relation between the 
concentration of DHEA in saliva and plasma 
free DHEA in control women (n=22) in the 
luteal phase of the menstrual cycle Salivary 
DHEA = 0 948 χ plasma free DHEA + 0 15 
nmol/l, r=0 878, p<0 001 
Lower left The relation between the 
concentration of DHEA in saliva and plasma 
free DHEA in control women (n=22) in the 
follicular phase and the luteal phase of the 
menstrual cycle Salivary DHEA = 0 898 χ 
plasma free DHEA + 0 14 nmol/l, r=0 880, 
p<0 001 
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Fig 3 1 3 Upper left The relation between the 
concentration of A4 in saliva and plasma total 
A4 in control women (n=22) in the follicular 
phase of the menstrual cycle Salivary A4 = 
0 075 χ plasma total A, + 0 00 nmol/l, r=0 874, 
p<0 001 
Upper right The relation between the 
concentration of A4 in saliva and plasma total 
A4 in control women (n-22) in the luteal phase 
of the menstrual cycle Salivary A4 = 0 069 χ 
plasma total A4 +0 02 nmol/l, r=0 949, p<0 001 
Lower left The relation between the 
concentration of A4 in saliva and plasma total 
A4 in control women (n-22) in the follicular 
phase and the luteal phase of the menstrual 
cycle Salivary A4 = 0 070 χ plasma total A4 + 
0 02 nmol/l, r=0 924, p<0 001 
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Fig 3 1 4 Upper left The relation between the 
concentration of A4 in saliva and plasma free 
A4 in control women (n-22) in the follicular 
phase of the menstrual cycle Salivary A4 = 
0 859 χ plasma free A4 + 0 00 nmol/l, r=0 861, 
p<0 001 
Upper right The relation between the 
concentration of A4 in saliva and plasma free 
A4 in control women (n=22) in the luteal phase 
of the menstrual cycle Salivary A4 = 0 789 χ 
plasma free A4+0 03 nmol/l, r=0 927, p<0 001 
Lower left The relation between the 
concentration of A4 in saliva and plasma free 
A4 in control women (n=22) in the follicular 
phase and the luteal phase of the menstrual 
cycle Salivary A4 = 0 808 χ plasma free A4 + 
0 02 птоІЛ, r=0 904, p<0 001 
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Fig 3 1 5 Upper left The relation between the 
concentration of Τ in saliva and plasma total Τ 
in control women (n=22) in the follicular phase 
of the menstrual cycle Salivary Τ = 0 014 χ 
plasma total Τ + 0 012 nmol/l, г = 0 763, 
p<0 001 
Upper right The relation between the 
concentration of Τ in saliva and plasma total Τ 
in control women (n=22) in the luteal phase of 
the menstrual cycle Salivary Τ = 0 008 χ 
plasma total Τ + 0 002 nmol/l, г = 0 643, 
p<0 001 
Lower left The relation between the 
concentration of Τ in saliva and plasma total Τ 
in control women (n-22) in the follicular phase 
and the luteal phase of the menstrual cycle 
Salivary Τ = 0 013 χ plasma total Τ + 0 013 
nmol/l, r=0 687, p<0001 
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Fig 3.1.6 Upper left The relation between the 
concentration of Τ in saliva and plasma free Τ 
in control women (n=22) in the follicular phase 
of the menstrual cycle. Salivary Τ = 0.923 χ 
plasma free Τ + 0 016 nmol/l, r = 0 589, 
p<0.01. 
Upper right. The relation between the 
concentration of Τ in saliva and plasma free Τ 
in control women (n=22) in the luteal phase of 
the menstrual cycle Salivary Τ = 1.398 χ 
plasma free Τ + 0 013 nmol/l, r=0.634, p<0.01 
Lower left. The relation between the 
concentration of Τ in saliva and plasma free Τ 
in control women (n=22) in the follicular phase 
and the luteal phase of the menstrual cycle. 
Salivary Τ = 1.192 χ plasma free Τ + 0.014 
nmol/l, r=0.616, p<0.001. 
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Fig 3 1 7 (Left) The diurnal variation of the concentration of salivary and plasma total 
and free and of salivary DHEA, Α
φ
 and Τ in a normal woman 
Concentrations of total Cortisol in plasma frmolA) dunng the day are also 
shown 
In one normal woman, we studied the diurnal variation of DHEA, A4 and Τ The 
early morning concentrations of these hormones in plasma were two- to threefold 
that of the afternoon concentrations The diurnal variation in the total concentration 
of these androgens was closely reflected by the concentrations of plasma free and 
of salivary levels, and coincided with the rhythm of Cortisol during the day (Fig 
3 17) 
The concentration of DHEA m saliva varied with age with low concentrations in 
children The level increases at the age of adrenarche and reaches a plateau at 
adolescence After 35 years of age the level apparently declines again (fig 3 18) 
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3.2 Plasma and salivary androgens during combined 
dexamethasone/synthetic ACTH administration in 
control women. 
After overnight dexamethasone suppression in ten control women the concentration 
of plasma Cortisol was nearly undetectable in both phases of the cycle and 
increased following synthetic corticotropin administration (Table 3.2.1). 
Similarly, basal dexamethasone-suppressed concentrations of DHEA in plasma and 
saliva were low, and increased after administration of synthetic corticotropin. 
There were no statistically significant differences between the basal concentrations 
of plasma and salivary DHEA between the follicular and the luteal phase of the 
menstrual cycle. After administration of synthetic corticotropin, stimulation peaks of 
plasma and salivary DHEA were observed at 45 - 75 min (Table 3.2.1). 
The concentration of DHEA in saliva was similar to the non-protein bound 
concentration in plasma. Also the 0-75 minutes increase in plasma free and salivary 
DHEA was very similar [0.99 (0.23) nmol/l and 0.92 (0.26) nmol/l, respectively]. 
There was a strong correlation (P <0.01, corrected for interindividual variation) be-
tween salivary DHEA and plasma total DHEA during the dynamic test in the 
follicular phase (r=0.895 p<0.01) and in the luteal phase of the menstrual cycle 
(r=0.929 p<0.01). The same holds for the correlation between salivary and plasma 
free DHEA in the follicular (r=0.783 p<0.01) and in the luteal phase (r=0.839 
p<0.01). 
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The dexamethasone-suppressed concentrations of androstenedione in plasma and 
saliva in the luteal phase were slightly but not significantly higher than their 
corresponding concentrations in the follicular phase of the menstrual cycle (Table 
3.2.1). 
Dexamethasone suppressed levels of plasma free A4 and salivary A4 did not 
significantly differ from each other during either phase of the cycle. 
Following synthetic corticotropin administration after overnight dexamethasone 
suppression the concentrations of plasma total, plasma free and salivary A4 
increased (p<0.01). 
During the test, at 45 and 75 min the concentration of A4 in saliva was slightly 
higher than plasma free A4 in controls in both phases of the menstrual cycle (p 
<0.01). The mean increment in the concentration of salivary A4 during the dynamic 
test in controls in the follicular as well as in the luteal phase of the menstrual cycle 
was higher than the increment in plasma free A4. 
Salivary A4 was correlated with plasma free A4 in the follicular phase (r=0.941 
p<0.01) and the luteal phase (r=0.907 p<0.01). Salivary A4 was also correlated with 
plasma total A4 in both phases of the cycle (follicular phase: r=0.924, luteal phase: 
r=0.911 p<0.01). 
Baseline dexamethasone suppressed concentrations of plasma total T, plasma free 
T, non-SHBG bound Τ and salivary Τ were similar during the follicular and luteal 
phase of the menstrual cycle in the normal women. After synthetic corticotropin 
administration the concentration of free testosterone at 45 and 75 min after 
corticotropin was significantly higher in the luteal phase of the menstrual cycle 
(p<0.05, paired Student's t-test). 
After overnight dexamethasone suppression and subsequent corticotropin 
administration in the normal women, salivary Τ values were about thrice higher than 
plasma free Τ concentrations within all time intervals (p <0.001, paired Student's t-
test). 
Following synthetic corticotropin infusion after overnight dexamethasone 
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administration the concentrations of plasma total and free Τ and salivary 
testosterone increased significantly (p <0.001, Friedman test). Remarkably, 
however, the concentration of non-SHBG-bound Τ remained virtually unchanged in 
the follicular phase and even decreased in the luteal phase of the menstrual cycle 
(p <0.05). The percentage non-SHBG bound Τ decreased (p<0.001) whereas the 
percentages free Τ increased (p<0.05). 
Whereas salivary Τ was positively correlated with plasma total Τ during the dynamic 
test in the luteal phase (r=0.632 p<0.05), this correlation did not reach significance 
in the follicular phase (r=0.590). The correlations between salivary and plasma free 
Τ were similar in both phases of the menstrual cycle (r=0.610 p<0.05 follicular 
phase, r=0.662 p<0.05 luteal phase). 
Salivary testosterone was even better correlated with plasma free androstenedione 
during the test in the follicular phase (r = 0.731) and in the luteal phase (r = 0.735). 
There was no correlation of salivary Τ with the concentration of non-SHBG bound Τ 
in the luteal phase of the menstrual cycle (r=0.473). In the follicular phase there was 
an inverse relationship of salivary Τ with non-SHBG bound Τ (p<0.05). The 
concentration of non-SHBG bound Τ was negatively correlated with plasma total 
Cortisol (P<0.01) in the normal women in the luteal phase (r = -0.657 p<0.01). Also, 
the percentage non-SHBG bound Τ and plasma total Cortisol were negatively 
correlated [r=0.878 p<0.01) in the follicular phase and r=0.916 p<0.01 in the luteal 
phase]. 
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Table 3.2.1 Mean (SD) concentrations of plasma total, plasma free, and salivary 
dehydroepiandrosterone (DHEA), androstenedione (AJ and testosterone (T) as well as sex 
hormone binding globulin and Cortisol during combined administration of dexamethasone 
and synthetic corticotropin in normal women (n=10) each in the luteal and the follicular 
phase of the menstrual cycle. 
Time after corti 
(min) 
cotropin 
follicular phase luteal phase 
Ρ 
Plasma total DHEA nmol/l 
0 
15 
45 
75 
7.59 (2.22) 
21.66(7.03) 
40.74 (13.05) 
46.36 (13.60) 
6.82 (2.79) 
18.51 (6.42) 
35.14 (9.72) 
41.69(9.52) 
η.s. 
n.s. 
η.s. 
n.s. 
Percent free DHEA 
0 
15 
45 
75 
2.70 (0.38) 
2.75 (0.29) 
2.72 (0.27) 
2.72 (0.43) 
2.76 (0.28) 
2.74 (0.25) 
2.73 (0.33) 
2.74 (0.32) 
n.s. 
n.s. 
n.s. 
n.s. 
Plasma free DHEA, nmol/l 
0 
15 
45 
75 
0.20 (0.04) 
0.59 (0.18) 
1.09 (0.30) 
1.23(0.25) 
0.19 (0.07) 
0.50 (0.25) 
0.96 (0.29) 
1.14(0.27) 
n.s. 
n.s. 
n.s. 
n.s. 
Salivary DHEA, nmol/l 
0 
15 
45 
75 
0.21 (0.08) 
0.23 (0.08) 
0.90 (0.18) 
1.12(0.22) 
0.20 (0.09) 
0.28 (0.12) 
0.97 (0.31) 
1.13(0.37) 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 3.2.1 Continued 
Time after corticotropin 
(min) follicular phase luteal phase 
Ρ 
Plasma total A4 nmol/l 
0 
15 
45 
75 
2.69 (0.68) 
3.53 (0.95) 
4.87(1.44) 
5.44(1.55) 
3.16(1.24) 
3.85(1.23) 
5.02(1.29) 
5.48(1.25) 
η.s. 
n.s. 
η.s. 
n.s. 
Percent free A4 
0 
15 
45 
75 
8.02 (0.72) 
8.02 (0.70) 
8.21 (0.71) 
8.42 (0.78) 
7.74 (0.53) 
7.95 (0.53) 
7.97 (0.55) 
7.94 (0.51) 
n.s. 
n.s. 
n.s. 
n.s. 
Plasma free A4, nmol/l 
0 
15 
45 
75 
0.21 (0.05) 
0.28 (0.06) 
0.39 (0.10) 
0.45 (0.12) 
0.24 (0.09) 
0.30 (0.10) 
0.40 (0.10) 
0.43 (0.09) 
n.s. 
n.s. 
n.s. 
n.s. 
Salivary AA, nmol/l 
0 
15 
45 
75 
0.21 (0.05) 
0.24 (0.05) 
0.47(0.11) 
0.54 (0.12) 
0.28 (0.11) 
0.31 (0.11) 
0.53 (0.15) 
0.56 (0.16) 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 3.2.1. Continued 
Time after corticotropin 
(min) follicular phase luteal phase 
Ρ 
Plasma total Τ nmol/l 
0 
15 
45 
75 
0.62 (0.16) 
0.66 (0.17) 
0.77 (0.19) 
0.85 (0.21) 
0.75 (0.31) 
0.80 (0.27) 
0.87 (0.21) 
0.93 (0.24) 
n.s. 
n.s. 
n.s. 
n.s. 
Percent free Τ 
0 
15 
45 
75 
1.24(0.52) 
1.24(0.54) 
1.22(0.47) 
1.31 (0.56) 
1.18 (0.53) 
1.22(0.57) 
1.38 (0.64) 
1.46(0.68) 
n.s. 
n.s. 
0.05 
0.05 
Plasma free T, pmol/l 
0 
15 
45 
75 
7.4 (2.5) 
7.9 (3.0) 
9.1 (3.5) 
10.8 (4.6) 
8.5 (3.6) 
9.3 (4.0) 
11.7(5.3) 
13.2 (5.9) 
n.s. 
n.s. 
n.s. 
n.s. 
Salivary T, pmol/l 
0 
15 
45 
75 
21.6(6.4) 
19.9 (4.1) 
25.7 (5.9) 
29.7 (6.8) 
26.6 (8.6) 
25.9 (7.9) 
32.8 (10.2) 
34.7 (9.6) 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 32 1 Continued 
Time after corti 
(mm) 
cotropm 
follicular phase luteal phase 
Ρ 
Percent non-SHBG-bound Τ 
0 
15 
45 
75 
45 1 (19 0) 
38 0(15 0) 
32 0(15 5) 
32 6 ( 1 6 3) 
42 7(15 9) 
35 6 ( 1 4 2) 
28 2 ( 1 2 5) 
28 9 ( 1 2 3) 
η s 
η s 
η s 
η s 
Plasma non-SHBG-bound T, nmol/l 
0 
15 
45 
75 
0 27 (0 09) 
0 24 (0 09) 
0 24 (0 12) 
0 2 7 ( 0 13) 
0 30(0 11) 
0 2 7 ( 0 10) 
0 2 4 ( 0 10) 
0 2 6 ( 0 11) 
η s 
η s 
η s 
η s 
Plasma total Cortisol, μιηοΙ/Ι 
0 
15 
45 
75 
0 0 5 ( 0 01) 
0 29 (0 07) 
0 6 2 ( 0 11) 
0 7 4 ( 0 10) 
0 05 (0 03) 
0 28 (0 05) 
0 59 (0 09) 
0 71 (0 10) 
η s 
η s 
η s 
η s 
Sex Hormone binding globulin (nmol/l) 
0 29 2 ( 1 3 4) 30 7(15 9) η s 
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3.3 Plasma and salivary dehydroepiandrosterone during 
combined dexamethasone/synthetic corticotropin 
administration in women with androgenizing disorders1 
As compared to the basal values of controls reported in paragraph 3.1, 
dexamethasone-suppressed concentrations of DHEA in plasma and saliva were low 
during dexamethasone/synthetic corticotropin administration in controls and hirsute 
women, though significantly higher in the latter (p<0.05). After administration of 
synthetic corticotropin, stimulation peaks were observed at 45 - 75 min (Table 
3.3.1). There was no significant difference in the plasma Cortisol responses between 
control women and women with androgenizing disorders. In the control women, 
increases in plasma free and salivary DHEA were virtually similar: 0.99 (0.23) nmol/l 
and 0.92 (0.26) nmol/l, respectively. The increases in free and salivary DHEA in the 
hirsute women were significantly different: 1.69 (0.90) nmol/l and 1.18 (0.82) nmol/l, 
respectively, p<0.01). There was a strong correlation (p<0.01) between salivary 
DHEA and plasma total and free DHEA in the hirsute women during the dynamic 
test (r=0.899 and r=0.878, respectively). The concentration of plasma total DHEA 
was significantly higher in the patients than in controls 15 min after synthetic 
corticotropin infusion. However, the plasma free as well as the mean salivary DHEA 
concentrations were significantly higher in women with androgenizing disorders at 
all intervals after corticotropin (p<0.05-<0.001, Table 3.3.1). 
At 15, 45, and 75 min after synthetic corticotropin administration plasma total DHEA 
concentrations of six patients exceeded the control mean response by >2SD. In this 
1
 Published in Clinical Chemistry 1990; 36: 2042-2046. 
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subgroup of "high-responders" at each sampling time, salivary ' rree DHEA was 
also significantly higher than the corresponding DHEA : ,,crols (p<0.01). In the 
remaining 19 women ("normal responders"), basal total DHEA and the responses to 
corticotropin obviously were not different from those of the control women. Plasma 
free DHEA, however, was significantly higher than in the controls at all intervals; the 
salivary DHEA only at 15 min (Table 3.3.1). 
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Table 3.3.1. Mean (SD) concentrations of plasma total, plasma free, and salivary DHEA 
during combined administration of dexamethasone and synthetic 
corticotropin in control women and patients with androgenizing disorders. 
Time after corticotropin (min) 
Controls 
(n=10)a 
hirsute women 
(n=25) 
"normal" 
responders 
(n=19) 
"high" 
responders 
(n=6)b 
Plasma total DHEA (nmol/l) 
0 
15 
45 
75 
7.21 (2.58) 
20.09 (6.75) 
37.94(11.56) 
44.03(11.67) 
8.14 (3.21) 
28.34 (14.82)c 
49.35 (26.64) 
55.90 (27.35) 
7.32 (2.93) 
21.72 (9.45) 
38.61 (15.89) 
44.86(19.69) 
10.60 (2.91)c 
48.19 (8.73)e 
83.36 (13.32)f 
90.85 (16.28>' 
Plasma free DHEA (nmol/l) 
0 
15 
45 
75 
0.19(0.06) 
0.55 (0.18) 
1.03(0.30) 
1.18(0.26) 
0.26 (0.11)c 
0.97 (0.52)e 
1.70(0.87)" 
1.91 (0.98)d 
0.23 (0.09) 
0.74 (0.34)c 
1.34(0.58)c 
1.53(0.69)c 
0.35 (0.13)c 
1.66(0.32)" 
2.86 (0.56)" 
3.12 (0.81)' 
Salivary DHEA (nmol/l) 
0 
15 
45 
75 
0.20 (0.08) 
0.26 (0.10) 
0.93 (0.25) 
1.12 (0.29) 
0.33 (0.20)c 
0.67 (0.36)c 
1.31 (0.70)c 
1.54(0.88)° 
0.32 (0.22) 
0.60 (0.34)" 
1.06(0.60) 
1.25(0.76) 
0.36 (0.12)c 
0.89 (0.36)' 
2.08 (0.31)' 
2.47 (0.52)e 
Plasma total Cortisol (μπιοΙ/Ι) 
0 
15 
45 
75 
0.05 (0.02) 
0.29 (0.06) 
0.61 (0.10) 
0.73 (0.10) 
0.04 (0.01) 
0.27 (0.05) 
0.58 (0.10) 
0.69(0.11) 
0.05 (0.02) 
0.29 (0.06) 
0.61 (0.10) 
0.73(0.10) 
0.04 (0.01) 
0.29 (0.05) 
0.63 (0.12) 
0.76 (0.15) 
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' Both in the luteal and follicular phase. 
" Six of the hirsute women showed a high response (total plasma DHEA at 15, 45 and 75 
min after administration of synthetic corticotropin exceeded the normal mean response 
by at least 2 SD). Salivary and plasma free DHEA in this group were also statistically 
different from the mean normal concentration. 
c
 ρ <0.05 vs normal women; 
" ρ <0.01; 
• ρ <0.001; 
' p<0.0001. 
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3.4 Plasma and salivary testosterone during combined 
dexamethasone/synthetic corticotropin administration in 
women with androgenizing disorders2 
After overnight dexamethasone suppression and subsequent corticotropin 
administration in the control women and 25 hirsute women, salivary Τ values were 
about thrice higher than plasma free Τ concentrations at all time intervals in both 
groups (p<0.001, paired Student's f-test) (Table 3.4.1). 
Throughout the test the mean concentrations of plasma total T, non-SHBG bound T, 
plasma free Τ and salivary Τ in the hirsute women were about twofold higher than 
the corresponding mean values in controls (p<0.01 -p<0.0001). From 25 hirsute 
women, 11 (44%) had elevated concentrations (mean value through the test >2 SD 
from control) of plasma total T, 14 (56%) of non-SHBG bound Τ and free Τ and 16 
women (64%) had elevated salivary Τ concentrations. 
The concentration of plasma SHBG did not change significantly throughout the test 
(data not shown). In the hirsute group, SHBG was lower than in controls. This 
difference was not significant. 
Following synthetic corticotropin infusion after overnight dexamethasone 
administration the concentrations of plasma Cortisol, total T, free Τ and salivary 
testosterone significantly increased (p<0.001, Friedman test) in the normal as well 
as in the hirsute women. Remarkably, however, the concentration of non-SHBG 
'published in Clinical Chemistry 1991; 37: 180-185. 
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bound Τ remained virtually unchanged in the normal women during the follicular 
phase and even decreased in the normal women in the luteal phase of the 
menstrual cycle (p<0.05) and in the hirsute women (p<0.001). The absolute 
decrease of the concentration of non-SHBG bound Τ from t=0 to t=75 min was more 
marked in the hirsute women (p<0.001) than in the control women in either phase of 
the cycle. The percentage of non-SHBG bound Τ decreased in all three groups 
(p<0.001). The percentages of free Τ increased (p<0.05) in the controls and in 
hirsute women. Salivary T, expressed as percent total Τ only increased significantly 
in the hirsute group (p<0.05). 
Salivary Τ was positively correlated with plasma total Τ and free Τ during the 
dynamic test in all three groups ( follicular control: r=0.590, n.s. and r=0.610 
p<0.05; luteal control r=0.632, p<0.06 and r=0.662, p<0.05; hirsute: r=0.524, p<0.01 
and r=0.554 p<0.01). There was no correlation of salivary Τ with non-SHBG bound 
Τ in the control women in the follicular phase and in hirsute women. In women in 
the luteal phase a negative correlation between salivary Τ and non-SHBG-bound Τ 
was found (r=0.625, p<0.05). The percentages of non-SHBG bound Τ were 
negatively correlated with plasma total Cortisol concentrations (p<0.01) in the normal 
women both in the follicular (r=0.878) and luteal phase (r=0.916) as well as in the 
hirsute women (r=0.850). In the follicular phase of the menstrual cycle there was no 
statistically significant correlation between the absolute levels of non-SHBG bound 
Τ and of plasma total Cortisol. In the normal women in the luteal phase, however, as 
well as in the hirsute women, there was a statistically significant negative correlation 
between the concentrations of n-SHBGT and plasma total Cortisol (r=-0.657 and r=-
0.680 respectively, p<0.001). 
Salivary Τ correlated slightly better with plasma free androstenedione than with 
plasma free testosterone (control follicular: r=0.731; control luteal: r=0.753; hirsute 
women: r=0.586). 
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Table 34 1 Mean (SD) concentrations of plasma total testosterone, plasma free 
testosterone, plasma non-SHBG bound testosterone, salivary testosterone, 
Sex hormone binding globulin and plasma total Cortisol dunng administration 
of dexamethasone/synthetic corticotropin in normal women dunng the 
follicular and the luteal phase of the menstrual cycle (n=10) and in 25 
women with androgemzing disorders 
Time after corticotropin (mm) 
control 
follicular 
(n=10) 
control 
luteal 
(n=10) 
hirsute 
women 
(n=25) 
Pa Pb 
Total testosterone (nmol/l) 
0 
15 
45 
75 
0 62 (0 16) 
0 6 6 ( 0 17) 
0 7 7 ( 0 19) 
0 8 5 ( 0 21) 
0 75(0 31) 
0 80 (0 27) 
0 87(0 21) 
0 93(0 21) 
1 24 (0 57) 
1 23 (0 54) 
1 35 (0 57) 
1 40 (0 53) 
0 0001 
0 0001 
0 0001 
0 0001 
0 01 
0 01 
0 01 
0 01 
Free testosterone (%) 
0 
15 
45 
75 
1 24 (0 52) 
1 24 (0 54) 
1 22 (0 47) 
1 31 (0 56) 
1 19(0 53) 
1 22 (0 57) 
1 38 (0 64c) 
1 46 (0 68c) 
1 34 (0 38) 
1 52 (0 46) 
1 58 (0 47) 
1 57 (0 48) 
η s 
η s 
0 05 
η s 
η s 
η s 
η s 
η s 
Free testosterone (pmol/l) 
0 
15 
45 
75 
7 4 (2 5) 
7 9 (3 0) 
9 1 (3 5) 
10 8 ( 4 6) 
8 5 (3 6) 
9 3 (4 0) 
11 7 (5 3C) 
13 2 ( 5 9c) 
16 4 ( 8 5) 
18 5 ( 9 5) 
21 3 ( 1 1 4 ) 
22 2 ( 1 1 4 ) 
Non-SHBG Bound Testosterone (%) 
0 
15 
45 
75 
45 3 (19 0) 
38 0 ( 1 5 9) 
32 0 ( 1 5 5) 
32 6 ( 1 6 3) 
42 7(15 9) 
35 6(14 2) 
28 2(12 5) 
28 9(12 3) 
49 3 ( 1 1 9) 
42 7 ( 1 0 7) 
32 6 (8 5) 
31 6 (7 9) 
0 0001 
0 0001 
0 0001 
0 0001 
0 001 
0 0001 
0 001 
0 001 
η s 
η s 
η s 
η s 
η s 
η s 
η s 
η s 
Non-SHBG Bound Testosterone (nmol/l) 
0 
15 
45 
75 
0 27 (0 09) 
0 24 (0 09) 
0 2 4 ( 0 12) 
0 2 7 ( 0 13) 
0 30(0 11) 
0 2 7 ( 0 10) 
0 2 4 ( 0 10) 
0 2 6 ( 0 11) 
0 63 (0 33) 
0 53 (0 27) 
0 45 (0 25) 
0 46 (0 25) 
0 0001 
0 0001 
0 0001 
0 01 
0 0001 
0 0001 
0 001 
0 001 
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Table 4 2 continued 
Time after corticotropin (mm) 
control 
follicular 
(n=10) 
control 
luteal 
(n=10) 
hirsute 
women 
(n=25) 
Pa Рь 
Salivary testosterone (%) 
0 
15 
45 
75 
3 66 (1 34) 
3 21 (1 14) 
3 65 (1 50) 
3 75 (1 38) 
3 71 (1 23) 
3 30 (0 78) 
3 80(1 19) 
3 78 (0 97) 
3 96(2 15) 
4 07 (1 80) 
4 10(1 50) 
4 32(1 71) 
η s 
η s 
η s 
η s 
η s 
π s 
π s 
π s 
Salivary testosterone (pmol/l) 
0 
15 
45 
75 
21 6 (6 4) 
19 9 (4 1) 
25 7 (5 9) 
29 7 (6 8) 
26 6 (8 6) 
25 9 (7 9) 
32 8 ( 1 0 2) 
34 7 (9 6) 
44 6 (24 0) 
45 8 (21 8) 
51 3 (20 8) 
56 6 (23 2) 
0 0001 
0 0001 
0 0001 
0 0001 
0 001 
0 0001 
0 001 
0 0001 
Sex hormone binding globulin (nmol/l) 
0 29 2 ( 1 7 6) 30 7 ( 1 5 9) | 23 6 ( 1 1 4 ) η s Ι η s 
Total Cortisol (//mol/l) 
0 
15 
45 
75 
0 0 5 ( 0 01) 
0 29 (0 07) 
0 6 2 ( 0 11) 
0 7 4 ( 0 10) 
0 05 (0 03) 
0 28 (0 05) 
0 59 (0 09) 
0 71 (0 10) 
0 0 4 ( 0 01) 
0 27 (0 05) 
0 58(0 10) 
0 69 (0 11) 
0 05 
η s 
η s 
η s 
η s 
η s 
η s 
η s 
* f-fesf ρ value of hirsute vs follicular concentrations 
" t-test ρ value of hirsute vs luteal concentrations 
c
 p<0 05, paired Student s t-test compared to levels in the follicular phase 
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3.5 Indirect evidence of increased in vivo conversion of 
androstenedione into testosterone by the salivary gland 
in women with androgenizing disorders3 
The concentrations of plasma total, plasma free, and salivary androstenedione 
during combined dexamethasone/synthetic corticotropin administration in controls 
and in hirsute women are given in Table 3.5.1 
Both in the luteal and in the follicular phase the dexamethasone-suppressed 
concentrations of plasma total and free androstenedione were significantly lower 
than those in hirsute women. The concentration of salivary androstenedione at 0 
min was significantly lower in the control women only in the follicular phase. 
Basal dexamethasone suppressed levels of plasma free and salivary 
androstenedione did not significantly differ in controls during either phase of the 
cycle. In the hirsute women however, salivary androstenedione was significantly 
lower than plasma free androstenedione (0.32 ± 0.19 vs 0.40 ± 0.22 nmol/l 
respectively, p<0.01). 
Following synthetic corticotropin administration after overnight dexamethasone 
suppression the concentrations of plasma total, free and salivary androstenedione 
increased in controls as well as in hirsute women (p<0.01). At all time intervals 
during the test the concentrations of total and free androstenedione were 
significantly higher in hirsute women than in controls during either phase of the 
3Published in Clinical Chemistry 1992; 38: 1819-1823. 
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menstrual cycle (p<0.01-0.001). Following synthetic corticotropin administration 
salivary androstenedione did not significantly differ between hirsute women and 
controls at t=45 and 75 min. Only in the follicular phase at t=0 and t=15 min, 
salivary androstenedione was lower in controls than in the hirsute women (p<0.05-
0.01). 
During the test, at 45 and 75 min salivary androstenedione was slightly higher than 
plasma free androstenedione in controls in both phases of the menstrual cycle 
(p<0.01). In the hirsute women on the other hand, salivary androstenedione was 
significantly lower than plasma free androstenedione at all time intervals (p<0.05-
0.01). 
The mean increment in the concentration of free androstenedione during the 
dynamic test (expressed as the area under the curve from baseline concentrations) 
was significantly higher in hirsute women than in controls [hirsute women: 16.9 ± 8.1 
nmol.min/l vs controls: 10.5 ± 4.6 nmol,min/l (p<0.05) in the follicular phase and 8.9 
± 4.0 nmol,min/l in the luteal phase (p<0.001), respectively], Interestingly, however, 
there was no significant difference between the increases in salivary 
androstenedione (hirsute women: 15.0 ± 9.6 vs controls: 13.1 ± 4.1 nmol,min/l in the 
follicular and 12.6 ± 4.5 nmol,min/l in the luteal phase). 
In controls the mean increment (AUC) in the concentration of salivary 
androstenedione was significantly higher than the increment in plasma free 
androstenedione (p <0.05 in both phases of the menstrual cycle), whereas there 
was no such difference between the increments of free and salivary 
androstenedione in hirsute women. 
The mean SA4/ST and FA</FT ratios were significantly lower in hirsute women than 
in controls except for the FA4/FT ratios in the luteal phase in controls which were 
similar to the values found in hirsute women (Table 3.5.1). 
After overnight dexamethasone administration the ratio SA4/ST both in the control 
women and in the hirsute women was two to three times lower (p<0.001) than the 
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FA4/FT ratio. This difference persisted during combined dexamethasone/synthetic 
corticotropin administration and was mainly due to the thrice higher ST as compared 
to FT levels (p<0.0001) in either group. Both the SA4/ST and FA4/FT ratios 
significantly (p<0.01) increased during corticotropin stimulation in the control as well 
as in the hirsute women. 
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Table 3 5 1 Mean (SD) concentrations of plasma total, plasma free, and salivary 
androstenedione and testosterone dunng combined administration of dexamethasone and 
synthetic corticotropin in controls and in hirsute women 
Time after corticot ropm (mm) 
control 
follicular 
(n=10) 
control 
luteal 
(n=10) 
hirsute 
women 
(n=25) 
Total androstenedione (nmol/l) 
0 
15 
45 
75 
2 69 (0 68)" 
3 53 (0 95)' 
4 87 (1 44)' 
5 44 (1 55)" 
3 16 (1 24)" 
3 85 (1 23)" 
5 02 (1 29)" 
5 48 (1 25)" 
4 65 (2 66) 
5 85 (2 79) 
7 62 (3 47) 
8 20 (3 75) 
Free androstenedione (nmol/l) 
0 
15 
45 
75 
0 21 (0 05)' 
0 28 (0 06)' 
0 39(0 10)' 
0 45(0 12)' 
0 24 (0 09)" 
0 30(0 10)' 
0 40(0 10)' 
0 43 (0 09)' 
0 40 (0 22) 
0 52 (0 22) 
0 69 (0 27) 
0 77 (0 31) 
Salivary androstenedione (nmol/l) 
0 
15 
45 
75 
0 21 (0 05)ans 
0 24 (0 05)"" 
0 47(0 11)nsy 
0 54 (0 12)nsz 
0 28(0 11)nsns 
0 31 (0 11)nsns 
0 53(0 15)nsy 
0 56(0 16)nsy 
0 32 (0 19)y 
0 43 (0 20)" 
0 57 (0 21)y 
0 64 (0 28)" 
Free androstenedione/free testosterone 
0 
15 
45 
75 
314(10 0)" 
37 9(10 4)" 
46 0(12 4)" 
46 2 (16 3)ns 
31 9(13 2)ns 
36 9 (14 6)ne 
37 7 (12 0)ns 
37 0(13 7)ns 
24 8 (7 1) 
29 6 (6 8) 
34 6 (7 6) 
36 2 (7 2) 
Salivary androstenedione/salivary testosterone 
0 
15 
45 
75 
11 1 (5 2)a z 
12 5(4 1) n " 
19 5(8 0 ) " 
19 3(6 6)"z 
116(6 0)a z 
13 5(8 2)n s z 
17 5(6 7)a z 
17 7(8 1)a z 
7 2 (3 0)z 
9 9 (3 6)z 
11 8 (3 7)z 
11 7 (3 8)z 
** f-fesf p-value vs hirsute women ' p<0 05, " p<0 01, ' p<0 001, "s not significant 
xz
 t-test p-value vs the corresponding plasma concentration or ratio ' p<0 05, r p<0 01, z 
p<0 001, ns not significant 
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Discussion 
Radioimmunoassay of steroids in plasma and saliva. 
Measurement of the steroid hormone concentration in saliva is an attractive 
alternative for their determination in plasma. However, the concentration of most of 
the steroid hormones in saliva is low, therefore very sensitive assays are required 
for the reliable assessment of the concentration of salivary steroids. 
In this study we used radioimmunoassays with prior extraction of the samples and 
subsequent chromatography of the extracts for the measurement of steroids. The 
samples are extracted with organic solvents in order to circumvent interference in 
the radioimmunoassay by endogenous (specific) binding proteins. Chromatography 
essentially increases the specificity of the assay. For the determination of steroids in 
saliva such an extraction step theoretically might be considered unnecessary as 
binding proteins do not occur in significant concentrations in saliva. In practice 
however the presence of salivary mucopolysaccharides may cause non-specific 
effects. Thus extraction is recommended. 
We demonstrated the necessity of an extraction step for the determination of steroid 
hormones in plasma in a study in which we determined, amongst others, plasma 
testosterone in women using different types of oral contraceptives (Swinkels ef al. 
1988). Many of the so-called "direct" plasma assays for the assessment of steroid 
hormones (which do not include extraction and chromatography) are biased due to 
interference by plasma binding proteins. This bias may either be negative or 
positive, depending on the type of separation of the antibody-bound and free 
fraction in the assay. Particularly when comparing groups of subjects that have 
different levels of binding proteins, e.g. hirsute women and controls, the use of a 
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direct assay for the assessment of steroid hormones may lead to erroneous 
conclusions. 
Chromatography is of crucial importance as demonstrated in the androgen assays 
described in this study, particularly in the assay of DHEA and testosterone. Although 
the DHEA antiserum shows 100% cross-reactivity with androstenediol, this steroid 
does not interfere with our DHEA assay, as both steroids are completely separated 
during paper chromatography. 
In the case of testosterone, cross-reactivity with dihydrotestosterone may lead to an 
overestimation of the concentration of testosterone (Riad-Fahmy et al. 1982). These 
authors suggest that "there is a need to improve the specificity of non-
chromatographic immunoassays used for measuring testosterone in female saliva, 
before attempting to assess the role that these assays may have to play in infertility 
studies". Our testosterone antiserum shows considerable cross-reactivity with DHT. 
However, DHT is effectively separated from testosterone by the paper 
chromatographic step included in our assay procedure. 
An advantage of the procedure used in the present study is the possibility to 
measure DHEA, androstenedione and testosterone (in addition to 17-OH-
progesterone, and -in plasma- oestradiol) in a single sample extract. This is possible 
because these steroids are readily and completely separated in the paper 
chromatographic system. 
In this study we demonstrated that DHEA is measurable in saliva. The lower limit of 
detection of our assay is 0.01 pmol/l of saliva when 1 ml of saliva is assayed which 
is well below the levels we measured in controls. Only a few other studies report 
measurements of the concentration of DHEA in saliva (Gaskell ef al. 1980, Vittek et 
al. 1983, Vittek eí al. 1984). These studies concern measurements of salivary DHEA 
in post- and premenopausal women. We are not aware of any report concerning 
measurements of salivary DHEA in hirsute women. As reported by Vittek ef al. 
(1983, 1984), average salivary DHEA at 08.45 h in postmenopausal women (51-70 
years) was 0.22 ± 0.02 nmol/l, which is clearly lower than the 08.00 h mean for 
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control women reported in this study (follicular: 0.61 ± 0.32 nmol/l, luteal 0.69 ± 40 
nmol/l). We found that the concentration of DHEA in saliva is very low until 
adrenarche, reaches peak levels at adolescence and declines with advancing age 
(fig 3.1.8). Zumoff er al. (1980) reported a similar pattern of plasma DHEA. Thus the 
age difference of the two study groups might explain the discrepancy between our 
values and those reported by Vittek et al (1983) for postmenopausal women. 
The sensitivity of the androstenedione assay, being better than 0.01 nmol/l when 3 
ml of saliva are assayed, permits measurement of this steroid in saliva. We found 
androstenedione concentrations in saliva obtained from control women (0.41 ±0.19 
nmol/l) agreeing with those reported by Baxendale era/. (1983) (0.27 ±0.11 nmol/l) 
and Putz er al. (1982) (0.35 ± 0.09 nmol/l). 
Considering the low concentration of testosterone in saliva, particularly in women, it 
is not surprising that there is a great variability in reported values among 
laboratories (see Table 1.4.3). The lower limit of detection of our assay (2 pmol/l 
with a sample volume of 3 ml of saliva) allows the measurement of salivary 
testosterone in control women (range 14-44 pmol/l). 
From a recent international inter-laboratory comparison of the performance of 
assays for the assessment of salivary testosterone in which we participated, it 
became clear that the discrepancies between reported values for a large part must 
be ascribed to methodological differences (Dabbs et al., to be published). As 
pointed out earlier, particularly when assays are applied which do not incorporate an 
extraction step or chromatographic purification, levels of testosterone may be 
overestimated (Vittek ef al. 1985, Osredkar et al. 1989). 
Measurement of non-protein-bound hormones in plasma 
Equilibrium dialysis followed by the measurement of free hormone by 
radioimmunoassay in the dialysate (i.e. direct equilibrium dialysis) is considered as 
the method of choice for the determination of free hormones in plasma despite the 
fact that sample dilution is inherent to this technique. This procedure for the 
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determination of free testosterone in plasma is hardly suitable for routine application 
as sample volumes required are relatively high and the method is time-consuming. 
The radiochemical purity of the tracer used in indirect equilibrium dialysis is of 
critical importance. Minor non-binding contamination of the radioactive hormone will 
lead to spuriously increased free fractions, particularly when the free fraction of the 
hormone is small (Ross 1980, Swinkels et al. 1987). For instance, if in indirect 
equilibrium dialysis a tracer is employed which is contaminated with 1% of a non-
binding radioactive component to determine the free fraction of a hormone in a 
plasma sample with a free fraction of 1%, the observed free fraction will be falsely 
elevated by 100%. The free fraction of testosterone in plasma is relatively small. 
For this reason plasma free testosterone was measured by symmetric dialysis (vide 
infra). 
We compared the levels of free DHEA obtained with direct and indirect equilibrium 
dialysis (page 74). The results agreed well and the lack of a significant intercept 
indicates that the tracer is free of contamination or that the effect of possible tracer 
contamination in the indirect determination of free DHEA is relatively small. 
Using a computer model of steroid hormone distribution, Dunn et al. (1981) 
calculated the free fraction of DHEA. The percentage they reported for 
premenopausal control women (4%) is higher than that we established (2.0%). It 
should be noted however that these authors used estimates of affinity constants 
which were determined under non-equilibrium conditions using Con-Α Sepharose. 
The free fraction of plasma androstenedione has been reported to be about 7.5% 
(Forest et al. 1968, Smith ef al. 1979). Slight contamination of the tracer used in 
indirect equilibrium dialysis therefore is not expected to lead to gross overestimation 
of the free fraction of androstenedione (Swinkels et al. 1988). 
Plasma free Τ was measured by symmetric dialysis of undiluted samples. This 
method does not suffer from the drawbacks encountered in current methods for the 
determination of free steroid hormones (Swinkels et al. 1987). 
In symmetric dialysis the rate of tracer hormone diffusion through the dialysis 
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membrane is a direct measure for the free fraction of the hormone, provided that 
diffusion through the membrane is a first order rate process following Fick's law 
(Christensen 1959, Ross 1978). This condition is fulfilled with the demonstration of 
direct proportionality of log tracer distribution with dialysis time (Fig 2.3.1). 
Moreover, a direct proportionality between the dialysis rate and the free fraction of Τ 
was demonstrated (Fig 2.3.2). The system is calibrated by direct equilibrium 
dialysis. The symmetric dialysis process is stopped when about 25% of the tracer 
has migrated from the original compartment. This explains why symmetric dialysis of 
testosterone is hardly affected by the purity of the radiolabelled testosterone used in 
the experiments (fig 2.3.3). 
The concentration of free testosterone, as assessed by symmetric dialysis in a set 
of five undiluted plasma samples decreased significantly when these samples were 
diluted once (0.871 ± 0.043). This decrease exceeds the predicted value (0.983 ± 
0.007). The decrease in the concentration of free Τ of the same samples when 
comparing twice diluted with ten times diluted plasma (0.867 ± 0.022) was similar to 
the predicted value (0.857 ± 0.044). The discrepancy between the predicted and the 
observed decrease of free testosterone when undiluted and twice diluted plasma are 
compared, may be the result of the introduction of buffer in the system (Nelson and 
Weiss 1985, Umstot and Andersen 1986). It follows that strictly spoken the fraction 
of free hormones as determined in diluted plasma is always an approximation. 
Thus, in contrast with the concentration of free thyroxin which is largely independent 
of dilution (Oppenheimer and Surks 1964, Ross 1980), the concentration of free 
testosterone decreases significantly with dilution. The effect of sample dilution, as a 
consequence of the law of mass action, is stronger in the case of testosterone as 
the fraction of free Τ is higher than the free fraction of thyroxin. Sample dilution may 
lead to erroneous conclusions when comparing concentrations of free testosterone 
between groups. A similar notion has been put forward by Ross (1980) and Geiseler 
er al. (1984). The latter author demonstrated that under certain conditions samples 
which originally have different concentrations of free Cortisol, may show similar free 
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concentrations upon dilution. 
Symmetric dialysis allows the measurement of free steroid hormones in undiluted 
plasma so that problems associated with dilution are avoided. On the other hand the 
pH of undiluted plasma is difficult to control. Generally the free hormone fraction in 
non-oxygenated and therefore more alkaline plasma samples will be higher than in 
samples with neutral pH. 
The concentration of plasma free testosterone in control women as assessed in this 
study by symmetric dialysis (about 8 pmol/l, 1.0 ± 0.27 %) is in close agreement 
with values reported by Hammond et al. (1980, 0.90 ± 0.09 % 'isodialysis', also 
undiluted samples) and Umstot et al. (1985, 6 pmol/l, indirect equilibrium dialysis, 
correction for dilution). Free testosterone levels in this study are lower than those 
reported by Dunn et al. (1981, 18 pmol/l, calculated values), Wheeler and Nanjee 
[1985, 22 ± 6 pmol/l (follicular phase) steady-state gel-filtration] and Södergard ef al. 
(1982, 1.5%, 30 pmol/l, calculation). 
The wide variety in the levels of free testosterone reported in the literature must be 
attributed to factors such as the assessment of plasma total testosterone (in indirect 
assays), the purity of the tracer, the methods used to calculate assay results and 
the assay buffer used. 
Non-SHBG-bound testosterone 
The 'free hormone hypothesis' has repeatedly been challenged. Some authors 
adhere to the concept that the non-SHBG-bound testosterone (that is albumin-
bound and free T) rather than the plasma free testosterone reflects the bioavailable 
testosterone (Pardridge 1990). 
In the present study the percentage non-SHBG-bound Τ was measured using 
ammonium sulphate precipitation of the SHBG-bound testosterone. Quantitatively 
the results of our measurements in control women (30.9 ± 8.1%) agree well with 
data calculated by Dunn ef al. (1981; 34%) and with those reported by Barini ef al. 
(40%), but were higher than those established by Manni ef al. (1985; 10-25%) and 
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Cumming et al. (1985, 12.4%). Banni ef al. used a method for the simultaneous 
measurement of non-SHBG-bound and free Τ by saturation of plasma SHBG with 
DHT followed by equilibrium dialysis (Barini et al. 1993). This method is based on a 
technique similar to the one which was introduced by Pearce et al. (1989) who used 
centrifugal ultrafiltration to determine the relative binding of testosterone after 
saturation of SHBG with DHT. 
From the present study the interesting, and in our view important, finding emerged 
that the plasma distribution of testosterone depends, amongst others, on the level of 
Cortisol. This opens up the possibility that Cortisol, aside from changes in the 
production or metabolism of testosterone, may play a role in determining the 
bioavailability of testosterone. 
Evidence for this interdependency was inferred from our observation that the 
concentration of non-SHBG-bound Τ decreased (from 0.63 to 0.46 nmol/l) during 
combined dexamethasone/synthetic corticotropin administration in hirsute women, 
whereas the concentration of plasma total and free Τ as well as salivary Τ 
increased (Table 3.4.1). We found a decline in the concentration of non-SHBG-
bound Τ in controls (0.30 to 0.26 nmol/l) which however did not reach significance. 
Moreover, in controls and in the hirsute women the percentage non-SHBG bound Τ 
decreased during the test (44.0 to 30.8% and 49.4 to 31.4%, respectively). There 
was a significant negative correlation between the percentage non-SHBG-bound Τ 
and the level of plasma total Cortisol. In accordance with this we found a decrease 
in the percentage non-SHBG-bound Τ after the addition of Cortisol to steroid-free 
plasma which was incubated in vitro with tritlated Τ (Fig 2.4.2). The decline of non-
SHBG-bound testosterone in vitro however was less (about 7 %) than the decline 
during combined dexamethasone/synthetic ACTH tests (about 14 to 18%). 
We confirmed Rosner's finding (Rosner 1972) that CBG was not precipitated with 
50% saturated ammonium sulphate. This was demonstrated by precipitating plasma 
incubated with radiolabelled Cortisol, with increasing concentrations of ammonium 
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sulphate. At 50% saturated ammonium sulphate the radiolabelled Cortisol remained 
in the supernatant. Moreover, this was confirmed by direct measurement of CBG in 
the supernatant after precipitation of samples with increasing concentrations of 
ammonium sulphate (Fig 2.4.1a and b). Therefore we hypothesize that the so-calles 
"non-SHBG-bound testosterone" includes not only albumin-bound testosterone and 
free testosterone but also CBG-bound testosterone. Actually we presented evidence 
that testosterone bound to CBG is displaced by Cortisol (Swinkels et al. 1991a, 
Swinkels et al. 1991b). 
Preliminary data favouring an interdependency of non-SHBG-bound testosterone 
and Cortisol were reported earlier by other investigators. Using DEAE cellulose 
chromatography, Lea and Stoa (1972) determined the ratio of testosterone bound to 
SHBG and CBG. These authors showed that, particularly in sera obtained from 
male controls, Cortisol displaced Τ from CBG when physiological concentrations of 
this steroid were added to plasma in vitro. Lea and Stoa suggest that this relation 
between Cortisol and testosterone may serve to synchronize the biological activity of 
testosterone with that of Cortisol. Reed et al. (1986) found a significant decrease in 
the percentage non-SHBG-bound Τ associated with the nocturnal increase of 
Cortisol in plasma of patients and control women, which, according to these authors, 
supports the suggestion that Cortisol influences the distribution of plasma 
testosterone. 
According to our computer simulation using the data from Dunn ef al. (1981), about 
4% of the plasma testosterone is bound to CBG during dexamethasone 
suppression. The mass action model predicts almost complete displacement of 
CBG-bound testosterone by Cortisol increasing to levels which were observed during 
combined dexamethasone/synthetic ACTH administration in vivo. The decline of 
non-SHBG-bound testosterone during this test (about 13%) cannot be explained 
with this model and the binding data reported by Dunn ef al. (1981) as this model 
predicts a shift within the non-SHBG-bound fraction from testosterone bound to 
CBG to albumin (which would therefore not result in a change in the level of non-
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SHBG-bound Τ). 
Cooke eí al. (1990, 1993) observed a rapid decline in the percentage of non-SHBG-
bound testosterone in normal men In the early morning after peaking of Cortisol. In 
the period from 0330 to 0900 h the level of non-SHBG-bound testosterone declined 
by 15-45 % over 1.5-3.0 hours. The diurnal variation in the levels of plasma 
testosterone could be simulated using a mass action computer model (Cooke et al. 
1993). These authors also suggest that the rise in the concentration of Cortisol is the 
probable cause of the decline in the level of non-SHBG-bound Τ but alternatively 
hypothesize that a substance competes with testosterone for albumin binding sites 
as the predicted displacement of about 4% of CBG-bound Τ by Cortisol does not 
quantitatively explain the decline in non-SHBG-bound Τ observed. However, in view 
of the almost unlimited binding capacity of albumin, it is very unlikely that a 
substance competes with testosterone for albumin binding sites. 
We suggest that the percentage of testosterone bound to CBG as calculated with 
the mass action model using Kd estimates obtained under non-equilibrium 
conditions (4%) should be critically reviewed. 
After publishing our results (Swinkels er al. 1991a), Pardridge and Demers (1991) 
commented on our findings in an editorial in "Clinical Chemistry". They argued that 
our observations with respect to the interdepency of non-SHBG-bound-T and 
Cortisol should be interpreted in terms of a model postulating that non-SHBG-bound 
Τ represents bioactive Τ and is the better index of clinical androgenicity. These 
authors (1991) explain the increase of plasma total and free testosterone which we 
observed during the dynamic tests in controls and hirsute women by assuming an 
impairment of testosterone metabolism by the acute increase in the level of Cortisol. 
They attribute the fact that the decreased or unchanged non-SHBG-bound Τ during 
the dexamethasone/synthetic corticotropin test is not reflected in the concentration 
of salivary Τ to an altered metabolism of testosterone in the salivary gland caused 
by the increased levels of Cortisol. According to these authors serum testosterone is 
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rapidly metabolized in the salivary gland, explaining that only 2-4% of the total 
serum Τ appears in saliva whereas the concentration of bioavailable Τ (in their view 
non-SHBG-bound T) in the glands is 15-20% 
Although these are very intriguing views, it is more likely that the increase in the 
concentration of plasma and salivary Τ is the direct result of stimulation of androgen 
production in the adrenal Moreover Pardndge and Demers misinterpreted our 
findings by suggesting that Cortisol displaces testosterone from albumin rather than 
from corticosteroid binding globulin Such displacement would imply competition by 
testosterone and Cortisol for a limited number of relatively high-affinity binding sites, 
and such sites have never been demonstrated to be present on albumin 
According to Pardndges model the decreased non-SHBG-bound Τ in hirsute women 
would reflect decreased availability of testosterone If this were true, the unexpected 
perspective of improvement of therapy by replacing dexamethasone by Cortisol 
would open up 
Androgens in saliva 
Collecting saliva instead of plasma has the great advantage of being a non-invasive 
intervention, causing no distress to the patient and permitting repeated sampling 
without hospitalization It is easy to perform and of particular importance in small 
children An additional point of interest is that the salivary steroids have been found 
to reflect the non-protein bound, free hormone fraction in plasma, which is 
considered to represent the biologically available hormone Although for many 
steroids the salivary concentration appears to be similar to the plasma free 
concentration, this is not true in all cases For many steroid hormones the 
concentration in saliva is similar to the plasma free concentration, suggesting that 
the salivary steroid hormone directly derives from the plasma free moiety 
The concentration of salivary DHEA was not significantly different from plasma free 
DHEA in control women during the follicular phase of the menstrual cycle In the 
luteal phase salivary DHEA slightly exceeded plasma free DHEA 
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Salivary DHEA levels were closely correlated with plasma total and free DHEA. The 
coefficients of correlation were similar. The diurnal variation of plasma total and free 
DHEA was reflected in the concentration of DHEA in saliva. There was no difference 
between the mean concentrations of plasma total DHEA in the follicular and in luteal 
phase, as previously reported (Vermeulen en Verdonk 1976); salivary and free 
DHEA were also similar in the two phases. The levels of DHEA appear to be 
relatively constant throughout the menstrual cycle. These observations indicate that 
the concentration of salivary DHEA does not depend on saliva flow rate, which was 
previously shown for other steroid hormones (Riad-Fahmy et al 1982). 
We found that salivary androstenedione concentrations were significantly lower than 
plasma free androstenedione in both phases of the menstrual cycle under basal 
unsuppressed conditions, in accordance with data from Baxendale et al. (1983). 
This supports our view that A4 is converted into Τ during passage through the 
salivary gland. Turkes and Read (1984) however found almost equal concentrations 
of salivary and plasma free androstenedione under basal conditions. Salivary A4 
correlated equally well with plasma total as with plasma free A4. 
In contrast with the concentrations of salivary DHEA and androstenedione salivary 
levels of Τ [24.7 (7.3) pmol/l] were about three times higher than the levels of 
plasma free Τ [8.7 (3.4) pmol/l] confirming data presented by Baxendale et al. 
(1982) which were also obtained by radioimmunoassay after extraction and 
chromatography in normal women under basal conditions [salivary T: 26.7 (9.0) 
pmol/l, plasma free Τ about 8.8 pmol/l]. Other authors report similar ratios (Vining 
and McGinley 1987, Wang ef al. 1986). The same quantitative relation between 
salivary and plasma free Τ was found in the present study in controls and in hirsute 
women during combined dexamethasone/synthetic corticotropin administration. 
Ruutiainen (ef a/. 1987) as well as Manni et al. (1985) found salivary Τ levels (by 
radioimmunoassay without chromatographic prepurification) in hirsute women which 
exceeded the plasma free level even by a factor of ten. These authors as well as 
Pardridge and Demers (1991) suggest that salivary Τ is directly derived from the 
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'bioavailable' fraction of albumin bound Τ and that the correlation of salivary Τ and 
plasma free Τ is fortuitous. 
Although in the majority of similar studies the discrepancy between plasma free Τ 
and salivary Τ is not that large, apparently, in women the origin of testosterone in 
saliva is not a matter of simple diffusion. It has been suggested (Baxendale et al. 
1982) that the high salivary compared to plasma free Τ levels may be accounted for 
by transfer of minute amounts of albumin from plasma to saliva. We consider this 
explanation unlikely, since it predicts a similar high salivary to plasma free Τ ratio 
for men, which is at variance with earlier observations (Baxendale eí al. 1980, Wang 
er al. 1981, Wellen et al. 1983, Sannikka er al. 1983). Moreover, the transfer of 
0.1% of the plasma proteins (Hammond and Langley 1986) is too small to explain 
the observed difference between plasma free and salivary T. The levels of salivary 
DHEA and A4 are closely correlated with their corresponding plasma total and free 
concentrations. The correlations of salivary Τ with plasma free and total Τ are less 
strong. 
Steroid metabolism in the salivary gland 
Salivary testosterone exceeds plasma free testosterone in control women under 
basal conditions. Moreover, both in controls and in the hirsute women the ratio 
salivary A4/salivary Τ was two to three times lower than the plasma free A4/plasma 
free Τ ratio after combined dexamethasone/synthetic corticotropin administration. In 
our view the quantitative difference between salivary and plasma free testosterone 
may be accounted for by conversion of androstenedione into testosterone during 
passage through the salivary gland. Support for this hypothesis is also derived from 
the observation that salivary testosterone is better correlated with plasma free 
androstenedione than with plasma free testosterone. 
Intrinsic 17-keto-oxidoreductase activity in the salivary gland has earlier been 
demonstrated in vitro in several animal species and in man (Cardinali er al. 1971, 
EIAttar 1974, Coffey and Crutchfield 1977, Booth 1977, Turkes and Read 1984). 
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There is no agreement in the literature on whether the in vitro metabolism of 
androgens in the rat salivary gland is primarily reductive or oxidative (Sirigu ef al. 
1982, Djoseland et al. 1982, Cefalu et al. 1986). 
Pardridge and Demers (1991) explain the quantitative difference between the 
concentrations of salivary and non-SHBG bound Τ by assuming conversion of Τ into 
androstenedione during passage through the salivary gland. Support for this 
hypothesis is derived from experiments (Cefalu et al. 1986) in which Τ was 
observed to be back-converted to A4 by homogenstes of male rat salivary glands. 
Unfortunately, Cefalu and co-workers did not evaluate the metabolism of A4 in their 
study. Moreover, the rat salivary gland shows functional and morphological 
differences related to sex (Sirigu ef al. 1982). Thus these experiments by no means 
exclude the possibility that the metabolism of steroids in female rat salivary glands 
is reductive (A4 into T) instead of oxidative as observed in male rats. Since human 
salivary glands do not appear to show sexual dimorphism (Coffey and Crutchfield 
1977), the rat salivary gland might not be the most suitable model for human 
salivary gland androgen metabolism. If oxidative metabolism of Τ into A4 would 
occur in the salivary gland, the concentration of salivary A4 would be expected to 
exceed plasma free A4, particularly in men and hirsute women. Rather the reverse 
was true, particularly in the latter group. Thus, the higher salivary than plasma free 
T, together with the similar or even lower salivary than plasma free A4 levels we 
observed under basal conditions in this study do not support the presumed in vivo 
back-conversion of Τ into A4 in the female salivary gland. 
It should be noted however that in this study salivary androstenedione exceeds 
plasma free A4 in controls 45 and 75 minutes after synthetic corticotropin infusion 
suggesting that active transport or formation of androstenedione in the salivary 
gland occurs. Indeed Putz ef al. (1982) found relatively high concentrations of 
salivary A4 compared to plasma total A4 in normal premenopausal wotr.en following 
synthetic corticotropin administration. The authors explained this phenomenon by 
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assuming an increased concentration of free A4 or, more likely, 'saturation' of the 
17-hydroxysteroid oxidoreductase enzyme activity by substrate excess. 
The rise in the ratios of free and salivary A4 over Τ we observed in our experiments, 
both in controls and hirsute women, indicates a similar presumed saturation of 
metabolic degradation in the adrenal and in the salivary gland. 
Interestingly in the hirsute women the salivary A4/salivary Τ ratio was significantly 
lower than in the control women both after overnight dexamethasone/synthetic 
corticotropin administration. This may point to an even more rapid metabolism by 
17-hydroxysteroid oxidoreductase of A4 to Τ in the salivary gland of hirsute women. 
The ratio of salivary A4 over Τ therefore may reflect peripheral androgen metabolism 
both in health and disease. 
Metabolic conversion of testosterone precursors in the salivary gland might add to 
the value of salivary Τ measurements as a marker of androgen excess, especially 
when increased peripheral metabolism of such precursors is the main mechanism 
causing hirsutism. 
Dynamic tests 
Dexamethasone suppression and synthetic corticotropin stimulation of adrenal 
function were reflected in the concentrations of salivary DHEA, A4 and Τ in controls 
and in hirsute women. Overnight dexamethasone suppression did not lower the 
levels of testosterone in plasma and saliva compared to those levels observed in 
the normal women under basal conditions. This confirms data presented by 
Rittmaster (et al. 1985). The concentrations of A4 were suppressed to about fifty 
percent of their basal level. The concentrations of DHEA were greatly suppressed, 
reflecting the adrenal origin of this steroid. 
During the test total DHEA in plasma of the hirsute women was significantly higher 
than in controls but this was observed only 15 min after administration of synthetic 
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corticotropin. Plasma free and salivary DHEA were significantly higher at all 
intervals after corticotropin. These parameters might represent the hormonal status 
more accurately than total DHEA. On the basis of an elevated plasma total DHEA 
(2SD from mean), six "high responders" could be indentified in the group of 25 hir-
sute women. The mean salivary and plasma free DHEA responses to corticotropin 
in this subgroup were also significantly higher than those ¡n the controls. This high 
response of DHEA in the dexamethasone/synthetic corticotropin test suggests a 
relative 3/?-hydroxysteroid dehydrogenase enzyme deficiency. In a comparable 
group of 31 women with acne and (or) hirsutism, Lucky ef al (1986) discerned 18 
women presenting with adrenal androgen hyper-responsiveness to corticotropin, 
compatible with adrenal enzyme defects. At least three of these patients had mild 
3ß-hydroxysteroid dehydrogenase deficiency. In nine others, hyper-responsiveness 
to corticotropin was accompanied by excessive increases in androstenedione and 
17-hydroxypregnenolone or DHEA, a response pattern resembling so called 
exaggerated adrenarche. We observed androstenedione hyper-responsiveness after 
corticotropin in three of the six DHEA hyper-responders . 
The mean plasma total and free A4 concentrations were significantly higher in 
hirsute women than in controls at all time intervals before and after ACTH infusion. 
The concentrations of A4 in saliva were also higher in hirsute women than in 
controls at t=0 and 15 min following synthetic corticotropin administration in the 
follicular phase. At the other time intervals there was no significant difference 
between salivary A4 levels in the control women as compared to those in the hirsute 
group. 
Baxendale ef al. (1983) reported basal levels of salivary A4 in women with idiopathic 
hirsutism which were twice higher than the concentrations in controls, whereas the 
concentrations of plasma total A4 were almost three times higher. This is in line with 
our observation that salivary A4 is less discriminative between hirsute women and 
controls than plasma total and free A4. 
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During the dynamic tests the plasma total concentration of either of the androgens 
dehydroepiandrosterone, androstenedione and testosterone was elevated (area 
under the curve >2SD from normal) in 16 out of 25 (64%) patients. Fourteen (48%) 
of the patients had elevated levels of plasma total testosterone (48%) which is 
comparable to the percentage found in hirsute women under basal conditions 
presented in other studies (James and Baxendale 1983, Derksen 1994). 
The free concentrations of these steroids were elevated in 18 out of 25 (72%) 
hirsute patients. Fifteen (60%) patients had non-SHBG-bound testosterone levels 
exceeding control values by 2SD. Salivary concentrations of DHEA, A4 and Τ were 
elevated in 20 (80%) patients (fig 4.1). 
In 92% of the patients at least one of these parameters was abnormal. Moltz and 
Schwartz (1986) found cumulative percentage indices of 88.3% of elevated 
peripheral vein steroids in 60 patients with non-neoplastic hyperandrogenism when 
including T, DHEAS, A, DHEA, DHT, and 170HP. Derksen (1994) measured the 
basal plasma total level of T, the T/SHBG ratio, the level of DHEAS, DHT, DHEA 
and A4 and found that one or more of these parameters was elevated in 45 out of 
73 patients (62%). In the present study, salivary testosterone appeared to be 
superior to any of the other plasma or saliva androgens in discriminating between 
hirsute women and controls [16 out of 25 patients (64%) had elevated levels, Fig 
5.1]. 
These data confirm the importance of the measurement of salivary T. Measurement 
of plasma or salivary androstenedione apparently did not improve the diagnosis of 
androgenizing disorders. Plasma free or salivary DHEA however were of additional 
value in this respect. In relation to salivary testosterone they added 5 out of 25 [total 
21 (84%)] and 4 out of 25 patients [total 20 (80%)], respectively). There were 2 
patients with elevated levels of non-SHBG bound T. Two patients apparently 
showed no abnormal response for any of the parameters measured. 
Hirsutism is often associated with decreased SHBG levels. Measurement of plasma 
SHBG has been put forward as a parameter which could separate hirsute females 
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Fig 4.1 Number of patients with elevated (>mean + 2SD from controls) plasma total, free 
and salivary androgens in a group of 25 women with androgenizing disorders 
during combined dexamethasone/synthetic ACTH administration. 
(TD: plasma total DHEA, TA:plasma total A4, TT.plasma total T, FD.plasma free 
DHEA, FA:plasma free A* FT.plasma free T, NS.plasma non-SHBG-bound T, 
SD.salivary DHEA, SA: salivary A«, ST.salivary T). 
from controls better than plasma total testosterone. Mathur et al (1981) found 
significantly lower SHBG levels in hirsute women than in controls: in a group of 39 
patients 72% had values beyond the range of controls. 
During the test the concentration of SHBG in patients and controls remained 
constant (data not shown). The levels of SHBG in the control group which 
underwent the dexamethasone/synthetic ACTH test was lower than the mean level 
in the group of controls in which basal androgen levels were studied. On the basis 
of these results we cannot exclude the possibility of dexamethasone suppression of 
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SHBG levels. Although in our study the mean SHBG level in women with 
androgenizing disorders tended to be lower than the mean level in controls, the 
difference was not significant. 
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Summary and conclusions 
The aim of the present study was to develop and evaluate measurements of plasma 
total, plasma free and salivary levels of the androgens testosterone (T) and 
androstenedione (A4) and the androgen precursor dehydroepiandrosterone (DHEA) 
as indicators of the clinical androgenicity status in women with androgenizing 
disorders. In addition we studied the relationship between the fractions of those 
hormones in plasma and saliva. In women these steroids are either of adrenal or of 
ovarian origin, or produced peripherically in the skin. The extensive literature 
relevant to this study is discussed in the introductory section of this thesis. 
Androgens in plasma for the greater part circulate in the protein-bound form leaving 
only a small fraction in the non-protein-bound, free form. As the concentration of 
plasma (specific) binding proteins, particularly Sex Hormone-Binding Globulin 
(SHBG), may vary, the plasma total concentration of androgens does not always 
parallel the free concentration. According to the "free hormone hypothesis", the free 
hormone in plasma, which is in equilibrium with the bound hormone, is available for 
target cells and therefore reflects the biological activity of these hormones. Some 
authors hold the view that the non-SHBG-bound fraction of androgens, i.e. the 
albumin-bound and free hormone, represents the biologically available fraction. 
Although controversy exists over this matter the free hormone hypothesis is widely 
accepted. 
The assessment of steroids in saliva has been advocated as a convenient 
alternative to the measurement of (free) hormones in plasma. For several steroids 
the concentration in saliva correlates with the concentration of the plasma free 
steroid. In fact for many, but not for all steroids, the concentration in saliva is similar 
to the plasma free concentration. In women the plasma and salivary concentrations 
of the above mentioned steroids are low. Very sensitive assays are required for 
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their measurement. 
We developed highly sensitive and specific assays which included extraction of the 
specimen with organic solvents and subsequent chromatographic separation of the 
different steroids. Absolute amounts of steroid as low as 2 picogram were 
detectable. Inter-assay coefficients of variation for levels within the normal range 
were about 5%. With these assays the low levels of androgens in saliva of women 
were reliably measurable. 
In addition we developed and thoroughly evaluated different procedures for the 
assessment of non-protein-bound, free steroid concentrations in plasma; i.e. direct 
equilibrium dialysis and symmetric dialysis for free Τ and indirect equilibrium dialysis 
for free DHEA and A4. Particular attention was paid to possible inaccuracies 
arising from sample dilution and tracer contamination. Unlike indirect equilibrium 
dialysis for the determination of plasma free Τ we demonstrated that its assessment 
by symmetric dialysis is not affected by tracer contamination and allows the 
assessment of free hormone in undiluted plasma samples. In addition, we evaluated 
the estimation of plasma non-SHBG bound T. We observed that its level was 
inversely related to the concentration of Cortisol in vitro. 
We found that salivary concentrations of DHEA and A4 were similar to their 
corresponding free concentration in plasma. Close correlations between the salivary 
and plasma levels of these androgens were observed. In the case of Τ there was no 
such similarity between plasma free and salivary concentrations: the salivary 
concentration of Τ is about threefold higher than the plasma free concentration. 
Moreover, only a moderate correlation between these levels was observed. 
Furthermore, salivary Τ correlated better with plasma free A4 than with plasma free 
T. Together with the higher salivary than plasma free Τ these findings suggest that 
A4 is converted into Τ during passage through the salivary gland. 
We employed combined administration of dexamethasone/ACTH in 25 hirsute and 
10 control women as an attempt to identify the source of androgen overproduction. 
In 6 out of 25 patients plasma and salivary DHEA showed an exaggerated response 
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suggestive of relative 3/?-dehydrogenase deficiency. 
During this dynamic test, plasma total and free, as well as salivary Τ increased. The 
fraction of non-SHBG-bound T, however, decreased. We present evidence that the 
decrease of the fraction of plasma non-SHBG-bound Τ is the result of displacement 
of Τ from corticosteroid binding protein (CBG) by the increasing level of Cortisol 
during the test. These findings shed new light on the value of the determination of 
non-SHBG-bound T. If this fraction represents the biologically available Τ as is 
claimed by some authors, it follows that the biologically available Τ also depends on 
the concentration of Cortisol. 
The determination of the concentration of androgens in saliva, particularly that of 
DHEA and of Τ evidently may contribute to the diagnosis of androgenizing 
disorders. The ratio of salivary A4 over Τ in hirsute women is less than in control 
women. This suggests a more intense peripheral conversion of A4 into Τ in women 
with androgenizing disorders. The additional value of assessment of salivary Τ over 
plasma total or free Τ is in line with our assumption that it reflects the peripheral 
metabolism of androgen precursors which may be of particular importance in those 
cases of hirsutism that cannot be traced back to adrenal and/or ovarian androgen 
overproduction. 
Finally, the most prominent findings of the present study are briefly summarised: 
1. non-SHBG-bound Τ is proven to consist partially of CBG-bound Τ and thus 
depends on serum Cortisol and its variations. Therefore it does not accurately 
reflect albumin-bound T, the fraction that by a number of investigators is 
considered as the biologically available fraction. 
2. The concentrations of salivary A4 and DHEA are very similar to their free 
moieties in plasma. 
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3. Salivary Τ is about three times higher than plasma free Τ and, on the other 
hand it is more than three times lower than non-SHBG-bound T. 
4. Most likely, the main source of salivary Τ (and evidently also of salivary A4) is 
plasma free A4, rather than either plasma free Τ or non-SHBG-bound T, for 
the following reasons: 
a. salivary Τ correlates much better with salivary A4 and plasma free A4 
than with plasma free T. Salivary Τ hardly correlates with non-SHBG-
bound T. 
b. Upon stimulation with ACTH, the relative increase of plasma free A4 is 
much higher than of salivary T, indicating that the latter derives from 
the former. 
5. During ACTH stimulation, both the ratio free A4/free Τ and the ratio salivary 
A4/salivary Τ rise, which suggests that A4 to Τ conversion in the adrenal and 
in the salivary gland display a similar saturation behaviour. In the hirsute 
subjects the salivary A4/salivary Τ ratio but not free A4/free Τ is lower than in 
controls, suggesting that salivary gland (peripheral) A4 to Τ conversion is 
enhanced. 
6. Within the context of the combined dexamethason/ACTH test, the plasma 
free and salivary androgens better reflect the hirsute status than total plasma 
levels. Salivary Τ is the best single indicator of increased peripheral 
androgen production. 
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Samenvatting en conclusies. 
Het doel van deze studie was het ontwikkelen en evalueren van bepalingen van de 
totale, de vrije en de speeksel spiegel van de androgenen testosteron (T) en 
androsteendion (A4) en de androgenen-voorloperdehydroepiandrosteran (DHEA) als 
aanwijzers van de androgenen status bij vrouwen met androgeniserende 
syndromen. Bovendien werd de relatie tussen de fracties van deze hormonen in 
plasma en speeksel bestudeerd. Deze Steroiden zijn bij vrouwen primair afkomstig 
uit de bijnier of de ovaría, en worden perifeer geproduceerd in de huid. De 
omvangrijke literatuur met betrekking tot deze studie wordt besproken in het 
inleidende deel van dit proefschrift. 
Androgenen in plasma circuleren grotendeels in eiwit-gebonden vorm. Slechts een 
gering deel, ongeveer 1-5% van de totale concentratie, circuleert in vrije vorm. 
Door variaties in de concentratie van het geslachtshormoon bindend globuline 
(SHBG) is de concentratie van het totale hormoon in plasma niet steeds evenredig 
met de concentratie van het vrije hormoon. Volgens de "vrije hormoon hypothese" is 
het juist het vrije hormoon dat, in evenwicht met de gebonden fractie, de biologische 
activiteit bepaalt. Sommige auteurs zijn van mening dat de fractie niet aan SHBG 
gebonden hormoon, dus het vrije en aan albumine gebonden hormoon, de beste 
maat is voor de biologische beschikbaarheid. Hoewel de vrije hormoon hypothese 
onderwerp van controverse is, wordt zij toch door velen geaccepteerd. 
Het meten van Steroidhormonen in speeksel is gepropageerd als een alternatief 
voor het meten van (vrij) hormoon in plasma. Voor diverse Steroidhormonen is de 
concentratie in speeksel gecorreleerd met de concentratie in plasma. Voor 
verschillende, maar niet voor alle Steroidhormonen blijkt de concentratie in speeksel 
vergelijkbaar te zijn met de vrije concentratie. 
Bij vrouwen is de concentratie van androgenen in plasma en speeksel zeer laag. 
Voor het meten van deze geringe concentraties van Steroiden in speeksel zijn zeer 
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specifieke en gevoelige bepalingen nodig. 
Voor deze studie werden zeer gevoelige en specifieke bepalingen ontwikkeld 
waarbij het monster met behulp van organische oplosmiddelen geëxtraheerd werd 
en vervolgens de onderscheiden Steroidhormonen chromatografisch gezuiverd 
werden. Hoeveelheden van slechts 2 picogram steroid bleken aantoonbaar. De 
gevoeligheid van deze bepalingen bleek ruimschoots toereikend om de lage 
androgenen spiegels in speeksel bij vrouwen te meten. 
Daarnaast werden bepalingen voor vrij hormoon in plasma opgezet en grondig 
geëvalueerd: hierbij werd gebruik gemaakt van directe evenwichtsdialyse en 
symmetrische dialyse voor de bepaling van vrij Τ en indirecte evenwichtsdialyse 
voor de bepaling van vrij A4 en DHEA. Bijzondere aandacht werd besteed aan 
mogelijke afwijkingen van de juiste waarde veroorzaakt door verdunning van plasma 
en tracer-verontreiniging. In tegenstelling tot de indirecte evenwichtsdialyse voor de 
bepaling van vrij Τ in plasma bleek symmetrische dialyse nauwelijks gevoelig voor 
tracer-verontreiniging, en maakt meting in onverdund plasma mogelijk. 
Tevens werd de bepaling van het niet-SHBG gebonden Τ geëvalueerd. In vitro 
bleek de fractie van het niet-SHBG gebonden Τ in plasma omgekeerd evenredig te 
zijn met de Cortisol concentratie. 
Voor A4 en DHEA bleek dat de vrije concentratie in plasma overeen te komen met 
de concentratie in speeksel. Wij stelden sterke correlaties tussen de spiegels van 
deze hormonen in plasma en speeksel vast. Voor het Τ geldt dit niet: de 
concentratie ervan in speeksel is ongeveer drie maal zo hoog als de vrije 
concentratie in plasma. 
Tevens is het speeksel Τ slechts matig gecorreleerd met het plasma vrije T. 
Bovendien is het speeksel Τ sterker gecorreleerd met het plasma vrije A4 dan met 
het plasma vrije T. Samen met de hogere speeksel Τ concentratie ten opzichte van 
de vrije Τ spiegel in plasma wijzen deze bevindingen op omzetting van A4 ¡η Τ 
tijdens passage door de speekselklier. 
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Wij maakten gebruik van de dexamethason/ACTH test bij 25 hirsute vrouwen en 10 
gezonde vrouwen om te trachten de bron van de androgenen overproductie aan te 
wijzen BIJ 6 van de 25 patiënten was de respons van DHEA m plasma en in 
speeksel gedurende de tests excessief, hetgeen past bij een partiele 3/7-
dehydrogenase deficiëntie 
Tijdens de gecombineerde dexamethason/synthetisch ACTH test bleek het totale en 
vrije Τ in plasma, evenals het speeksel Τ te stijgen Het percentage niet aan SHBG 
gebonden Τ daalde echter Wij toonden aan dat deze daling het gevolg is van 
verdringing van Τ van het corticosteroid bindend eiwit (CBG) veroorzaakt door de 
toename van de cortisol-spiegel tijdens de test Deze bevinding werpt een nieuw 
licht op de waarde van de bepaling van het niet-SHBG gebonden Τ Indien deze 
fractie een afspiegeling zou zijn van het biologisch beschikbare T, zoals door 
sommige auteurs wordt beweerd, dan zou hieruit volgen, dat het biologisch 
beschikbare Τ mede bepaald wordt door de concentratie Cortisol 
De bepaling van androgenen in speeksel, -met name van Τ en DHEA-, kan de 
diagnose bij vrouwen met androgeniserende syndromen verfijnen De verhouding 
A4/T in speeksel is bij hirsute vrouwen lager dan in de controle-groep Dit wijst op 
een intensievere perifere omzetting van A4 naar Τ bij vrouwen met 
androgeniserende syndromen De additionele waarde van de bepaling van speeksel 
Τ in vergelijking met het totale of vrije testosteron sluit aan bij onze aanname dat 
het speeksel Τ het perifere metabolisme van voorlopers van androgenen 
weerspiegelt Dit kan met name dan van belang zijn, wanneer geen duidelijke 
overproduce van androgenen vanuit de bijnier of de ovaría aangetoond kan 
worden 
Tot slot worden de belangrijkste bevindingen van deze studie samengevat 
1 Aangetoond werd dat niet-SHBG-gebonden Τ voor een deel bestaat uit CBG-
gebonden Τ en dus mede afhankelijk is van plasma Cortisol Om deze reden 
weerspiegelt deze fractie niet op juiste wijze het albumine gebonden T, de 
fractie die door een aantal onderzoekers beschouwd wordt als de biologisch 
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beschikbare fractie. 
2. De concentraties van speeksel A4 en DHEA zijn vrijwel gelijk aan hun vrije 
concentratie in plasma. 
3. Speeksel Τ is ongeveer drie maal hoger dan plasma vrij Τ maar meer dan 
drie maal zo laag als het niet-SHBG-gebonden T. 
4. De belangrijkste bron van het speeksel Τ (en speeksel A4) is het plasma vrij 
A4, in plaats van het vrij Τ of het niet-SHBG gebonden T, om de volgende 
redenen: 
a. Speeksel Τ correleert veel beter met speeksel en vrij A4 dan met vrij 
T. Speeksel Τ correleert niet met niet-SHBG gebonden T. 
b. Na stimulatie met ACTH is de relatieve toename van het speeksel A4 
veel groter dan die van het speeksel T, hetgeen wijst op het ontstaan 
van Τ uit A4. 
5. Gedurende ACTH stimulatie, stijgen zowel de ratio vrij A4/vrij Τ als de ratio 
speeksel A4/speeksel T, wat duidt op een vergelijkbaar verzadigings-gedrag 
van de A4 - Τ conversie in de bijnier en in de speekselklier. In tegenstelling 
tot de ratio vrij A4/vrij Τ is de ratio speeksel A4/speeksel Τ bij hirsute vrouwen 
lager dan bij controles hetgeen wijst op verhoogde (perifere) A4 - Τ conversie 
in de speekselklier van vrouwen met androgeniserende syndromen. 
6. In de context van de gecombineerde dexamethason/ACTH test, 
weerspiegelen plasma vrije spiegels en de spiegels van androgenen in 
speeksel het hyperandrogenisme beter dan de totale plasma spiegels. 
Speeksel Τ is de beste enkelvoudige indicator van toegenomen perifere 
androgenen productie. 
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Woorden van dank 
Zonder de hulp van velen zou dit proefschrift niet tot stand zijn gekomen. 
Als eerste wil ik graag mijn ouders bedanken die dit alles mogelijk gemaakt hebben. 
Ik wil ook de patiënten en vrijwilligers bedanken die bereid waren de dynamische 
testen te ondergaan en daarbij speeksel te verzamelen. Nico Meessen heeft op 
voortreffelijke wijze de gezonde vrijwilligers begeleid. 
Mijn dank gaat uit naar de huidige en voormalige medewerk(st)ers van de afdeling 
Experimentele en Chemische Endocrinologie (hoofd prof. dr. Th.J. Benraad) en het 
Laboratorium Endocrinologie en Voortplanting (hoofd prof. dr. Th.J. Benraad). Ik heb 
steeds kunnen steunen op hun kennis van en hun ervaring met de verschillende 
dialyse- en bindingsanalyse-technieken. Samen met de medewerk(st)ers van de 
afdeling Endocriene Ziekten (hoofd prof. dr. P.W.C. Kloppenborg) hebben zij het 
werken in het laboratorium tot een plezierige en fascinerende beleving gemaakt. 
Het doet mij genoegen Harry van Hoof te kunnen bedanken voor zijn bijdrage aan 
dit onderzoek. In het kader van zijn chemie-studie heeft hij aan de bepaling van het 
niet-SHBG-gebonden testosteron gewerkt. Maar ook in de tijd daarna, was zijn hulp 
bij het werken met de computer onmisbaar. 
Ingrid, jij hebt als secretaresse van onze afdeling daadwerkelijk aan dit proefschrift 
bijgedragen. Daarvoor bedankt. Ik wil je echter vooral bedanken voor het geduld dat 
je al die tijd opgebracht hebt. 
177 
Woorden van dank 
178 
Curriculum vitae 
Curriculum vitae 
De schrijver van dit proefschrift werd geboren op 13 december 1955 te Tilburg. Na 
het behalen van het VWO-diploma in 1974 vervolgde hij zijn opleiding aan de 
Nieuwe Leraren Opleiding "Moller Instituut" te Tilburg. Het diploma werd behaald in 
1979. In hetzelfde jaar begon hij met de studie Biologie aan de Katholieke 
Universiteit te Nijmegen. Het doctoraalexamen (met onderwijsbevoegdheid) werd in 
1983 behaald. 
In april 1983 werd hij aangesteld als wetenschappelijk assistent bij de afdeling 
Experimentele en Chemische Endocrinologie (hoofd prof. dr. Th.J. Benraad). In 
1984 werd gestart met het hier beschreven promotie-onderzoek. In 1987 werd hij 
aangesteld in het Laboratorium Endocrinologie en Voortplanting. Naast zijn taken in 
het laboratorium was hij verantwoordelijk voor keuze-onderwijs projecten voor 
geneeskunde studenten en droeg hij zorg voor de begeleiding van MLO- en HLO-
stagiaires, geneeskunde- en biologie-studenten, evenals van klinisch chemici in 
opleiding, gedurende hun stage in het endocrinologisch laboratorium. Hij was nauw 
betrokken bij de contacten met het Muhimbili Medical Centre te Dar-es-Salaam, 
Tanzania en de MSc-opleiding van dr. E. Kabyemela van dit instituut. Tevens is hij 
sinds 1990 reviewer voor het tijdschrift "Clinical Chemistry". 
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Stellingen 
behorende bij het proefschrift 
Plasma and salivary androgens in normal women 
and in women with androgenizing disorders 
1 Het testosteron in speeksel weerspiegelt niet alleen de concentratie van het 
vrije testosteron in plasma, maar tevens de perifere omzetting van 
androsteendion (dit proefschrift) 
2 De fractie testosteron, niet gebonden aan geslachtshormoon-bindend eiwit, bestaat 
voor een deel uit testosteron gebonden aan corticosteroidhormoon-bindend eiwit De 
grootte van deze fractie is daardoor afhankelijk van de concentratie van het Cortisol 
in plasma (dit proefschrift) 
3 Voor vele directe bepalingen van testosteron in plasma geldt, dat de meetwaarde 
afhankelijk is van de spiegel van het geslachtshormoon-bindend eiwit Bepaling van 
testosteron zou derhalve bijvoorkeur na extractie en chromatografische voorzuivenng 
van het plasma moeten plaatsvinden (dit proefschrift) 
4 De bepaling van dehydroepiandrosteron in speeksel tijdens de gecombineerde 
dexamethason-synacthen test kan een rol spelen bij het vaststellen van milde 
3/?-hydroxysteroiddehydrogenase deficiëntie (dit proefschrift) 
5 Het verdient aanbeveling vnj testosteron in plasma te meten met behulp van 
symmetrische dialyse (dit proefschrift) 
6 In Nederland is de geografische ligging niet alleen van invloed op de etiologie van 
schildklierziekten, maar, gezien de verbreiding van analoog-tracer methoden voorde 
bepaling van vnj thyroxine, ook op de kwaliteit van de diagnostiek ervan 
7 Voor de borging van de kwaliteit in het endocnnologisch laboratorium zijn 
consciëntieuze analisten belangrijker dan een kwaliteitssysteem 
β Indien aan ziekenhuislaboratona in ontwikkelingslanden matenalen voor het meten 
van klinisch-chemische parameters worden verstrekt, verdient het aanbeveling daar 
tevens een kosten-baten analyse aan te verbinden 
9 Als de omschnjving voor Steroidhormonen in het 'Stijlboek' van De Volkskrant 
maatgevend is voor de wijze waarop wetenschapsjoumahstiek wordt bedreven, 
verdient het aanbeveling krantebenchten aangaande Endocrinologie vóór publicatie 
te laten beoordelen door deskundigen op dit gebied 
10 BIJ de huidige snelheid in de ontwikkeling van software is de aanduiding 'standaard' 
weinig zinvol 
11 Om meer dan één reden is voor een aantal subfertiele mannen mtracytoplasmatische 
sperma-injectie te verkiezen boven heterologe donor-inseminatie 
12 Het draait allemaal om haar 
Nijmegen, 13 december 1994 Leon M J W Swinkels 
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